---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description. Covers Product description and Place of product in therapy. 399 evidence topics quoted from 168 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Summary: development stage and regulatory timing

Lanifibranor is an investigational oral product in phase 3 development for adults with noncirrhotic MASH and F2 to F3 fibrosis. The last participant completed the final 72-week visit of the NATiV3 phase 3 trial, and NATiV3 topline results were expected in the fourth quarter of 2026. Inventiva states that, if the results are favorable, it anticipates a regulatory submission in the first half of 2027 under the FDA accelerated approval pathway and is preparing for a potential U.S. launch in 2028, subject to FDA approval. The FDA granted Fast Track designation and, in October 2020, Breakthrough Therapy designation, and the Chinese NMPA granted Breakthrough Therapy designation in December 2023. Company guidance for NATiV3 topline results changed across successive releases: from the second half of 2024 to the second half of 2025, the first half of 2026, the beginning of the second half of 2026, the second half of 2026, and the fourth quarter of 2026.

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf); [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf); [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm); [Inventiva CTTQ milestone release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-CTTQ-milestone-EN-07-07-2025.pdf); [Inventiva NATiV3 initiation release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf); [Inventiva first half 2022 results announcement (2022)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-H1-2022-EN-22092022-FINAL-2-1.pdf); [Inventiva NATiV3 status update release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-First-patient-randomized-in-China-and-NATiV3-status-update-EN-12-20-2023-2.pdf); [Inventiva NATiV3 and financial update release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-and-fiancial-situation-updates-EN-07-05-2024.pdf); [Inventiva structured financing release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Project-Sulphur-EN-10-13-2024-_Version-finale.pdf); [Inventiva full year 2025 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Full-Year-results-2025-EN-03-30-2026-1.pdf)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Submission planned; NDA for accelerated approval planned for the first half of 2027

> “If the NATiV3 topline results are favorable, the Company anticipates regulatory submission in the first half of 2027”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

> “If the results are favorable, the Company anticipates regulatory submission in the first half of 2027”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

> “We are on track for our anticipated top-line Phase 3 readout in the fourth quarter of 2026, followed by an anticipated regulatory filing in the first half of 2027”

Source: [Inventiva debt and equity financing release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Debt-and-Equity-EN-06-02-2026.pdf)

> “If the results are positive and subject to regulatory approval, we target the potential NDA submission for the first half of 2027, with a view to potential commercialization in 2028.”
> “We anticipate submission of an NDA to the FDA for accelerated approval based on liver histological endpoints of approximately 950 patients treated over a 72-week period for our Phase 3 trial, if the data is positive.”
> “If the data from our ongoing NATiV3 Phase 3 clinical trial of lanifibranor in MASH are positive, we intend to seek approval under the FDA’s accelerated approval pathway and the European Commission’s conditional authorization pathway.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.1-3"></a>

##### Launch: Anticipated in 2028

> “is preparing for a potential U.S. launch of lanifibranor in 2028, subject to U.S. Food and Drug Administration (“FDA”) approval.”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

> “is preparing for a potential U.S. launch of lanifibranor in 2028, subject to FDA approval.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

<a id="topic-2.1.1-4"></a>

##### NATiV3 topline timing: fourth quarter of 2026, as of October 2026

> “Lanifibranor is currently being evaluated in the Phase 3 NATiV3 clinical trial for the treatment of patients with MASH with moderate and advanced fibrosis, with topline results expected in the fourth quarter of this year.”

Source: [Inventiva AASLD 2026 abstracts release (2026)](https://inventivapharma.com/wp-content/uploads/INVENTIVA-AALSD-Abstracts-PR-EN-10.6.2026-1.pdf)

> “Inventiva expects to report topline results from the Phase 3 clinical trial NATiV3 in the fourth quarter of 2026.”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

> “In alignment with the careful sequencing of our clinical and operational milestones, we are refining our expected data readout to the fourth quarter of 2026.”

Source: [Inventiva full year 2025 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Full-Year-results-2025-EN-03-30-2026-1.pdf)

<a id="topic-2.1.1-5"></a>

##### NATiV3 last patient visit, September 2026

> “today announced the last patient has completed their final 72-week visit in the NATiV3 Phase 3 clinical trial evaluating lanifibranor for the treatment of patients with MASH with moderate and advanced fibrosis.”
> “With the last patient having completed their final visit, all patients have completed the 72-week treatment period.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

<a id="topic-2.1.1-6"></a>

##### Approval status: not approved by any regulatory authority

> “Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority.”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

<a id="topic-2.1.1-7"></a>

##### Accelerated approval and conditional authorization: completion of the trial required for full approval

> “We may seek accelerated approval from the FDA and conditional authorization from the European Commission if our NATiV3 Phase 3 clinical trial of lanifibranor in MASH is successful at the 72-week endpoint but, even if granted, accelerated approval and conditional authorization require completion of the trial to obtain full approval.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.1-8"></a>

##### Planned phase 3 outcome trial in MASH with compensated cirrhosis

> “Under the new trial design, the originally-planned Part 2 of the NATiV3 trial, a clinical outcome trial that was planned to be conducted in approximately 2,000 patients with F2 and F3 fibrosis for a maximum period of seven years, will be replaced by a placebo-controlled Phase 3 outcome trial which will be event driven and is expected to last approximately three years, depending on patient enrollment.”
> “If the results of the outcome trial in patients with MASH and compensated cirrhosis confirm sufficient clinical benefit, we anticipate the results will be used in our planned submission of an NDA to the FDA for full approval and the potential expansion of the addressable patient population beyond patients with F2 and F3 fibrosis to include patients with MASH and compensated cirrhosis”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.1-9"></a>

##### FDA Fast Track designation for NASH, September 2019

> “today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s lead product candidate, lanifibranor, for the treatment of non-alcoholic steatohepatitis (NASH).”

Source: [Inventiva Fast Track designation release (2019)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Lanifibranor-FDA-Fast-Track-EN-26092019-VF.pdf)

<a id="topic-2.1.1-10"></a>

##### FDA Breakthrough Therapy designation for NASH, October 2020

> “today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to lanifibranor, the Company’s lead drug candidate, for the treatment of NASH.”
> “The designation of lanifibranor as a Breakthrough Therapy for the treatment of NASH follows the publication in June 2020 of positive topline results from Inventiva’s NATIVE Phase IIb clinical trial with lanifibranor in NASH patients.”

Source: [Inventiva Breakthrough Therapy designation release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Lanifibranor-Breakthrough-Therapy-Designation-EN-12-10-20.pdf)

> “The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of MASH.”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

<a id="topic-2.1.1-11"></a>

##### FDA Fast Track designation extended to NASH with compensated cirrhosis, September 2021

> “today announced that the U.S. Food and Drug Administration (FDA) has decided that the Fast Track designation previously granted to lanifibranor in NASH encompasses the treatment of NASH patients with compensated cirrhosis.”

Source: [Inventiva Fast Track compensated cirrhosis release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Fast-Track-EN-21092021.pdf)

<a id="topic-2.1.1-12"></a>

##### China NMPA Breakthrough Therapy designation for MASH, December 2023

> “Based on the results from the Phase 2b NATIVE clinical trial, lanifibranor was granted Breakthrough Therapy Designation for MASH by the U.S. Food and Drug Administration in October 2020 and by the Chinese National Medical Products Administration (NMPA) in December 2023.”

Source: [Inventiva CTTQ milestone release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-CTTQ-milestone-EN-07-07-2025.pdf)

> “In December 2023, we announced that our licensee CTTQ, who joined our NATiV3 trial, randomized the first patient in China and that lanifibranor was granted Breakthrough Therapy Designation for MASH by the Chinese NMPA.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.1-13"></a>

##### EU PRIME designation

No evidence found.

<a id="topic-2.1.1-14"></a>

##### Development in China and Japan: regulatory approval in China to rest on NATiV3; pivotal trial in Japan and South Korea after NATiV3 results

> “CTTQ joined Inventiva’s ongoing NATiV3 pivotal Phase 3 clinical trial, which includes over 60 sites across mainland China.”
> “Furthermore, CTTQ has completed a Phase I bridging study and confirmed no significant ethnic differences, thereby paving the way to seek regulatory approval in China based on the results of the NATiV3 trial.”

Source: [Inventiva CTTQ milestone release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-CTTQ-milestone-EN-07-07-2025.pdf)

> “In 2025, Hepalys conducted a Phase 1 trial of lanifibranor in Japan. The results of this Phase 1 trial were positive and are expected to support the initiation of a dedicated pivotal trial in patients with MASH in the Hepalys Territory, which is planned to start once the results of NATiV3 are available.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.1-15"></a>

##### NATiV3 topline timing, September 2021, superseded in September 2022

> “The last visit of the last patient enrolled in part 1 of the NATiV3 Phase III clinical trial is planned for the first half of 2024, with the publication of the topline results of part 1 of the trial expected for the second half of 2024.”
> “If part 1 of the NATiV3 trial is successful, Inventiva intends to seek accelerated approval in the United States and conditional approval in the EU for lanifibranor.”

Source: [Inventiva NATiV3 initiation release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf)

<a id="topic-2.1.1-16"></a>

##### NATiV3 topline timing, September 2022, superseded in December 2023

> “Accordingly, the publication of the topline results of the part 1 of NATiV3 is now targeted for second half of 2025.”

Source: [Inventiva first half 2022 results announcement (2022)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-H1-2022-EN-22092022-FINAL-2-1.pdf)

<a id="topic-2.1.1-17"></a>

##### NATiV3 topline timing, December 2023, superseded in July 2024

> “Topline results for the Phase III NATiV3 clinical trial are now expected to be published in the first half of 2026 versus the second half of 2025, as previously communicated.”

Source: [Inventiva NATiV3 status update release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-First-patient-randomized-in-China-and-NATiV3-status-update-EN-12-20-2023-2.pdf)

<a id="topic-2.1.1-18"></a>

##### NATiV3 topline timing, July 2024, superseded in October 2024

> “First visit of the last patient of NATiV3 is anticipated to occur during the second half of 2024, and topline results are expected at the beginning of the second half of 2026.”

Source: [Inventiva NATiV3 and financial update release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-and-fiancial-situation-updates-EN-07-05-2024.pdf)

<a id="topic-2.1.1-19"></a>

##### NATiV3 topline timing, October 2024 to November 2025, superseded in March 2026

> “The Company also estimates that, prior to the Transaction, it would need approximately €250 million to finance its activities until the topline results from its NATiV3 trial, targeted for the second half of 2026.”

Source: [Inventiva structured financing release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Project-Sulphur-EN-10-13-2024-_Version-finale.pdf)

> “Topline results from NATiV3 projected in the second half of 2026 and, if positive, expected to be the basis for submission for regulatory approval”
> “Topline results of NATiV3 are expected in the second half of 2026.”

Source: [Inventiva NATiV3 enrollment completion release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-End-of-Patient-Randomization-EN-04-01-2025.pdf)

> “Topline results of NATiV3 – expected in the second half of 2026”

Source: [Inventiva third quarter 2025 results announcement (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Q3-2025-CA-Cash-EN-11-21-2025.pdf)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Generic name, chemical name, and identifiers

| Field | Quoted record |
| --- | --- |
| International nonproprietary name (Latin) | “lanifibranorum” |
| International nonproprietary name (English) | “lanifibranor” |
| Chemical name | “4-[1-(1,3-benzothiazole-6-sulfonyl)-5-chloro-1H-indol- 2-yl]butanoic acid” |
| Functional description | “peroxisome proliferator-activated receptors (PPAR) agonist” |
| Molecular formula | “C19H15ClN2O4S2” |
| CAS registry number | “927961-18-0” |
| INN list | “Proposed INN: List 116” |

Source: [WHO Drug Information (2016)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl116.pdf)

<a id="topic-2.1.2.1-2"></a>

###### Development code: IVA337

> “In June 2020, we announced positive topline results from our NATIVE Phase 2b clinical trial (Nash Trial to Validate IVA337 Efficacity) of lanifibranor in patients with MASH.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

> “The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

| Field | Quoted record |
| --- | --- |
| Arm | “Lanifibranor (IVA 337) (800 mg/day)” |
| Arm | “Lanifibranor (IVA 337) (1200 mg/day)” |

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.1-3"></a>

###### Brand name

No evidence found.

<a id="topic-2.1.2.1-4"></a>

###### Manufacturer: Inventiva

> “Lanifibranor, Inventiva’s lead product candidate, is an orally available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (“PPAR”) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression.”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

> “In accordance with the announcement we made in February 2025, we decided to focus exclusively on the development of lanifibranor, to expand the lanifibranor program team to prepare for potential filings for marketing approval and, if approved, the subsequent commercialization of lanifibranor for patients with MASH”
> “Currently, lanifibranor is our only product candidate in development.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

| Field | Quoted record |
| --- | --- |
| Sponsor | “Inventiva Pharma” |

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.1-5"></a>

###### Regulatory applicants outside the United States: CTTQ in Greater China and Hepalys in Japan and South Korea

> “CTTQ shall be solely responsible, at its own expense, for all regulatory activities with respect to the Licensed Products in the CTTQ Territory, including preparing, filing, obtaining and maintaining regulatory approvals for the Licensed Products.”
> “Hepalys will be responsible for conducting and financing all development trials in the Hepalys Territory needed to file for a new drug application in these territories.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.2.1-6"></a>

###### Therapeutic class: oral pan-PPAR agonist

> “Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ.”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

> “The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.”

Source: [Inventiva CTTQ milestone release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-CTTQ-milestone-EN-07-07-2025.pdf)

> “We believe that this pan-PPAR approach provides for a combination of anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic effects that cannot be obtained with single and dual PPAR agonists.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Investigational dosage form: 400 mg film-coated immediate-release tablet

> “The Investigational Medicinal Product is a white to off-white bi-convex tablet, weighing approximately 927 mg and showing a breakline to facilitate the administration to patients.”
> “The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation.”
> “Each active tablet contains 400 mg of the active substance lanifibranor in an immediate release formulation.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.2-2"></a>

###### Tablets per daily dose in NATiV3: two or three 400 mg tablets

> “2 Lanifibranor tablets 400mg + 1 Placebo to match tablet with food”
> “3 Lanifibranor tablets 400mg with food”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.2-3"></a>

###### Tablets per daily dose in LEGEND: two 400 mg tablets

> “Tablets of lanifibranor 400 mg, administered on a daily dose of 800 mg lanifibranor or placebo, i.e., 2 tablets of 400 mg/placebo orally once daily (QD) during breakfast, for a total of 24 weeks”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.2-4"></a>

###### Packaging of the investigational tablets: HDPE bottles

> “The lanifibranor tablets and PTM are packaged into High-density polyethylene (HDPE) bottles of 100 ml (38 tablets for a treatment period of one month, plus a use margin of 1 week) with proper closures fitted with a silicagel cartridge.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

> “Two bottles of 30 tablets are placed into a carton to get a 4-weeks kit (see Figure 2).”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.2-5"></a>

###### Storage and stability of the investigational tablets

> “Based on the results of the ongoing stability studies, a shelf life of 2 years (storage at 25°C or below) is proposed for the Investigational Medicinal Product provided it is stored in the original package, the HDPE bottles.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

> “The IMP should be stored at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). It should be stored in the original containers (i.e., bottles).”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.2-6"></a>

###### Bioequivalence study in healthy volunteers, France, February to May 2026

> “A Randomised, Open-Label, Single-Centre, Study to Evaluate the Bioequivalence of Lanifibranor”

Source: [EU Clinical Trials Information System 2025-524385-18-00](https://euclinicaltrials.eu/ctis-public/view/2025-524385-18-00)

<a id="topic-2.1.2.2-7"></a>

###### Commercial strengths and package sizes

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### AHFS classification

No evidence found.

<a id="topic-2.1.2.4-2"></a>

###### WHO INN functional description: peroxisome proliferator-activated receptors agonist

> “peroxisome proliferator-activated receptors (PPAR) agonist”

Source: [WHO Drug Information (2016)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl116.pdf)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Population of the pivotal NATiV3 trial: adults with biopsy-proven noncirrhotic MASH and F2 to F3 fibrosis

> “NATiV3 enrolled 1,009 adults with biopsy-proven non-cirrhotic MASH and F2/F3 fibrosis, with an additional 410 patients enrolled in an exploratory cohort.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

> “Male or female, aged ≥18 years at the time of signing informed consent”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.5-2"></a>

###### Company wording of the target population: MASH with moderate and advanced fibrosis

> “Lanifibranor is currently being evaluated in the Phase 3 NATiV3 clinical trial for the treatment of patients with MASH with moderate and advanced fibrosis”

Source: [Inventiva AASLD 2026 abstracts release (2026)](https://inventivapharma.com/wp-content/uploads/INVENTIVA-AALSD-Abstracts-PR-EN-10.6.2026-1.pdf)

> “We are developing lanifibranor for the treatment of patients with metabolic dysfunction-associated steatohepatitis, a progressive, chronic liver disease.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.2.5-3"></a>

###### Indication named in the FDA designations: treatment of MASH

> “The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of MASH.”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

<a id="topic-2.1.2.5-4"></a>

###### Population expansion planned: MASH with compensated cirrhosis

> “potentially expanding the addressable patient population to include patients with MASH and compensated cirrhosis through an additional Phase 3 outcome trial, rather than the originally planned Part 2 of our NATiV3 Phase 3 clinical trial of lanifibranor in MASH.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.2.5-5"></a>

###### Proposed labeling

No evidence found.

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Pan-PPAR agonist: company description of isoform activation

> “Lanifibranor, Inventiva’s lead product candidate, is an orally available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor”
> “Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ.”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

> “Lanifibranor is a PPAR agonist designed to activate all three PPAR isoforms in a moderate and equipotent manner, with balanced activation of PPARα and PPARδ, and partial activation of PPARγ.”

Source: [Inventiva EASL Congress 2026 abstracts release (2026)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Abstracts-EASL-2026-EN-05-13-2026.pdf)

<a id="topic-2.1.2.6.1-2"></a>

###### Company rationale for activating all three isoforms

> “PPARs are well-characterized nuclear receptor proteins that regulate gene expression, and their relevance for the fibrotic, inflammatory, vascular and metabolic processes that characterize MASH is well-established.”
> “We believe that this pan-PPAR approach provides for a combination of anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic effects that cannot be obtained with single and dual PPAR agonists.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.2.6.1-3"></a>

###### Chemical class: indole sulfonamide small molecule

> “Here, we describe the identification and synthesis of novel indole sulfonamide derivatives that activate the three peroxisome proliferator activated receptor (PPAR) isoforms.”
> “Starting with a PPARα activator, compound 4, identified during a high throughput screening (HTS) of our proprietary screening library, a systematic optimization led to the discovery of lanifibranor (IVA337) 5, a moderately potent and well balanced pan PPAR agonist with an excellent safety profile.”

Source: [Boubia et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29446942/)

> “Small molecule”
> “Differentiated structure – not a glitazone”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.1.2.6.1-4"></a>

###### Transactivation potency and maximal effect at human PPAR isoforms

> “In the transactivation assay (see Supporting Information), IVA337 acts as a pan‐PPAR agonist with moderate and balanced activity on the three PPAR isoforms.”
> “IVA337 50% effective concentration (EC50) levels for the human PPARs (hPPARs) were 1.63E‐06 M for PPARα, 8.49E‐07 M for PPARδ, and 2.28E‐07 M for PPARγ.”
> “The maximal effect (Emax) reached 100% for both hPPARα and hPPARδ and 80% for hPPARγ when compared to fenofibrate, GW501516, and rosiglitazone, respectively.”
> “The potency of IVA337 for PPARα and PPARγ is in the same range as that of fenofibrate (EC50, 2 µM; PPARα) and pioglitazone (EC50, 0.3 µM; PPARγ), two clinically used and well‐tolerated PPAR agonists with a good efficacy/safety ratio.”

Source: [Wettstein et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5678909/)

<a id="topic-2.1.2.6.1-5"></a>

###### Isoform potency and PPARγ efficacy relative to pioglitazone

> “This study was designed so as to provide functional and structural insights into the potency, efficacy, and selectivity against PPARα/δ/γ of lanifibranor, seladelpar, and elafibranor.”
> “The EC50 values for PPARα/δ/γ were in small ranges (0.4–5 µM in Figure 1B and 3–14 µM in Figure 2A,B), and therefore, lanifibranor in clinical doses seems to be able to activate all PPAR subtypes at once.”
> “Due to the fact that its efficacies for PPARγ activation often match with those of pioglitazone (Figure 2A vs. Figure 2I, Figure 2B vs. Figure 2J, and Figure 3B vs. Figure 3F), PPARγ-related undesirable side effects (such as weight gain, edema, bone loss, and congestive heart failure) [42] should be closely monitored in the case of lanifibranor.”

Source: [Kamata et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10451623/)

<a id="topic-2.1.2.6.1-6"></a>

###### Isoform-specific pathways attributed to each PPAR subtype

> “Among other effects, PPARα agonists reduce TG levels by increasing mitochondrial FA β-oxidation; PPARβ/δ ligands increase HDL-C levels, have anti-inflammatory effects and improve glucose utilization of skeletal muscle, while PPARγ activity exerts antifibrotic effects on activated hepatic stellate cells and improves IS in liver, adipose tissue and skeletal muscle.”
> “The clinical metabolic-immune improvements with lanifibranor indeed substantiate the pan-PPAR activating mechanism across all three subtypes, exemplified by the effects on TG, HDL-C and IR reflecting mainly PPARα, β/δ and γ mediated mechanisms, respectively”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-2.1.2.6.1-7"></a>

###### Preclinical efficacy compared with single and dual PPAR agonists

> “In preclinical models, the indole sulfonamide lanifibranor (IVA337), a pan-PPAR agonist, improved insulin sensitivity and macrophage activation and reduced liver fibrosis and inflammatory gene expression with higher efficacy than single or dual PPAR agonists.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

> “Lanifibranor improved all histological features of steatohepatitis in CDAA-HFD-fed mice, including liver fibrosis, thereby combining and exceeding specific effects of the single PPAR agonists.”

Source: [Lefere et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32360434/)

<a id="topic-2.1.2.6.1-8"></a>

###### Hepatic stellate cell proliferation and activation

> “IVA337 dose dependently and completely inhibited PDGF‐induced hHSC proliferation (Fig. 7A).”
> “In contrast, the selective PPAR agonists demonstrated only partial effects up to the highest concentrations (Fig. 7A).”

Source: [Wettstein et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5678909/)

> “Lanifibranor was able to fully inhibit the proliferation induced by PDGF and was able to prevent the overexpression of α-SMA and the hallmark of myofibroblast, induced by stiffness.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.6.1-9"></a>

###### Hepatic macrophage activation: PPARδ-dependent effect

> “Lanifibranor attenuated the accompanying inflammatory activation in both murine palmitic acid-stimulated bone marrow-derived macrophages, as well as patient-derived circulating monocytes, in a PPARδ-dependent fashion.”
> “PPARδ agonism and lanifibranor directly modulate macrophage activation, but not infiltration, thereby synergizing with beneficial metabolic effects of PPARα/γ agonists.”

Source: [Lefere et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32360434/)

Additional sources: [Guo et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42702283/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Adiponectin as a marker of PPARγ engagement: phase 1 multiple ascending dose study in healthy participants

> “After Group 6 of the SAD cohort completed evaluation, multiple ascending doses (MAD) of oral lanifibranor were administered to young healthy males for 14 days, progressing to a higher dose after the safety and tolerability of the previous dose was established”
> “Lanifibranor significantly increased adiponectin versus placebo at 400, 1000, and 1500 mg daily doses, with high–molecular weight (HMW) adiponectin increases at 1000 and 1500 mg daily (Figure 2 and Figure 3)”

Source: [Francque et al. (2026)](https://inventivapharma.com/wp-content/uploads/MASH-2026-Clinical-PK-PD-poster_LUM-03426_v2.pdf)

<a id="topic-2.1.2.6.2-2"></a>

###### Adiponectin, lipids, glucose, and fluid retention markers at day 28: phase 2a study in participants with type 2 diabetes on metformin

> “The phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 28-day study evaluated lanifibranor in participants with T2DM who were on metformin monotherapy (Figure 1)”
> “Lanifibranor (400, 800, and 1400 mg) consistently induced dose- and time-related increases in total and HMW adiponectin (Figure 4), which is indicative of PPARγ engagement”
> “Exposures of about 50 µg·h/mL for area under the curve from time zero to the last measurable concentration (AUC0-τ) and about 7 µg/mL for the maximal concentration (Cmax) resulted in more than 200% increase for the percent change from baseline total adiponectin”
> “Dose-related improvements in insulin, pro-insulin, and insulin resistance were observed with lanifibranor, with a significant reduction in pro-insulin with 1400 mg versus placebo.”
> “Reductions in average and postprandial blood glucose were observed at 1400 mg (Table 2), which were consistent with the PPARγ insulin-sensitizing mechanism”
> “Lanifibranor 800 and 1400 mg showed significant (P<0.05) change from baseline in high-density lipoprotein (HDL) cholesterol and triglycerides compared with placebo (Figure 5 and Table 2)”
> “At Day 28, lanifibranor showed no fluid-retention signals (pedal edema, ankle foot volume, ankle circumference, or body-weight increase) versus placebo, with no changes in hematology, albumin, or brain natriuretic peptide (BNP; Table 3)”

Source: [Francque et al. (2026)](https://inventivapharma.com/wp-content/uploads/MASH-2026-Clinical-PK-PD-poster_LUM-03426_v2.pdf)

| Mean (SD) percent change from baseline at day 28 | Lanifibranor 400 mg (n=17) | Lanifibranor 800 mg (n=15) | Lanifibranor 1400 mg (n=15) | Placebo (n=14) |
| --- | --- | --- | --- | --- |
| Triglycerides | “–19.7 (33.9)” | “–20.8 (23.5)” | “–31.7 (31.2)” | “–5.81 (27.6)” |
| HDL-C | “13.4 (15.3)” | “16.7 (17.2)” | “27.7 (25.9)” | “2.52 (12.2)” |
| Pro-insulin | “–26.7 (35.6)” | “–21.1 (45.0)” | “–37.4 (26.3)” | “–3.28 (49.9)” |

Source: [Francque et al. (2026)](https://inventivapharma.com/wp-content/uploads/MASH-2026-Clinical-PK-PD-poster_LUM-03426_v2.pdf)

| Mean (SD) value reported for change from baseline at day 28 | Lanifibranor 400 mg (n=17) | Lanifibranor 800 mg (n=15) | Lanifibranor 1400 mg (n=15) | Placebo (n=14) |
| --- | --- | --- | --- | --- |
| Ankle foot volume, cm3 | “3.75 (14.51)” | “–5.31 (15.51)” | “3.91 (11.14)” | “–5.42 (11.07)” |
| Body weight change at Day 28, kg | “0.55 (1.97)” | “0.11 (1.72)” | “0.94 (2.05)” | “–0.36 (2.68)” |
| Hemoglobin, g/L | “–5.63 (4.81)” | “–5.04 (6.75)” | “–5.96 (5.55)” | “–3.70 (5.29)” |

Source: [Francque et al. (2026)](https://inventivapharma.com/wp-content/uploads/MASH-2026-Clinical-PK-PD-poster_LUM-03426_v2.pdf)

<a id="topic-2.1.2.6.2-3"></a>

###### Pharmacodynamic biomarkers used for dose selection

> “Doses have been selected based on the available biomarker (adiponectin, HDL cholesterol, triglycerides) results in diabetes type 2 patients (Phase IIa study):”
> “The two doses chosen for the trial demonstrated significant improvement in biomarkers of PPAR α, γ and probably δ in diabetic patients.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.6.2-4"></a>

###### Adiponectin, triglycerides, HDL cholesterol, and diastolic blood pressure after 24 weeks: NATIVE

> “This manuscript reports the results of several secondary objectives of the NATIVE trial, that were prespecified in the protocol and the Statistical Analysis Plan (SAP), including the effect of lanifibranor 1200 mg/day and 800 mg/day versus placebo on CMH markers, evaluated after 24 weeks of treatment (EOT) compared to baseline, and for some markers also at TW4.”
> “Higher increase of adiponectin levels was observed in the lanifibranor 1200 mg (mean fold 4.5) compared to lanifibranor 800 mg (3.8) at EOT, 86% of patients on lanifibranor 800 mg had moderate (58%) or high (29%) increase and 95% of those on 1200 mg had moderate (52%) or high (42%) increase.”
> “With placebo only 10% had moderate, and none high increase (Supplementary Table 6).”
> “Adiponectin is a pleiotropic adipokine and PPARγ downstream mediator, while PPARα activity may affect adiponectin signaling through receptor upregulation”
> “Fasting total serum triglycerides (TG) levels decreased significantly with lanifibranor compared to placebo, with an AMD at EOT of −0.5 mmol/L (95%CI: −0.8 to −0.3, equivalent to −44.3 mg/dL, p < 0.001) with both lanifibranor 1200 mg and 800 mg groups (Table 1).”
> “Fasting high density lipoprotein cholesterol (HDL-C) increased significantly at treatment week 4 (TW4), maintained until EOT: patients receiving lanifibranor 1200 mg and 800 mg had an AMD at EOT of 0.10 mmol/L (95%CI: 0.03 to 0.16, p = 0.003, equivalent to 3.9 mg/dL) and 0.16 mmol/L (95%CI: 0.09 to 0.22, p < 0.001, equivalent to 6.2 mg/dL), respectively (Table 1).”
> “No significant LDL-C change was observed with either lanifibranor dose versus placebo (Table 1, Fig. 1C).”
> “From TW4 and maintained during treatment, diastolic BP (DBP) decreased with both lanifibranor doses (AMD at EOT was −2.5 mmHg [95%CI: −5.5 to 0.6, p = 0.110] with lanifibranor 1200 mg and −3.9 mmHg [95%CI: −6.9 to −0.9, p = 0.012] with 800 mg, [Table 1, Fig. 1I]).”
> “Systolic BP did not change significantly.”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

> “There was a dose-dependent increase in serum adiponectin level, which suggests that there was an improvement in adipose-tissue function.”
> “This improvement in adipose tissue function is most likely the main reason for the observed increase in body weight.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-2.1.2.6.2-5"></a>

###### NT-proBNP, hemoglobin, and the PPARγ class history of edema and heart failure

> “While PPARγ-associated weight gain is thus indicative of maturation of adipose tissue, some contributing effect on fluid retention is suggested by the treatment effect on NT-proBNP.”
> “Past pure PPARγ agonists such as the thiazolidinediones pioglitazone and rosiglitazone are effective for glycemic control and improving IR, but also have been associated with an increased risk of edema and heart failure”
> “There was no clinical evidence for congestion in patients on lanifibranor in NATIVE.”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

> “A reduction in hemoglobin levels was observed in the lanifibranor groups, a finding that is consistent with those in previous reports of other compounds with PPARγ agonism; such a reduction has several potential underlying mechanisms.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-2.1.2.6.2-6"></a>

###### Important risks identified for the PPAR agonist class

> “Clinical experience with medicinal products from the same therapeutic class identified the following important risks:”
> “Hypoglycemia”
> “Peripheral edema”
> “Heart failure”
> “Weight gain”
> “Anemia”
> “Some of these risks have been observed during clinical development with lanifibranor in patients with NASH, including peripheral edema, weight gain and anemia.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.6.2-7"></a>

###### Plasma volume and cardiac effects in rats compared with rosiglitazone, muraglitazar, and tesaglitazar

> “In a 9-week head-to-head comparative study in rats aimed at evaluating side effects of PPAR agonists such as plasma volume expansion and secondary cardiac hypertrophy, or skeletal muscle toxicity, daily doses of lanifibranor up to 1000 mg/kg compared favorably with other PPAR agonists rosiglitazone, muraglitazar and tesaglitazar.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.6.2-8"></a>

###### Hepatic, muscle, and adipose tissue insulin sensitivity by clamp: participants with type 2 diabetes and MASLD

> “In this single-center phase II study, 38 patients with type 2 diabetes and MASLD were randomized 1:1 to receive lanifibranor 800 mg or placebo for 24 weeks.”
> “The main prespecified secondary endpoint was the change in hepatic, muscle and adipose tissue insulin sensitivity using the gold-standard euglycemic hyperinsulinemic clamp technique to measure glucose turnover.”
> “Lanifibranor significantly improved hepatic and peripheral IR (i.e. fasting endogenous [primarily hepatic] glucose production, hepatic IR, and insulin-stimulated muscle glucose disposal or Rd).”
> “Secondary metabolic endpoints also improved (fasting glucose, insulin, HOMA-IR, HbA1c, HDL-C), and adiponectin increased 2.4-fold (all p <0.001).”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-2.1.2.6.2-9"></a>

###### Liver sinusoidal endothelial cell capillarisation in NATIVE liver biopsies

> “We analysed CD34 expression, a marker of LSEC capillarisation, on liver biopsies from patients considered for inclusion in the NATIVE trial at baseline (n = 249), and after 24 weeks of placebo or lanifibranor (n = 173).”
> “In patients with MASH randomised into the NATIVE trial, 24-week treatment with lanifibranor at both dosages had no effect on the density of CD34-positive vessels (Fig. 5A).”
> “Improvement in periportal score was more common in patients treated with lanifibranor than in those treated with placebo, with a dose–response effect (placebo: 7.5%. lanifibranor 800 mg: 18.5%. lanifibranor 1,200 mg: 23.2%. p = 0.025, Fig. 5C).”
> “In both patients and rats with MASLD, lanifibranor treatment was associated with improvement in liver endothelial phenotype.”

Source: [Rautou et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12142333/)

<a id="topic-2.1.2.6.2-10"></a>

###### Portal pressure and fibrosis in cirrhotic rat models

> “TAA-cirrhotic rats receiving lanifibranor showed significantly lower portal pressure compared with vehicle-treated animals (-15%; p = 0.003) without decreasing portal blood flow, indicating improved hepatic vascular resistance.”
> “Moreover, lanifibranor-treated TAA-rats showed decreased ascites, improved LSEC and HSC phenotypes, ameliorated hepatic microvascular function, reduced hepatic inflammation, and significant fibrosis regression (-32%; p = 0.020).”

Source: [Boyer-Diaz et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33278455/)

<a id="topic-2.1.2.6.2-11"></a>

###### Electrocardiographic findings in healthy volunteers and patients with type 2 diabetes

> “In clinical trials performed in healthy volunteers and patients with type 2 diabetes, lanifibranor was safe and well tolerated.”
> “There were no clinically relevant time or dose-related changes on cardiac and muscle markers, liver enzymes or markers of renal function.”
> “The 12-lead electrocardiogram (ECG) did not show clinically significant changes.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

Additional sources: [Sabatini and Gastaldelli (2025)](https://pubmed.ncbi.nlm.nih.gov/40089070/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Clinical pharmacology studies described in the NATIVE protocol

> “Three clinical studies have been conducted in healthy subjects, one study in patients with type 2 diabetes, and one phase II study is ongoing in the treatment of diffuse cutaneous systemic sclerosis.”
> “The objectives of study S337.1.001 were to assess pharmacokinetics, pharmacodynamics, safety and tolerability of lanifibranor after single increasing doses and after multiple increasing doses.”
> “The objectives of study S337.1.005 were to assess the relative bioavailability of lanifibranor oral suspension and capsules (cross-over design), and to assess, in vivo in human, the completeness of excretion, routes and rates of elimination of radioactivity, the metabolic pathways, and identity of lanifibranor metabolites after single administration of 14C-IVA337.”
> “Treatments included single doses of 25 mg to 1000 mg, multiple doses of 150 mg to 1500 mg once daily for 14 consecutive days, and once daily doses of 400, 800, and 1400 mg for 4 weeks.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.6.3-2"></a>

###### Absorption: solubility class and food effect

> “Lanifibranor is considered as a class II compound as regard to the Biopharmaceutics Classification System (BCS) Guidance: high permeability and low solubility.”
> “It was evidenced in all tested species that lanifibranor absorption is dependent on the drug substance form and formulation, leading to a bioavailability in animals from 15% up to >80%.”
> “An enterohepatic recycling was evidenced, and a food effect was observed in human in the presence of high fat breakfast.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.6.3-3"></a>

###### Time to maximum concentration, half-life, dose proportionality, and steady state in humans

> “After oral administration in human, maximum plasma levels (Cmax) of lanifibranor were reached at about 1.0-3.5 h, and terminal plasma elimination half-life was around 10-15 h.”
> “Both Area Under the Curve (AUC) and Cmax increased in a linear but slightly less than dose-proportional manner.”
> “Steady-state lanifibranor concentrations were generally achieved by Day 3 after daily dose administration, with no significant accumulation.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.6.3-4"></a>

###### Less than dose-proportional exposure at 400, 800, and 1400 mg: participants with type 2 diabetes

> “The phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 28-day study evaluated lanifibranor in participants with T2DM who were on metformin monotherapy (Figure 1)”
> “Exposure to lanifibranor increased in a less than dose-proportional manner following oral dosing with 400, 800, and 1400 mg once daily”

Source: [Francque et al. (2026)](https://inventivapharma.com/wp-content/uploads/MASH-2026-Clinical-PK-PD-poster_LUM-03426_v2.pdf)

<a id="topic-2.1.2.6.3-5"></a>

###### Distribution and plasma protein binding

> “The mean apparent volume of distribution Vz/F ranged from 318 to 607 L in healthy subjects.”
> “IVA337 binds very highly to plasma proteins in all tested species (~99.9%) and no affinity to blood cells was observed.”
> “By autoradiography in rat, lanifibranor was shown to be mainly distributed in the excretory organs (liver, kidneys, lungs, gastrointestinal tract) and in placenta in pregnant rats with no affinity for the melanin tissues and with very limited central nervous system penetration.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.6.3-6"></a>

###### Metabolism: circulating parent drug and main human metabolites

> “AUC indicated approximately 23% of the radioactivity in plasma were related to lanifibranor, while 77% were related to its metabolites.”
> “Among metabolites identified in plasma, faeces and urine, the main lanifibranor metabolites observed in human were the acyl glucuronide (IV1197736, with similar exposure to that of the parent compound), a monohydroxylated (IV1537661) and the benzothiazole ring opened lanifibranor derivative (IV1197347).”
> “The three major human metabolites, IV1197736, IV1197347 and IV1537661, were also found devoid of genotoxic potential in a bacterial reverse mutation test and a mammalian cell assay.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.6.3-7"></a>

###### Elimination: faecal excretion in the radiolabeled study

> “Lanifibranor-related radioactivity elimination was mainly faecal (>85%) and the urinary excretion was minor (<7%) with a very low renal clearance.”
> “The excretion was essentially complete after 3 days.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.6.3-8"></a>

###### Supratherapeutic multiple ascending dose study in healthy men

> “The study will be a double-blind, randomized, placebo-controlled, multiple ascending dose study with lanifibranor.”
> “A Double-blind, Placebo-controlled, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Volunteers in Order to Define Lanifibranor (IVA337) Supra-therapeutic Dose in a Multiple Dosing Regimen”
> “The study will consist of up to 3 cohorts of 12 subjects each; therefore, approximately 36 subjects will be included in this study.”
> “All subject will receive first a single dose of 400 mg moxifloxacin, under open-label fasting conditions at Day -8 (assay sensitivity).”
> “Single daily oral dose during 14 days”

Source: [ClinicalTrials.gov NCT03866369](https://clinicaltrials.gov/study/NCT03866369)

<a id="topic-2.1.2.6.3-9"></a>

###### QT/QTc study in 217 healthy participants at 1200 and 2400 mg/day

> “In December 2021, we announced positive results of a clinical QT/QTc study demonstrating lanifibranor had no impact on QT/QTc intervals.”
> “The QT/QTc study was conducted in 217 healthy subjects who were randomized into 4 arms: placebo, lanifibranor 1200mg/day, lanifibranor 2400 mg/day and moxifloxacin 400mg/ day (positive control).”
> “The primary endpoint was electrocardiogram (ECG) and monitored during the first 24 hours.”
> “Results showed that repeated daily administration of lanifibranor dosed at 2-fold higher than anticipated maximal therapeutic dose had no effect on cardiac electrical activity as shown by achieving the pre-specified primary endpoint of demonstrating no prolongation of the QT interval in healthy subjects.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.2.6.3-10"></a>

###### Pharmacokinetic study in healthy Chinese adults at 800 and 1200 mg

> “The primary objective of this study is to evaluate the pharmacokinetic profile of lanifibranor after single dose and multiple doses 800 and 1200 mg in healthy adult Chinese subjects.”
> “Approximately 24 healthy Chinese volunteers, male and female will be recruited and divided into two equal groups (12 subjects per dose).”
> “In Part B, lanifibranor 800 mg is given once daily for 7 consecutive days (followed by 7 days follow-up).”

Source: [ClinicalTrials.gov NCT06126562](https://clinicaltrials.gov/study/NCT06126562)

> “In addition, CTTQ will also conduct in parallel a Phase I clinical pharmacology study to evaluate the pharmacokinetics of the 800mg/day and 1200mg/day doses of lanifibranor in healthy Chinese subjects.”

Source: [Inventiva CTTQ China IND release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-IND-Lanifibranor-China-EN-05-25-2023.pdf)

<a id="topic-2.1.2.6.3-11"></a>

###### Phase 1 study in Japan: 32 participants dosed once daily for 14 days

> “As part of the single-center study, 32 subjects will be separated randomly into four cohorts and will receive lanifibranor once daily for 14 days.”

Source: [Inventiva Hepalys phase 1 initiation release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Phase-1-Hepalys-Pharma-EN-02-20-2025.pdf)

<a id="topic-2.1.2.6.3-12"></a>

###### Bioequivalence study in healthy volunteers

> “A Randomised, Open-Label, Single-Centre, Study to Evaluate the Bioequivalence of Lanifibranor”
> “Human Pharmacology (Phase I)- Bioequivalence Study”

Source: [EU Clinical Trials Information System 2025-524385-18-00](https://euclinicaltrials.eu/ctis-public/view/2025-524385-18-00)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Older adults: exposure in elderly compared with young healthy participants

> “There were a 22% increase in Cmax and 39% increase in AUC of lanifibranor in elderly subjects as compared to young subjects.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

> “Single ascending doses (SAD) of oral lanifibranor were administered to 7 groups of young healthy male participants and 1 group of elderly healthy male and female participants following an interval of at least 6 days between dose levels to ensure safety and tolerability”
> “Aged 60-80 years inclusive.”

Source: [Francque et al. (2026)](https://inventivapharma.com/wp-content/uploads/MASH-2026-Clinical-PK-PD-poster_LUM-03426_v2.pdf)

<a id="topic-2.1.2.8-2"></a>

###### Chinese adults: bridging study and ethnic differences

> “Furthermore, CTTQ has completed a Phase I bridging study and confirmed no significant ethnic differences, thereby paving the way to seek regulatory approval in China based on the results of the NATiV3 trial.”

Source: [Inventiva CTTQ milestone release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-CTTQ-milestone-EN-07-07-2025.pdf)

<a id="topic-2.1.2.8-3"></a>

###### Japanese adults: phase 1 study results

> “In 2025, Hepalys conducted a Phase 1 trial of lanifibranor in Japan. The results of this Phase 1 trial were positive and are expected to support the initiation of a dedicated pivotal trial in patients with MASH in the Hepalys Territory, which is planned to start once the results of NATiV3 are available.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.2.8-4"></a>

###### Renal impairment: minor urinary excretion

> “Lanifibranor-related radioactivity elimination was mainly faecal (>85%) and the urinary excretion was minor (<7%) with a very low renal clearance.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.8-5"></a>

###### Renal impairment: effect on kidney function

> “No effect on kidney function or markers of bone turnover was observed.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-2.1.2.8-6"></a>

###### Renal impairment: renal function eligibility criteria

> “Serum creatinin < 115 µmol/L (1.3 mg/dL) (men) or < 97 µmol/L (1.1 mg/dL) (women) or estimated glomerular filtration rate ≥ 60 mL/min/1.73m2”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

> “Renal impairment measured as eGFR value < 60 mL/min as determined by Modification of Diet in Renal Disease [MDRD]”
> “In Renal Impairment guidances, FDA and EMA recommend expressing GFR in mL/mn because renal clearance of a drug is proportional to individual GFR and not to BSA-standardized GFR.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.8-7"></a>

###### Renal impairment: dedicated pharmacokinetic study

No evidence found.

<a id="topic-2.1.2.8-8"></a>

###### Hepatic impairment: compensated liver disease eligibility criteria

> “Compensated liver disease with the following hematologic and biochemical criteria before randomization:”
> “Platelets > 100 10^9/L (100 10^3/µL)”
> “Albumin > 36 g/L (3.6 g/dL)”
> “INR < 1.4”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.8-9"></a>

###### Hepatic impairment: cirrhosis and abnormal synthetic liver function as exclusion criteria

> “Histologically documented liver cirrhosis (fibrosis stage F4)”
> “Abnormal synthetic liver function as defined by Screening central laboratory evaluation”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.8-10"></a>

###### Hepatic impairment: dedicated pharmacokinetic study

No evidence found.

<a id="topic-2.1.2.8-11"></a>

###### Autoimmune liver or thyroid disease: exclusion added after a suspected unexpected serious adverse reaction

> “Following the Suspected Unexpected Serious Adverse Reaction”
> “in a patient enrolled in the study, Inventiva chose to voluntarily pause screening and randomization of new patients in the NATiV3 trial to implement the recommendations of the independent Data Monitoring Committee”
> “which included liver monitoring every 6 weeks for each patient enrolled in the trial, and amending the protocol to exclude newly screened patients diagnosed or with a predisposition to autoimmune liver and thyroid disease.”

Source: [Inventiva NATiV3 screening resumption release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-screening-update-EN-03-07-2024-final.pdf)

> “Patients with a personal or close family history of autoimmune liver diseases or a personal history of autoimmune thyroid disease may be at a higher risk for this to occur.”
> “Patients with these conditions will not be eligible to enrol in the study.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.8-12"></a>

###### Type 2 diabetes: histologic and glycemic response in participants with diabetes

> “A total of 103 patients who underwent randomization had type 2 diabetes mellitus; the mean age of these patients was 56 years, the mean body-mass index was 33, 62 (60%) were women, 83 (81%) had significant or advanced fibrosis, and 84 (82%) had an NAS of 6 or greater.”
> “The patients with diabetes had improvements in histologic features of NASH that were similar to those in the full analysis population, and they had more pronounced reductions in fasting levels of glucose, insulin, and glycated hemoglobin than those observed in the full analysis population.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-2.1.2.8-13"></a>

###### Prediabetes: participants without type 2 diabetes

> “Among 144 patients without T2D, 47 (33%) had prediabetes.”
> “With prediabetes, FG decreased at EOT to <5.6 mmol/L in 71% (95%CI: 48 to 95, p = 0.009) of patients on lanifibranor 1200 mg, 67% (95%CI: 45 to 88, p = 0.013) on 800 mg versus 11% (95%CI: 0 to 32) on placebo, indicating return to normoglycemia in the majority of lanifibranor-treated patients.”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-2.1.2.8-14"></a>

###### Heart failure: exclusion criteria

> “History of heart failure with reduced left ventricular ejection fraction (LVEF)”
> “Unstable heart failure”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

> “Significant systemic or major illnesses other than liver disease, including congestive heart failure (class C and D of the AHA), unstable coronary artery disease, cerebrovascular disease, pulmonary disease, renal failure, organ transplantation, serious psychiatric disease, malignancy that, in the opinion of the Investigator, would preclude treatment with lanifibranor and/or adequate follow up.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.8-15"></a>

###### Anemia: hemoglobin exclusion threshold

> “Haemoglobin <110 g/L (11 g/dL) for females and <120 g/L (12 g/dL) for males”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.8-16"></a>

###### Pregnancy: placental distribution and reproductive toxicity in animals

> “By autoradiography in rat, lanifibranor was shown to be mainly distributed in the excretory organs (liver, kidneys, lungs, gastrointestinal tract) and in placenta in pregnant rats with no affinity for the melanin tissues and with very limited central nervous system penetration.”
> “No potential risks have been identified from pivotal toxicology studies with lanifibranor in rat and in monkey and segment II reproductive toxicity studies in rats and rabbits.”
> “The safety margins over expected human exposure established in segment II reproductive toxicity studies were 9-fold in rats and 2-fold in rabbits (Table 4).”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.8-17"></a>

###### Pregnancy, breastfeeding, and contraception: trial requirements

> “Pregnancy or lactation or inability to adhere to adequate contraception in women of child-bearing potential.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

> “Negative serum pregnancy test at study Screening for females of childbearing potential confirmed by central laboratory. Females of childbearing potential must practice a consistent and proper use of highly effective method of contraception throughout the study and for 1 month after treatment discontinuation.”
> “Women currently breastfeeding”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.8-18"></a>

###### Ovulation resumption: listed among important risks of the therapeutic class

> “Clinical experience with medicinal products from the same therapeutic class identified the following important risks:”
> “Ovulation resumption”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.8-19"></a>

###### Pediatric population: age criterion of 18 years or older

> “Male or female, aged ≥18 years at the time of signing informed consent”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.8-20"></a>

###### Pediatric population: pediatric studies

No evidence found.

<a id="topic-2.1.2.8-21"></a>

###### Lactose intolerance: lactose monohydrate excipient

> “Have a known hypersensitivity to any of the ingredients or excipients of the IMP including: Lactose monohydrate, Hypromellose, Sodium laurilsulfate, Sodium starch glycolate (type A), Magnesium stearate, Opadry™ II 85F18422”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

> “Rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Lanifibranor

<a id="topic-2.1.2.9.1-1"></a>

###### Metabolizing enzymes in vitro: CYP2C8, CYP2C19, CYP3A4, and UGT isoforms

> “Lanifibranor was observed in vitro to be metabolized either by enzymes of phase I (mainly via CYP isoforms CYP2C8, 2C19 and 3A4) and phase II (mainly via UGT 2B7, 1A1 and 1A3).”
> “No affinity of lanifibranor to uptake or efflux transporters as substrate was evidenced in vitro.”
> “No significant drug-drug interaction was observed with Simvastatin (<2-fold), and no PK/genotype (CYP450 isoenzymes and UGTs isoform) relationship has been identified.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.9.1-2"></a>

###### Strong CYP2C8 inducers and inhibitors: exclusion and washout before treatment

> “Treatment with strong inducers or inhibitors of CYP2C8. When administered chronically, they should be replaced 3 months before Screening visit. If not administered chronically, they should be stopped at least 7 days before treatment initiation (See Section 6.7 and Section 13.2).”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.9.1-3"></a>

###### Strong CYP2C8 inducers and inhibitors: prohibited concomitant medications, with rifampin, gemfibrozil, and clopidogrel as examples

> “CYP2C8 strong inducers (e.g. rifampin). However, if medically necessary, these drugs may be taken for a maximum duration of 3 weeks.”
> “CYP2C8 strong inhibitors, when systemically administered, i.e. by oral, intra-venous or intra-muscular route of administration (e.g. gemfibrozil, clopidogrel).”
> “The antiplatelets agents (incl. low-dose aspirin, ticlopidine, prasugrel, ticagrelor) are allowed (but not clopidogrel).”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.9.1-4"></a>

###### Protocol amendment driven by preliminary results of drug-drug interaction study 337HVPK21014

> “Clarification regarding prohibited medication: treatment with substrates of CYP2B6 and CYP2C8, CYP2C8 strong inducers and CYP2C8 strong inhibitors excluded.”
> “Driven by the preliminary results of the Drug-Drug Interaction study 337HVPK21014”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.9.1-5"></a>

###### Concomitant PPAR agonists: fibrates and thiazolidinediones excluded

> “For obvious reasons, fibrates, as they are PPARα ligands, are not allowed, but dyslipidaemias can be treated with statins, which are allowed.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

> “Treatment with PPAR-gamma agonists (thiazolidinediones [TZDs]) 12 months before screening or historical biopsy.”
> “Concomitant treatment with PPAR-alpha agonists (fibrates)”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.9.1-6"></a>

###### Published results of drug-drug interaction study 337HVPK21014

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Lanifibranor on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### In vitro inhibition of CYP2C8, CYP2C9, CYP2C19, and CYP2B6

> “Lanifibranor was shown to be an inhibitor of CYP2C8 (IC50 4µM, Ki 8µM), CYP2C9 (IC50 8µM, Ki 21µM), CYP2C19 (IC50 25µM) and CYP2B6 (IC50 8µM).”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.9.2-2"></a>

###### In vitro CYP3A4 induction

> “A limited risk of CYP induction could be expected in vivo, as only a slight CYP3A4 induction was observed at 20 µM of lanifibranor in one among all tested donors.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.9.2-3"></a>

###### In vitro inhibition of UGT isoforms and drug transporters

> “Lanifibranor directly inhibited UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, UGT2B15 and UGT2B17 with IC50 values of 13, 26 to 38, 20, 83, 42, 33, 23 and 22 μM, respectively.”
> “Lanifibranor was shown to inhibit uptake and efflux transporters but with relatively high IC50 values: MDR1 (8.5 μM), BCRP (15.2 μM), BSEP (16.8 μM), OCT2 (267 μM), except for OATP1B1/3 (~1 µM).”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.9.2-4"></a>

###### Simvastatin: clinical interaction study S337.1.002

> “The objectives of study S337.1.002 were to study the effect of lanifibranor on the pharmacokinetics of simvastatin and simvastatin acid and to evaluate the pharmacokinetics of the two crystalline anhydrous solid alpha and beta forms of lanifibranor.”
> “No significant drug-drug interaction was observed with Simvastatin (<2-fold), and no PK/genotype (CYP450 isoenzymes and UGTs isoform) relationship has been identified.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.9.2-5"></a>

###### CYP2B6 and CYP2C8 substrates: excluded by protocol amendment

> “Clarification regarding prohibited medication: treatment with substrates of CYP2B6 and CYP2C8, CYP2C8 strong inducers and CYP2C8 strong inhibitors excluded.”
> “Prohibited medications listed in this protocol or that meet the criteria of a prohibited medication by class or substrate may not be used in this study.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.9.2-6"></a>

###### Empagliflozin: combination assessed for interaction on glycemic control

> “Confirm a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control (i.e., conservation of the effect when associated with an SGLT2 inhibitor, no deleterious effect, no negative interaction on glycemic control), while assessing the safety and tolerability”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Doses in NATiV3: 800 mg or 1200 mg once daily

> “Patients will be randomized 1:1:1 to receive lanifibranor (800mg once daily or 1200mg once daily) or placebo.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

> “NATiV3 is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the long-term efficacy and safety of lanifibranor (800mg/daily and 1200mg/daily) in 1009 adult patients with biopsy-proven non-cirrhotic MASH and F2/F3 stage of liver fibrosis.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

| Arm | Registered regimen |
| --- | --- |
| Lanifibranor 800 mg/day | “2 Lanifibranor tablets 400mg + 1 Placebo to match tablet with food” |
| Lanifibranor 1200 mg/day | “3 Lanifibranor tablets 400mg with food” |
| Placebo | “3 Placebo to match tablets with food” |

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.10.1-2"></a>

###### Company description of the dosing regimen

> “Once daily”
> “Two doses: 800mg and 1200mg”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.1.2.10.1-3"></a>

###### Doses of 800 mg and 1200 mg once daily for 24 weeks and the biomarker basis for their selection

> “The evaluated treatment will be as tablets of lanifibranor 400 mg, two doses of lanifibranor (800 and 1200 mg once a day (QD)) versus placebo, i.e. three tablets (lanifibranor or indistinguishable placebo) per os, once daily, for 24 weeks.”
> “Doses have been selected based on the available biomarker (adiponectin, HDL cholesterol, triglycerides) results in diabetes type 2 patients (Phase IIa study):”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

> “Patients were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of oral lanifibranor or placebo once daily for 24 weeks; randomization was stratified according to diabetic status (absence or presence).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-2.1.2.10.1-4"></a>

###### Daily dose of 800 mg as 2 tablets of 400 mg for 24 weeks

> “Tablets of lanifibranor 400 mg, administered on a daily dose of 800 mg lanifibranor or placebo, i.e., 2 tablets of 400 mg/placebo orally once daily (QD) during breakfast, for a total of 24 weeks”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.10.1-5"></a>

###### Single-center phase 2 study in type 2 diabetes and MASLD: 800 mg

> “In this single-center phase II study, 38 patients with type 2 diabetes and MASLD were randomized 1:1 to receive lanifibranor 800 mg or placebo for 24 weeks.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-2.1.2.10.1-6"></a>

###### Dose modification and treatment interruption in the trials

> “Dosage modifications are not permitted.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

> “No lanifibranor or empagliflozin dose adjustment is allowed in the study.”
> “Interruption of the IMP(s) due to AEs is allowed as per the Investigator’s discretion and medical judgment for a maximum of 15 days, and should occur only once during the 24-week treatment period, taking into account that the IMP(s) will have to be administered during the last 15 days before Week 24.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.10.1-7"></a>

###### Commercial dose and dose adjustment for special populations

No evidence found.

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Oral film-coated 400 mg immediate-release tablet with a breakline

> “The Investigational Medicinal Product is a white to off-white bi-convex tablet, weighing approximately 927 mg and showing a breakline to facilitate the administration to patients.”
> “The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.10.2-2"></a>

###### Administration of 3 tablets with food in the morning

> “To improve bioavailability, drug intake is combined with food.”
> “They are instructed to take morning 3 tablets with food, i.e. one tablet from each of the containers A, B, and C.”
> “Take 3 tablets by mouth once daily with food (morning), one from bottle A, one from bottle B, and one from bottle C.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.10.2-3"></a>

###### Administration with breakfast at site visits

> “Because patients will attend all site visits while fasting, the study treatment will be administrated at the investigational site with breakfast and the IMP intake will occur under study staff supervision and timing will be collected.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.10.2-4"></a>

###### Storage conditions for the investigational tablets

> “Store in original container at 25°C or below. Do not freeze.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

> “The IMP should be stored at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). It should be stored in the original containers (i.e., bottles).”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Manufacturing by third parties for clinical and commercial supply

> “We rely completely on third parties to manufacture our pre-clinical and clinical drug supplies and we intend to rely on third parties to produce commercial supplies of any approved product candidate.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.2.11-2"></a>

###### U.S. commercial infrastructure, pricing, and reimbursement still to be established

> “Furthermore, even if we or our current or future collaborators obtain regulatory approval for lanifibranor, we will still need to develop a commercial infrastructure, or otherwise develop relationships with collaborators to commercialize, establish a commercially viable pricing structure and obtain coverage and adequate reimbursement from third-party payors, including any government healthcare programs.”
> “We may collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.2.11-3"></a>

###### Pre-commercial preparation, 2025 to 2026

> “Our regulatory and commercial infrastructure is advancing in lockstep, to position us to act with speed and conviction once we have the trial data.”

Source: [Inventiva full year 2025 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Full-Year-results-2025-EN-03-30-2026-1.pdf)

> “Marketing and business development expenses amounted to €2.6 million for the first half of 2026, compared to €0.7 million for the same period in 2025, primarily reflecting increased personnel costs and expenses related to preparations for the potential commercial development of lanifibranor, if approved.”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

<a id="topic-2.1.2.11-4"></a>

###### Company market access goal: monotherapy and combination use

> “Demonstrate lanifibranor’s value as monotherapy and in combination to secure broad and rapid market access”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.1.2.11-5"></a>

###### Commercialization rights in Greater China: CTTQ

> “Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ will oversee the development and commercialization of lanifibranor in Greater China”

Source: [Inventiva Sino Biopharm license release (2022)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-Sino-Biopharm-Licensing-Agreement-EN-21-09-2022-1.pdf)

> “On September 21, 2022, we entered into the CTTQ License Agreement with CTTQ to develop and commercialize lanifibranor in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan, or each a CTTQ Region.”
> “Under the terms of the CTTQ License Agreement, CTTQ has the sole right and is solely responsible for all aspects of the commercialization of the Licensed Products in the CTTQ Territory, subject to regulatory approval, including (i) developing and executing a commercial launch and pre-launch plan, (ii) negotiating the price and reimbursement statuses of the Licensed Products with applicable governmental authorities”
> “We shall own and retain all right, title and interest in and to all trademarks, logos and trade names associate with any Licensed Product worldwide and have the sole right to register and maintain all such trademarks, logos and trade names worldwide.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

> “Revenue recognized in the first half of 2025 was attributable to the 2022 License Agreement with Chia Tai Tianging Pharmaceutical Group Co., Ltd. (as amended and assigned to Chia Tai Tianging (Guangzhou) Co., Ltd).”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

<a id="topic-2.1.2.11-6"></a>

###### Commercialization rights in Japan and South Korea: Hepalys Pharma

> “Hepalys Pharma, Inc., a company incorporated in Japan and incubated by Catalys Pacific, have entered into an exclusive licensing agreement (the “Agreement”) to develop and commercialize Inventiva’s proprietary drug candidate lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH) in Japan and South Korea.”

Source: [Inventiva Hepalys license release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Japan-Licensing-Agreement-EN-09-20-2023-1.pdf)

<a id="topic-2.1.2.11-7"></a>

###### Specialty pharmacy or distribution network

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Background therapies permitted at a stable dose in NATiV3: GLP-1 receptor agonists, SGLT2 inhibitors, vitamin E, and statins

> “Antidiabetic treatment if glucagon-like peptide-1 receptor agonists (GLP1 receptor agonists) or sodium-glucose co-transporter-2 inhibitors (SGLT2 inhibitors): for at least 3 months”
> “Statins: for at least 3 months”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

> “Patients under a stable dose of GLP-1-RA for at least 3 months prior to screening can be included”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.1.2.12-2"></a>

###### Therapies excluded in NATiV3: approved NASH or obesity treatment, insulin, thiazolidinediones, and fibrates

> “Patient currently receiving any approved treatment for NASH or obesity”
> “Current treatment with insulin”
> “Treatment with PPAR-gamma agonists (thiazolidinediones [TZDs]) 12 months before screening or historical biopsy.”
> “Concomitant treatment with PPAR-alpha agonists (fibrates)”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.12-3"></a>

###### Company position: NATiV3 assesses lanifibranor with GLP-1 receptor agonists and SGLT2 inhibitors

> “NATiV3 uniquely positioned to assess lanifibranor in combination with GLP-1 and SGLT2 inhibitors: Reflecting the evolving treatment paradigm and supporting its potential as a backbone therapy.”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.1.2.12-4"></a>

###### Combination with empagliflozin in LEGEND: no further study planned

> “The LEGEND trial was intended to demonstrate proof of concept and the potential additional benefits of the combination between lanifibranor and empagliflozin and the possibility to address the weight gain observed in some patients treated with lanifibranor alone.”
> “We do not expect to further study the combination of lanifibranor and empagliflozin but expect to include the safety data from the LEGEND trial in a potential submission for marketing approval.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Lanifibranor on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### HEDIS Glycemic Status Assessment for Patients With Diabetes (GSD)

> “The percentage of persons 18–75 years of age with diabetes (type 1 or type 2) whose most recent glycemic status (hemoglobin A1c [HbA1c] or glucose management indicator [GMI]) was at the following levels during the measurement period:”

Source: [NCQA](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/glycemic-status-assessment-for-patients-with-diabetes-gsd/)

<a id="topic-2.1.2.13-2"></a>

###### HbA1c change with lanifibranor in participants with MASH and type 2 diabetes, LEGEND interim analysis

> “As planned per protocol, the interim analysis was done once half of the 63 planned randomized patients with MASH completed the 24-week treatment period or prematurely discontinued from treatment.”
> “The study achieved the primary efficacy endpoint with an absolute reduction in Hemoglobin A1c, or HbA1c, of 1.14% and 1.59% in patients with MASH and T2D treated with lanifibranor (800mg daily) or in combination with empagliflozin (10mg daily) at week 24 compared to an increase of 0.26% observed in the placebo arm.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.2.13-3"></a>

###### Product-specific effect on quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Lanifibranor: company statement of its position among PPAR agonists

> “Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ.”
> “While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan-PPAR agonist in clinical development for the treatment of MASH.”

Source: [Inventiva AASLD 2026 abstracts release (2026)](https://inventivapharma.com/wp-content/uploads/INVENTIVA-AALSD-Abstracts-PR-EN-10.6.2026-1.pdf)

<a id="topic-2.1.2.14-2"></a>

###### Approved and phase 3 competitors named by Inventiva in its annual report

> “In March 2024, Madrigal received FDA approval of Rezdiffra for the treatment of patients with MASH with moderate to advanced liver fibrosis and received a conditional marketing authorization from the European Commission in August 2025.”
> “For example, Boehringer Ingelheim, Eli Lilly, Akero Therapeutics (a subsidiary of Novo Nordisk), GSK and Roche and 89bio are also evaluating their respective investigational MASH medications in Phase 3 clinical trials in patients with non-cirrhotic MASH and in patients with cirrhotic MASH.”
> “Other companies, including Sagimet, Boston Pharmaceuticals, Altimmune, AstraZeneca, Eli Lilly, NorthSea, Terns, Viking, BMS, Pfizer, and Regeneron and Gilead Sciences have drug candidates for the treatment of MASH that are in less advanced clinical or pre-clinical development stages.”
> “We may lose lanifibranor’s Fast Track Designation if the FDA concludes that Rezdiffra and/or Wegovy addresses the unmet medical need for patients with MASH.”
> “For example, lanifibranor has caused weight gain in certain patients and the potential for this side effect may, if approved, lead patients to prefer a GLP-1 agent for the treatment of MASH.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.2.14-3"></a>

###### Lanifibranor with GLP-1 receptor agonists: company presentation of potential synergy

> “Potential synergy between pan-PPAR and GLP-1 reduces metabolic burden and fibrogenic drive”
> “Weight loss-independent PPAR benefit with weight-dependent mechanism of GLP-1s”
> “MASH drug selection will be on this background”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.1.2.14-4"></a>

###### Resmetirom (REZDIFFRA): indication and accelerated approval

> “REZDIFFRA® is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).”
> “This indication is approved under accelerated approval based on improvement of MASH and fibrosis [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.”
> “Avoid use of REZDIFFRA in patients with decompensated cirrhosis”

Source: [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

###### Resmetirom: mechanism of action, partial thyroid hormone receptor-beta agonist

> “Resmetirom is a partial agonist of the thyroid hormone receptor-beta (THR-β).”
> “THR-β is the major form of THR in the liver, and stimulation of THR-β in the liver reduces intrahepatic triglycerides, whereas actions of thyroid hormone outside the liver, including in heart and bone, are largely mediated through THR-α.”

Source: [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf)

<a id="topic-2.1.2.14-6"></a>

###### Resmetirom: oral once-daily dosing based on body weight

> “The recommended dosage of REZDIFFRA is based on actual body weight.”
> “<100 kg, the recommended dosage is 80 mg orally once daily.”
> “≥100 kg, the recommended dosage is 100 mg orally once daily.”
> “Concomitant use of REZDIFFRA with strong CYP2C8 inhibitors (e.g., gemfibrozil) is not recommended”

Source: [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf)

<a id="topic-2.1.2.14-7"></a>

###### Resmetirom: month 12 histology in Trial 1 (NCT03900429), 888 F2 and F3 participants, missing biopsy counted as nonresponse

> “The efficacy of REZDIFFRA was evaluated based on an efficacy analysis at Month 12 in Trial 1 (NCT03900429), a 54-month, randomized, double-blind, placebo-controlled trial.”
> “The month 12 analysis included 888 F2 and F3 (at eligibility) patients randomized 1:1:1 to receive placebo (n = 294), REZDIFFRA 80 mg once daily (n = 298), or REZDIFFRA 100 mg once daily (n = 296), in addition to lifestyle counseling on nutrition and exercise.”
> “Two pathologists, Pathologist A and Pathologist B, independently read the liver biopsies for each patient.”
> “Patients with missing liver biopsy at Month 12 are considered a non-responder.”

Source: [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf)

| Endpoint at month 12 | Placebo (N=294) | REZDIFFRA 80 mg (N=298) | REZDIFFRA 100 mg (N=296) |
| --- | --- | --- | --- |
| Resolution of steatohepatitis and no worsening of liver fibrosis, Pathologist A (%) | “13” | “27” | “36” |
| Difference vs. placebo (95% CI), Pathologist A | Not applicable | “14 (8, 20)” | “23 (16, 30)” |
| Resolution of steatohepatitis and no worsening of liver fibrosis, Pathologist B (%) | “9” | “26” | “24” |
| Difference vs. placebo (95% CI), Pathologist B | Not applicable | “17 (11, 23)” | “15 (9, 21)” |
| Improvement in liver fibrosis and no worsening of steatohepatitis, Pathologist A (%) | “15” | “23” | “28” |
| Difference vs. placebo (95% CI), Pathologist A | Not applicable | “8 (2, 14)” | “13 (7, 20)” |
| Improvement in liver fibrosis and no worsening of steatohepatitis, Pathologist B (%) | “13” | “23” | “24” |
| Difference vs. placebo (95% CI), Pathologist B | Not applicable | “11 (5, 17)” | “11 (5, 17)” |

Source: [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

###### Resmetirom: MAESTRO-NASH week 52 primary analysis population of 966 participants

> “We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]).”
> “Overall, 966 patients formed the primary analysis population (322 in the 80-mg resmetirom group, 323 in the 100-mg resmetirom group, and 321 in the placebo group). NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group and 29.9% of those in the 100-mg resmetirom group, as compared with 9.7% of those in the placebo group (P<0.001 for both comparisons with placebo). Fibrosis improvement by at least one stage with no worsening of the NAFLD activity score was achieved in 24.2% of the patients in the 80-mg resmetirom group and 25.9% of those in the 100-mg resmetirom group, as compared with 14.2% of those in the placebo group (P<0.001 for both comparisons with placebo).”
> “Diarrhea and nausea were more frequent with resmetirom than with placebo.”
> “(Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.)”

Source: [Harrison et al. (2024)](https://www.nejm.org/doi/full/10.1056/NEJMoa2309000)

<a id="topic-2.1.2.14-9"></a>

###### Semaglutide (WEGOVY): MASH indication and accelerated approval

> “For the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis [see Clinical Studies (14.4)]. Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial.”

Source: [Novo Nordisk WEGOVY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf)

<a id="topic-2.1.2.14-10"></a>

###### Semaglutide: mechanism of action, GLP-1 receptor agonist

> “Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.”
> “For treatment of MASH in humans, the precise mechanism of action of semaglutide is not fully understood and may involve multiple pathways mediated by weight loss and other factors.”

Source: [Novo Nordisk WEGOVY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf)

<a id="topic-2.1.2.14-11"></a>

###### Semaglutide: subcutaneous once-weekly maintenance dosing for MASH

> “The recommended maintenance dosage of WEGOVY injection for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults is 2.4 mg injected subcutaneously once weekly. If patients do not tolerate the maintenance dosage of 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly.”

Source: [Novo Nordisk WEGOVY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf)

<a id="topic-2.1.2.14-12"></a>

###### Semaglutide: week 72 histology in Study 11 (NCT04822181), 800 F2 and F3 participants, reference-based multiple imputation

> “The efficacy of WEGOVY injection was evaluated based on an efficacy analysis at Week 72 in Study 11 (NCT#04822181), a 240-week, randomized, double-blind, placebo-controlled trial.”
> “The Week 72 analysis included 800 F2 and F3 (at eligibility) patients randomized 1:2 to receive placebo (n=266) or WEGOVY once weekly (n=534), in addition to standard of care for cardiometabolic comorbidities and healthy lifestyle counseling.”
> “Estimated using pooled Mantel-Haenszel (MH) estimates stratified by baseline type 2 diabetes status (presence or absence) and baseline fibrosis stage (F2 or F3) with missing data handled by reference-based multiple imputation”
> “Patients treated with WEGOVY injection (mean baseline body weight 95.4 kg) achieved an average of 10.5% weight loss from baseline at Week 72, and patients treated with placebo (mean baseline weight 97.6 kg) achieved an average of 2% weight loss from baseline at Week 72”

Source: [Novo Nordisk WEGOVY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf)

| Endpoint at week 72 | Placebo (N=266) | WEGOVY injection (N=534) | Difference vs. placebo (95% CI) |
| --- | --- | --- | --- |
| Resolution of steatohepatitis and no worsening of liver fibrosis, response rate (%) | “34” | “63” | “29 (21, 36)” |
| Improvement in liver fibrosis and no worsening of steatohepatitis, response rate (%) | “22” | “37” | “14 (8, 21)” |
| Resolution of steatohepatitis and improvement in liver fibrosis, response rate (%) | “16” | “33” | “17 (10, 23)” |

Source: [Novo Nordisk WEGOVY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf)

<a id="topic-2.1.2.14-13"></a>

###### Semaglutide: phase 3 part 1 interim analysis at week 72 in the first 800 of 1197 participants

> “In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks. The results of a planned interim analysis conducted at week 72 involving the first 800 patients are reported here (part 1).”
> “Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001). A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001).”
> “Gastrointestinal adverse events were more common in the semaglutide group.”

Source: [Sanyal et al. (2025)](https://www.nejm.org/doi/full/10.1056/NEJMoa2413258)

<a id="topic-2.1.2.14-14"></a>

###### Efruxifermin: acquisition of Akero Therapeutics by Novo Nordisk completed in December 2025

> “Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025”
> “today announced that Novo Nordisk’s acquisition of Akero, announced on 9 October 2025, has been completed.”
> “At the completion of the transaction, Akero became a wholly owned subsidiary of Novo Nordisk.”
> “Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease).”

Source: [Novo Nordisk Akero acquisition completion release (2025)](https://akerotx.com/wp-content/uploads/2025/12/pr251209-akero-closing.pdf)

<a id="topic-2.1.2.14-15"></a>

###### Efruxifermin: phase 3 trial in F2 or F3 MASH (NCT06215716), registry record

> “This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of efruxifermin (EFX) in subjects with non-cirrhotic nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stage 2 or 3 (F2 or F3).”

Source: [ClinicalTrials.gov NCT06215716](https://clinicaltrials.gov/study/NCT06215716)

| Field | Quoted record |
| --- | --- |
| Sponsor | “Akero Therapeutics, Inc” |
| Status | “Recruiting” |
| Study start (actual) | “2023-12-01” |
| Primary completion (estimated) | “2033-02” |
| Enrollment (estimated) | “1650” |
| Primary outcome, cohort 1 | “Cohort 1 Only: Resolution of NASH/MASH and a ≥ 1 stage improvement in fibrosis” |
| Primary outcome | “Event-free survival” |

Source: [ClinicalTrials.gov NCT06215716](https://clinicaltrials.gov/study/NCT06215716)

<a id="topic-2.1.2.14-16"></a>

###### Efruxifermin: HARMONY phase 2b week 24 histology, liver biopsy analysis set and full analysis set

> “HARMONY is a multicentre, randomised, double-blind, placebo-controlled, 96-week, phase 2b trial that was initiated at 41 clinics in the USA.”
> “In the LBAS (n=113), eight (20%) of 41 patients in the placebo group had an improvement in fibrosis of at least 1 stage and no worsening of NASH by week 24 versus 15 (39%) of 38 patients in the efruxifermin 28 mg group (risk ratio [RR] 2·3 [95% CI 1·1-4·8]; p=0·025) and 14 (41%) of 34 patients in the efruxifermin 50 mg group (2·2 [1·0-5·0]; p=0·036).”
> “Based on the FAS (n=128), eight (19%) of 43 patients in the placebo group met this endpoint versus 15 (36%) of 42 in the efruxifermin 28 mg group (RR 2·2 [95% CI 1·0-4·8]; p=0·033) and 14 (33%) of 43 in the efruxifermin 50 mg group (1·9 [0·8-4·3]; p=0·123).”

Source: [Harrison et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37802088/)

<a id="topic-2.1.2.14-17"></a>

###### Pegozafermin: acquisition of 89bio by Roche, agreement in September 2025 and tender offer completed in October 2025

> “Basel, 18 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire 89bio, Inc. (Nasdaq: ETNB), a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases.”
> “89bio’s pegozafermin is a FGF21 analog currently in late-stage development for MASH in moderate and severe fibrotic patients (F2 and F3 stages) as well as cirrhotic patients (F4 stage).”
> “Roche to acquire 89bio for US$14.50 per share in cash at closing, representing a total equity value of approximately US$2.4 billion.”

Source: [Roche 89bio merger agreement release (2025)](https://www.roche.com/media/releases/med-cor-2025-09-18)

> “Basel, 30 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche’s wholly owned subsidiary Bluefin Merger Subsidiary, Inc., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of 89bio, Inc.”
> “Following completion of the merger, 89bio will become a wholly owned subsidiary of Roche, and 89bio’s shares will cease to be traded on the Nasdaq Global Market.”
> “89bio is in Phase 3 trials for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis, including patients with compensated cirrhosis, and severe hypertriglyceridemia (SHTG).”

Source: [Roche 89bio tender offer release (2025)](https://www.roche.com/media/releases/med-cor-2025-10-30)

<a id="topic-2.1.2.14-18"></a>

###### Pegozafermin: ENLIGHTEN-Fibrosis phase 3 trial (NCT06318169), registry record

> “The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.”

Source: [ClinicalTrials.gov NCT06318169](https://clinicaltrials.gov/study/NCT06318169)

| Field | Quoted record |
| --- | --- |
| Sponsor | “Hoffmann-La Roche” |
| Status | “Recruiting” |
| Study start (actual) | “2024-03-13” |
| Primary completion (estimated) | “2029-02” |
| Enrollment (estimated) | “1350” |
| Primary outcome | “Number of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of Steatohepatitis at Week 52” |
| Primary outcome | “Number of Participants With Resolution of Steatohepatitis Without Worsening of Fibrosis at Week 52” |
| Primary outcome | “Time to First Occurrence of Disease Progression” |

Source: [ClinicalTrials.gov NCT06318169](https://clinicaltrials.gov/study/NCT06318169)

<a id="topic-2.1.2.14-19"></a>

###### Pegozafermin: ENLIVEN phase 2b week 24 histology, full analysis population with multiple imputation

> “In this phase 2b, multicenter, double-blind, 24-week, randomized, placebo-controlled trial, we randomly assigned patients with biopsy-confirmed NASH and stage F2 or F3 (moderate or severe) fibrosis to receive subcutaneous pegozafermin at a dose of 15 mg or 30 mg weekly or 44 mg once every 2 weeks or placebo weekly or every 2 weeks.”
> “Among the 222 patients who underwent randomization, 219 received pegozafermin or placebo. The percentage of patients who met the criteria for fibrosis improvement was 7% in the pooled placebo group, 22% in the 15-mg pegozafermin group (difference vs. placebo, 14 percentage points; 95% confidence interval [CI], −9 to 38), 26% in the 30-mg pegozafermin group (difference, 19 percentage points; 95% CI, 5 to 32; P = 0.009), and 27% in the 44-mg pegozafermin group (difference, 20 percentage points; 95% CI, 5 to 35; P = 0.008). The percentage of patients who met the criteria for NASH resolution was 2% in the placebo group, 37% in the 15-mg pegozafermin group (difference vs. placebo, 35 percentage points; 95% CI, 10 to 59), 23% in the 30-mg pegozafermin group (difference, 21 percentage points; 95% CI, 9 to 33), and 26% in the 44-mg pegozafermin group (difference, 24 percentage points; 95% CI, 10 to 37).”
> “Missing end-point data (for 28 patients) were imputed with the use of multiple imputation by means of logistic regression with all collected outcomes. The full analysis population included all the enrolled patients who had undergone randomization and received at least one dose of pegozafermin or placebo and who had confirmed fibrosis stage F2 or F3 (indicating moderate or severe fibrosis) and a nonalcoholic fatty liver disease activity score of at least 4 at baseline, as assessed on independent review by a three-pathologist panel.”

Source: [Loomba et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10718287/)

<a id="topic-2.1.2.14-20"></a>

###### Efimosfermin alfa (GSK): once-monthly FGF21 analog in phase 3, FDA Breakthrough Therapy and EMA PRIME designations in April 2026

> “27 April 2026”
> “GSK plc (LSE/NYSE: GSK) today announced that efimosfermin, a once-monthly investigational liver therapy, has been granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) and Priority Medicines (PRIME) Designation by the European Medicines Agency (EMA) for the treatment of MASH.”
> “Efimosfermin is currently in phase III with the ZENITH-1 and ZENITH-2 trials investigating efficacy and safety in MASH patients with F2/F3 fibrosis. Phase III trials in MASH patients with F4 fibrosis are expected to start this year.”
> “Efimosfermin is an investigational, once-monthly subcutaneous injection of a long-acting variant of FGF21 that is designed to regulate key metabolic pathways to decrease liver fat, ameliorate liver inflammation, and reverse liver fibrosis in patients with MASH.”

Source: [GSK efimosfermin Breakthrough Therapy and PRIME designation release (2026)](https://www.gsk.com/en-gb/media/press-releases/gsk-s-investigational-liver-therapy-efimosfermin-receives-us-fda-breakthrough-therapy/)

<a id="topic-2.1.2.14-21"></a>

###### Efimosfermin alfa: ZENITH-1 phase 3 trial in F2 or F3 MASH (NCT07221227), registry record

> “The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.”

Source: [ClinicalTrials.gov NCT07221227](https://clinicaltrials.gov/study/NCT07221227)

| Field | Quoted record |
| --- | --- |
| Sponsor | “GlaxoSmithKline” |
| Status | “Recruiting” |
| Study start (actual) | “2025-10-24” |
| Primary completion (estimated) | “2028-03-29” |
| Enrollment (estimated) | “1200” |
| Primary outcome | “Proportion of participants experiencing improvement in fibrosis by >=1 stage and no worsening of steatohepatitis at Week 52” |
| Primary outcome | “Time from randomization to an adjudicated composite liver-related clinical outcome” |

Source: [ClinicalTrials.gov NCT07221227](https://clinicaltrials.gov/study/NCT07221227)

<a id="topic-2.1.2.14-22"></a>

###### Efimosfermin alfa: phase 2 trial in F2 or F3 MASH with a safety primary endpoint at week 24

> “Participants were randomly assigned 1:1 to efimosfermin 300 mg or placebo administered by subcutaneous injection every 4 weeks (Q4W) over 24 weeks, stratified by MASH fibrosis stage (F2 vs F3 stage).”
> “The primary endpoint was safety and tolerability (ie, treatment-emergent adverse events, changes from baseline to week 24 in blood pressure and heart rate, and the incidence of grade 3 and grade 4 laboratory abnormalities at week 24), analysed in all participants who received at least one dose.”
> “Between May 4, 2023, and March 22, 2024, of 1171 participants screened, 84 participants were randomly assigned to efimosfermin 300 mg Q4W (n=43) or placebo (n=41)”
> “Adverse events were reported in 29 (67%) of 43 participants receiving efimosfermin and 22 (55%) of 40 receiving placebo.”

Source: [Noureddin et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41655584/)

<a id="topic-2.1.2.14-23"></a>

###### Survodutide: LIVERAGE phase 3 trial in noncirrhotic F2 to F3 MASH (NCT06632444), registry record

> “A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase III Trial Evaluating Long-term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants With Noncirrhotic Non-alcoholic Steatohepatitis/Metabolic Dysfunction-associated Steatohepatitis (NASH/MASH) and (F2) - (F3) Stage of Liver Fibrosis”

Source: [ClinicalTrials.gov NCT06632444](https://clinicaltrials.gov/study/NCT06632444)

| Field | Quoted record |
| --- | --- |
| Sponsor | “Boehringer Ingelheim” |
| Status | “Recruiting” |
| Study start (actual) | “2024-10-14” |
| Primary completion (estimated) | “2031-12-27” |
| Enrollment (estimated) | “1800” |
| Primary outcome, part 1 | “Part 1: Resolution of MASH without worsening of liver fibrosis on MASH Clinical Research Network (CRN) fibrosis score” |
| Primary outcome, part 1 | “Part 1: At least a 1-point improvement in fibrosis stage with no worsening of MASH” |

Source: [ClinicalTrials.gov NCT06632444](https://clinicaltrials.gov/study/NCT06632444)

<a id="topic-2.1.2.14-24"></a>

###### Survodutide: phase 2 week 48 histology in F1 to F3 MASH, 293 participants who received at least one dose

> “In this 48-week, phase 2 trial, we randomly assigned adults with biopsy-confirmed MASH and fibrosis stage F1 through F3 in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of survodutide at a dose of 2.4, 4.8, or 6.0 mg or placebo.”
> “A total of 293 randomly assigned participants received at least one dose of survodutide or placebo. Improvement in MASH with no worsening of fibrosis occurred in 47% of the participants in the survodutide 2.4-mg group, 62% of those in the 4.8-mg group, and 43% of those in the 6.0-mg group, as compared with 14% of those in the placebo group (P<0.001 for the quadratic dose-response curve as best-fitting model).”
> “improvement in fibrosis by at least one stage occurred in 34%, 36%, 34%, and 22%, respectively.”
> “Adverse events that were more frequent with survodutide than with placebo included nausea (66% vs. 23%), diarrhea (49% vs. 23%), and vomiting (41% vs. 4%)”

Source: [Sanyal et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38847460/)

<a id="topic-2.1.2.14-25"></a>

###### Tirzepatide: SYNERGY-Outcomes phase 3 master protocol in high-risk MASLD selected by noninvasive tests (NCT07165028), registry record

> “The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO.”

Source: [ClinicalTrials.gov NCT07165028](https://clinicaltrials.gov/study/NCT07165028)

| Field | Quoted record |
| --- | --- |
| Sponsor | “Eli Lilly and Company” |
| Status | “Recruiting” |
| Study start (actual) | “2025-10-15” |
| Primary completion (estimated) | “2030-08” |
| Enrollment (estimated) | “4500” |
| Primary outcome | “Time to First Occurrence of Any Component of the Composite Endpoint for Major Adverse Liver Outcomes (MALO)” |

Source: [ClinicalTrials.gov NCT07165028](https://clinicaltrials.gov/study/NCT07165028)

<a id="topic-2.1.2.14-26"></a>

###### Tirzepatide: SYNERGY-NASH phase 2 week 52 histology in F2 or F3 MASH, 190 randomized with missing biopsies imputed

> “We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks.”
> “Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group. The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons). The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42).”
> “(Funded by Eli Lilly; SYNERGY-NASH ClinicalTrials.gov number, NCT04166773.)”

Source: [Loomba et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38856224/)

<a id="topic-2.1.2.14-27"></a>

###### Pemvidutide: PERFORMA phase 3 trial in F2 to F3 MASH initiated in August 2026

> “Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on serious liver diseases, today announced that the company has begun enrolling patients in the PERFORMA Phase 3 trial evaluating the efficacy and safety of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH).”
> “The 52-week data readout from the trial is anticipated in 2029.”
> “The PERFORMA Phase 3 trial, a global, randomized, double-blind, placebo-controlled, parallel-group study of pemvidutide in patients with MASH was initiated in August 2026.”
> “The study includes two parallel cohorts; Cohort 1 will enroll approximately 990 patients and is designed to support the accelerated approval pathway based on a biopsy-assessed primary efficacy endpoint of MASH resolution and/or fibrosis improvement at 52 weeks. A second cohort will enroll approximately 800 patients with fibrosis as evidenced through non-invasive tests (NITs) to add to the safety dataset.”

Source: [Altimmune PERFORMA initiation release (2026)](https://altimmune.gcs-web.com/node/17931)

| Field | Quoted record |
| --- | --- |
| Sponsor | “Altimmune, Inc.” |
| Status | “Recruiting” |
| Study start (actual) | “2026-07-30” |
| Primary completion (estimated) | “2028-12” |
| Enrollment (estimated) | “1800” |
| Arms | “Pemvidutide 1.8 mg” |
| Arms | “Pemvidutide 2.4 mg” |

Source: [ClinicalTrials.gov NCT07795164](https://clinicaltrials.gov/study/NCT07795164)

<a id="topic-2.1.2.14-28"></a>

###### Pemvidutide: IMPACT phase 2b week 24 histology in F2 or F3 MASH, intention-to-treat population

> “IMPACT is an ongoing 48-week international, randomised, double-blind, placebo-controlled, phase 2b trial in patients with biopsy-confirmed MASH and fibrosis stage F2 or F3.”
> “The dual primary endpoints were MASH resolution without worsening of fibrosis or at least one stage liver fibrosis improvement without worsening of MASH at 24 weeks in the intention-to-treat population.”
> “MASH resolution without fibrosis worsening was observed in 18 (20%) of 86 patients in the placebo group, 24 (58%) of 41 patients in the 1·2 mg pemvidutide group (difference of 38% [95% CI 21-56]; p<0·0001), and 45 (52%) of 85 patients in the 1·8 mg pemvidutide group (difference of 32% [95% CI 19-46]; p<0·0001). Fibrosis improvement without worsening of MASH was observed in 24 (28%) of 86 patients in the placebo group, 13 (33%) of 41 patients in the 1·2 mg pemvidutide group (difference of 5% [95% CI -13 to 22]; p=0·59), and 30 (36%) of 85 patients in the 1·8 mg pemvidutide group (difference of 8% [95% CI -6 to 22]; p=0·27).”
> “Pemvidutide treatment met the primary endpoint of MASH resolution without worsening of fibrosis at 24 weeks but did not meet the other primary endpoint of fibrosis improvement without worsening of MASH at this timepoint.”

Source: [Noureddin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41237796/)

<a id="topic-2.1.2.14-29"></a>

###### Denifanstat: phase 3 FASCINATE-3 trial withdrawn and further MASH development deferred pending non-dilutive financing

| Field | Quoted record |
| --- | --- |
| Sponsor | “Sagimet Biosciences Inc.” |
| Status | “Withdrawn” |
| Why stopped | “Business decision” |
| Enrollment (actual) | “0” |

Source: [ClinicalTrials.gov NCT06594523](https://clinicaltrials.gov/study/NCT06594523)

> “Further MASH development to be undertaken only upon securing non-dilutive funding”
> “The Company anticipates that the denifanstat and resmetirom combination program will be ready to advance into Phase 2 in the second half of 2026. The Company will undertake no further clinical development in MASH until non-dilutive financing is achieved.”

Source: [Sagimet Biosciences strategic and corporate updates release (2026)](https://ir.sagimet.com/news-releases/news-release-details/sagimet-biosciences-provides-strategic-and-corporate-updates)

<a id="topic-2.1.2.14-30"></a>

###### Denifanstat: FASCINATE-2 phase 2b week 52 histology in F2 or F3 MASH, intention-to-treat population

> “participants aged 18 years and older with biopsy-confirmed MASH and stage F2 or F3 fibrosis were randomly assigned (2:1) to receive either 50 mg oral denifanstat or placebo once per day for 52 weeks.”
> “In the ITT population, 42 (38%) of 112 participants in the denifanstat group had a 2-point or greater improvement in NAS without a worsening of fibrosis versus nine (16%) of 56 participants in the placebo group (common risk difference 21·0%, 95% CI 8·1-33·9; p=0·0035). 29 (26%) of 112 participants in the denifanstat group showed MASH resolution with a 2-point or greater improvement in NAS without a worsening of fibrosis compared with six (11%) of 56 participants in the placebo group (common risk difference 13·0%, 0·7-25·3; p=0·0173).”

Source: [Loomba et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39396529/)

<a id="topic-2.1.2.14-31"></a>

###### Cross-trial comparison of histologic response: company presentation, with its caveat that results may not be comparable

> “Resolution of MASH and fibrosis improvement ≥ least 1 stage”
> “Compares favorably to other oral and injectable compounds”
> “Fibrosis improvement ≥ 1 stage with no worsening of MASH”
> “Resmetirom and semaglutide have been approved under accelerated approval by the FDA.”
> “No head-to-head clinical trials have been conducted; results obtained from different trials, with different designs, endpoints and patient populations. Results may not be comparable.”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.1.2.14-32"></a>

###### Cross-trial comparison of adiponectin change: lanifibranor, resmetirom, efruxifermin, and pegozafermin, with the authors’ caveat that results may not be comparable

> “Data from late-stage therapeutics in MASH were collected from publications.”
> “Among MASH therapeutics in clinical development, lanifibranor induces the largest reported increase in ADP, with substantial changes that correlate with histologic improvement in both MASH activity and fibrosis6.”
> “No head-to-head clinical trials amongst late stage agents have been conducted, results obtained from different published trials with different patient populations. Results may not be comparable.”

Source: [Rinella et al. (2026a)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-MASH-TAG-2026-final-version.pdf)

| Product (trial, time point) | Dose | Absolute change in adiponectin from baseline at end of treatment, µg/ml |
| --- | --- | --- |
| Lanifibranor (NATIVE, 24 weeks) | “800mg” | “+ 11.95 (8.97 to14.94)” |
| Lanifibranor (NATIVE, 24 weeks) | “1200mg” | “+ 17.12 (14.29 to 19.96)” |
| Resmetirom (MAESTRO-NASH, 52 weeks) | “80mg” | “+ 0.86 (0.19)” |
| Resmetirom (MAESTRO-NASH, 52 weeks) | “100mg” | “+ 1.1 (0.19)” |
| Efruxifermin (HARMONY, 24 weeks) | “28mg” | “+ 1.4(0.74 to 2.08)” |
| Efruxifermin (HARMONY, 24 weeks) | “50mg” | “+ 3.0(2.34 to 3.71)” |
| Pegozafermin (ENLIVEN, 24 weeks) | “15mg” | “+ 1.1(0.7)” |
| Pegozafermin (ENLIVEN, 24 weeks) | “30mg” | “+ 1.1(0.3)” |
| Pegozafermin (ENLIVEN, 24 weeks) | “44mg” | “+ 1.2 (0.4)” |

Source: [Rinella et al. (2026a)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-MASH-TAG-2026-final-version.pdf)

<a id="topic-2.1.2.14-33"></a>

###### Network meta-analysis of 29 randomized trials including lanifibranor, with the authors’ stated limitations

> “We searched PubMed and Embase databases from January 1, 2020 to December 1, 2024, for published randomized controlled trials comparing pharmacological interventions in patients with biopsy-proven MASH.”
> “A total of 29 randomized controlled trials (n=9324) were included.”
> “Data from eligible studies were extracted as intention-to-treat (ITT) analyses.”
> “Pegozafermin (RR: 3.46, CrI: 1.54–11.15), cilofexor + firsocostat (RR: 2.67, CrI: 1.05–8.13), denifanstat (RR: 1.94, CrI: 1.04–4.04), survodutide (RR: 1.86, CrI: 1.18– 3.28), obeticholic acid (RR: 1.85, CrI: 1.30–2.75), tirzepatide (RR: 1.77, CrI: 1.17–2.94), resmetirom (RR: 1.64, CrI: 1.27–2.20), and semaglutide (RR: 1.51, CrI: 1.23–1.90) were statistically better than placebo in achieving ≥1 stage of fibrosis improvement without worsening MASH (Figure 3A).”
> “Pegozafermin (RR: 8.65, CrI: 2.63–59.42), survodutide (RR: 6.62, CrI: 3.13–17.97), tirzepatide (RR: 4.65, CrI: 2.31–10.66), efruxifermin (RR: 3.51, CrI: 1.83–8.17), liraglutide (RR: 3.23, CrI: 1.11–14.17), vitamin E + pioglitazone (RR: 3.03, CrI: 1.31–9.04), resmetirom (RR: 2.54, CrI: 1.86–3.55), pioglitazone (RR: 2.29, CrI: 1.41–4.03), denifanstat (RR: 2.03, CrI: 1.04–4.72), semaglutide (RR: 1.87, CrI: 1.60–2.24), and lanifibranor (RR: 1.93, CrI: 1.30–3.02) were statistically better than placebo in achieving MASH resolution without worsening fibrosis.”
> “First, we acknowledge the modest number of trials with direct comparisons between pharmacological therapies, and the small number of trials for each agent; hence, most comparisons between treatments were based on indirect evidence; head-to-head trials versus other drugs should be considered to validate our findings.”
> “Comparability between trials was further limited by their heterogeneity in design and population (eg, demographics and comorbidities).”

Source: [Souza et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12614381/)

| Treatment | SUCRA, fibrosis improvement ≥1 stage without worsening MASH |
| --- | --- |
| Pegozafermin | “79.92” |
| Denifanstat | “60.64” |
| Survodutide | “59.89” |
| Tirzepatide | “57.37” |
| Efruxifermin | “56.20” |
| Resmetirom | “50.14” |
| Semaglutide | “47.04” |
| Lanifibranor | “46.56” |

Source: [Souza et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12614381/)

Additional sources: [Mangia and Valenti (2025)](https://pubmed.ncbi.nlm.nih.gov/40815181/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Steatotic liver disease nomenclature: MASLD replaces NAFLD and MASH replaces NASH

> “Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis.”
> “The name chosen to replace NAFLD was metabolic dysfunction–associated steatotic liver disease.”
> “There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors.”
> “In total, 75% of respondents of the external expert committee chose MASLD as the replacement term for NAFLD and 88% metabolic dysfunction–associated steatohepatitis (MASH) as the replacement term for NASH.”
> “Persons with MASLD and steatohepatitis will be designated as metabolic dysfunction associated steatohepatitis (MASH).”

Source: [Rinella et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10653297/)

<a id="topic-2.2.1.1-2"></a>

###### MASLD as a disease spectrum from steatosis to MASH, fibrosis, cirrhosis, and hepatocellular carcinoma

> “Metabolic dysfunction-associated steatotic liver disease (MASLD) is the umbrella term that comprises metabolic dysfunction-associated steatotic liver, or isolated hepatic steatosis, through to metabolic dysfunction-associated steatohepatitis, the progressive necroinflammatory disease form that can progress to fibrosis, cirrhosis and hepatocellular carcinoma.”
> “MASLD is closely associated with insulin resistance, obesity, gut microbial dysbiosis and genetic risk factors.”

Source: [Huang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40050362/)

<a id="topic-2.2.1.1-3"></a>

###### Fibrosis staging retained under the new nomenclature, including MASH with stage 3 fibrosis

> “The new names also allow for further characterisation of fibrotic severity, for example, MASH with stage 3 fibrosis.”
> “Disease staging and severity are not altered by this process although it is anticipated that, in the near to medium term, disease staging will be achieved using noninvasive tests, which can be incorporated into further clarifications of disease stage.”

Source: [Rinella et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10653297/)

<a id="topic-2.2.1.1-4"></a>

###### At-risk NASH defined as biopsy-proven NASH with stage 2 or higher fibrosis

> “Identifying patients with “at-risk” NASH (biopsy-proven NASH with stage 2 or higher fibrosis) is a more recent area of interest.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.1-5"></a>

###### Continuity of NAFLD and NASH evidence with MASLD and MASH: European registry and US NHANES overlap

> “an analysis of the LITMUS consortium European was performed, which demonstrated that 98% of the existing registry cohort of patients with NAFLD would fulfill the new criteria for MASLD”
> “maintenance of the term, and clinical definition, of steatohepatitis ensures retention and validity of prior data from clinical trials and biomarker discovery studies of patients with NASH to be generalisable to individuals classified as MASLD or MASH under the new nomenclature, without impeding the efficiency of research.”

Source: [Rinella et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10653297/)

> “There was 99% overlap in cases of NAFLD and MASLD.”
> “Among those with NAFLD or MASLD, 99.0% (95% CI 97.6%–99.6%) met the criteria for both NAFLD and MASLD.”

Source: [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11232657/)

<a id="topic-2.2.1.1-6"></a>

###### Cardiometabolic risk factors in the definition of MASLD: adult criteria

> “Hepatic steatosis is the hallmark of MASLD, defined as the presence of hepatic steatosis in conjunction with at least one cardiometabolic risk factor (Table 3) and no other discernible cause.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

| Metabolic risk factor | Adult criteria |
| --- | --- |
| Overweight or obesity: body mass index | “≥25 kg/m2 (≥23 kg/m2 in people of Asian ethnicity)” |
| Overweight or obesity: waist circumference (Europeans) | “≥94 cm in men and ≥80 cm in women (Europeans)” |
| Overweight or obesity: waist circumference (South Asians and Chinese) | “≥90 cm in men and ≥80 cm in women (South Asians and Chinese)” |
| Dysglycaemia: prediabetes | “Prediabetes: HbA1c 39-47 mmol/mol (5.7-6.4%) or fasting plasma glucose 5.6-6.9 mmol/L (100-125 mg/dl)” |
| Type 2 diabetes | “Type 2 diabetes: HbA1c ≥48 mmol/mol (≥6.5%) or fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dl)”; “Treatment for type 2 diabetes” |
| Plasma triglycerides | “≥1.7 mmol/L (≥150 mg/dl) or lipid-lowering treatment” |
| HDL-cholesterol | “≤1.0 mmol/L (≤39 mg/dl) in men and ≤1.3 mmol/L (≤50 mg/dl) in women or lipid-lowering treatment” |
| Blood pressure | “≥130/85 mmHg or treatment for hypertension” |

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.1.1-7"></a>

###### Alcohol intake thresholds separating MASLD, MetALD, and alcohol-related liver disease

> “MASLD and ALD (alcohol intake >50 g/day for females and >60 g/day for males) comprise the most common causes of SLD.”
> “A new category, requiring further characterisation, termed MetALD, describes those with MASLD who consume greater amounts of alcohol (20-50 g/day for females and 30-60 g/day for males, respectively), but do not meet the criteria for ALD.”
> “MASLD, ALD and MetALD are the most common causes of SLD, but other causes such as drug-induced liver disease and monogenic SLD should be considered, depending on the context (LoE 3, strong recommendation, strong consensus).”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.1.1-8"></a>

###### Etiology: type 2 diabetes, obesity, age, and menopausal status as risk factors for progressive fibrosis

> “Type 2 diabetes and obesity (particularly abdominal obesity) are the metabolic diseases with the strongest impact on the natural history of MASLD, including progression to MASLD/MASH-related advanced fibrosis, cirrhosis and hepatocellular carcinoma (LoE 2, strong consensus).”
> “Males aged >50 years, postmenopausal women, and individuals with multiple cardiometabolic risk factors are at increased risk of progressive fibrosis and the development of cirrhosis and its complications (LoE 2, strong consensus).”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

> “T2DM is the most impactful risk factor for the development of NAFLD, fibrosis progression, and HCC”
> “NAFLD is closely linked to and often precedes the development of metabolic abnormalities (insulin resistance, dyslipidemia, central obesity, and hypertension).”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.1-9"></a>

###### Etiology: inherited risk, PNPLA3 and TM6SF2 variants, and heritability

> “Inherited factors play a major role in the development and progression of MASLD, synergising with the metabolic causes of the disease.”
> “Overall evidence suggests that the PNPLA3 p.I148M and TM6SF2 p.E167K variants are major risk factors for progressive MASLD”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

> “NAFLD and NASH have a heritable component that is estimated to be between 35%–61%”
> “The PNPLA3 gene is a major driver of NAFLD, NASH, cirrhosis, and HCC risk in individuals who have metabolic risk factors such as obesity, diabetes, and metabolic syndrome.”

Source: [Loomba et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12168897/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

<a id="topic-2.2.1.2.1-1"></a>

###### US adults with newly coded NASH with F2 to F3 fibrosis: claims-based annual incidence, 2020

> “In the base case, the annual incidence was calculated by dividing the projected number of newly coded patients with F2/F3 NASH in 2020 (73,085) in the US population by the total adult population (257,279,447), resulting in a rate of 28.4 cases per 100,000 adults”
> “other diagnosed NASH incidence rates were obtained from analyses conducted using the Optum CDM and Veradigm® EHR (linked with Komodo Health claims), which provided a range of values (20.4–64.0 per 100,000 adults)”

Source: [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/)

<a id="topic-2.2.1.2.1-2"></a>

###### US adults with NASH: incident and prevalent cases in 2017, Markov model

> “Our models estimated that there are 6.65 million adults (18+ years old) with NASH in the United States and that there were 232,000 incident cases in 2017.”

Source: [Younossi et al. (2019a)](https://pubmed.ncbi.nlm.nih.gov/30180285/)

<a id="topic-2.2.1.2.1-3"></a>

###### Adults with fatty liver developing NASH: paired biopsy and imaging meta-analysis of observational studies

> “We screened 9,744 articles and included 54 studies involving 26,738 patients.”
> “In addition, 31% of patients developed NASH after 4.7 years (incidence rate=7.4/100 person-years) whereas in 29% of those with NASH, resolution occurred after a median of 3.5 years (incidence rate=5.1/100 person-years).”

Source: [Le et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9898457/)

<a id="topic-2.2.1.2.1-4"></a>

###### US incident NAFL cases, 2015 and projected to 2030, Markov model

> “In 2015, an estimated 3.44 million incident NAFL cases occurred. By 2030, incident NAFL cases decreased 31% to 2.50 million.”

Source: [Estes et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5767767/)

<a id="topic-2.2.1.2.1-5"></a>

###### Global NAFLD incidence in adults diagnosed by imaging: meta-analysis

> “The overall incidence of NAFLD was estimated to be 46·9 cases per 1000 person-years (36·4-57·5); 70·8 cases per 1000 person-years (48·7-92·8) in men and 29·6 cases per 1000 person-years (20·2-38·9) in women (p<0·0001).”

Source: [Riazi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35798021/)

<a id="topic-2.2.1.2.1-6"></a>

###### Global NAFLD incidence in ultrasound-diagnosed cohorts: meta-analysis of 12 studies

> “Incidence rates were reported in 12 studies involving a total sample size of 256,757 subjects at baseline with total PY of 800,853. The pooled incidence estimate of NAFLD was 48.89 per 1000 PY.”
> “The pooled NAFLD incidence numerically increased by +58.0% from 37.41 per 1000 PY (95% CI: 24.36–57.06) in 1994–2006 to 59.11 per 1000 (39.64–87.26) in 2010–2014 survey year”

Source: [Younossi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10026948/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

<a id="topic-2.2.1.2.2-1"></a>

###### US adults with NASH and non-cirrhotic F2 to F3 fibrosis: prevalence inputs of an eligible-population model

> “In the base case, a NASH prevalence of 4.6% was modeled (range 1.3–14.2%). This value was multiplied by the proportion estimated to have non-cirrhotic MALF (i.e., 35%).”
> “Therefore, taking patient counts estimates using FIB-4 for F2 and F3 over the total subgroup patient count, we get (3735 + 2725)/18,612 ≈ 35% of the patients were diagnosed with F2/F3 NASH (Table 1)”
> “Assuming a 1-million commercial-member population, the resmetirom treatment-eligible population was estimated as 1255–1699 in Years 1–3 following approval.”

Source: [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/)

<a id="topic-2.2.1.2.2-2"></a>

###### US adults with NASH and moderate to severe fibrosis: ICER budget impact population, 2023 to 2027

> “we applied a prevalence estimate of 1.4% to the 2023-2027 projected US population aged 18 years of age and older.”
> “Our estimate was based on a 4% prevalence of NASH in the overall US population [based on a reported average of 1.5% to 6.5%]”
> “the proportion of patients with NASH who have moderate to severe fibrosis which was reported to be 35%.”
> “Applying these sources resulted in an average estimated prevalence of 3.81 million eligible patients in the US.”

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

<a id="topic-2.2.1.2.2-3"></a>

###### US adults meeting liberal and restrictive resmetirom eligibility criteria, NHANES 2017 to March 2020

> “Two eligibility scenarios were examined: a liberal scenario requiring ALT >17 U/L for women or >20 U/L for men, controlled attenuation parameter (CAP) >280 dB/m, and liver stiffness measurement (LSM) >8 kPa; and a restrictive scenario requiring ALT >30 U/L for both sexes, CAP >280 dB/m, and LSM >10 kPa.”
> “An estimated 8.3 million (95% CI: 6.6–9.9 million) adults met the liberal eligibility criteria, while 2.3 million (95% CI: 1.4–3.2 million) met the restrictive criteria.”
> “Among adults with T2DM, 3.5 million (95% CI: 2.4–4.5 million; 12.2%) met liberal, whereas 0.85 million (95% CI: 0.5–1.2 million; 3.0%) restrictive criteria.”

Source: [Le et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12180822/)

<a id="topic-2.2.1.2.2-4"></a>

###### US adults with NAFLD: at-risk NASH by FAST score (proxy for NAS of 4 or more and F2 or higher), NHANES 2017 to 2018

> “Patients with a FAST score >0.35 were considered to have at-risk NASH, defined as NASH with NAFLD activity score ≥4 and fibrosis stage ≥2 on liver biopsy.”
> “The overall prevalence of at-risk NASH was 11.6% (95% CI: 8.8–15.1) and was higher in males than females (15.8% vs. 6.5%; p < 0.001).”
> “We estimated ~9 million people in the US have at-risk NASH and may benefit from active surveillance and therapy.”

Source: [Payne et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9833447/)

<a id="topic-2.2.1.2.2-5"></a>

###### US adults with MASLD by liver stiffness: 8 to 12 kPa and 12 kPa or higher, NHANES 2017 to 2020

> “In the survey data, 2,691 subjects, projecting to 75.8 million US adults, were found to have MASLD, of whom 11% had LSM 8–12 kPa and 6% LSM ≥12 kPa.”

Source: [Kim et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12832100/)

<a id="topic-2.2.1.2.2-6"></a>

###### US adults aged 50 years or older with type 2 diabetes: MASLD, at-risk MASH, and cirrhosis, prospective cohort 2016 to 2023

> “This prospective study enrolled adults age ≥ 50 with T2DM from primary care and endocrinology clinics in southern California from 2016 to 2023.”
> “Among patients with T2DM, the prevalence of MASLD, at-risk MASH and cirrhosis was 69.6%, 13.6%, and 6.8%, respectively.”
> “At-risk MASH was defined by an either positive MEFIB score (MRE > 3.3 kPa + Fib4 > 1.6), FAST score ≥ 0.67, or MAST score ≥ 0.242”

Source: [Mittal et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12425555/)

<a id="topic-2.2.1.2.2-7"></a>

###### US adults with SLD, MASLD, and MetALD, NHANES January 2017 to March 2020

> “Among 7367 participants, 2549 met the new definition for SLD (mean age 51 years, 57.7% male, 63.2% non-Hispanic White; Table 1).”
> “The estimated prevalence of SLD was 34.2% (95% CI 31.9%–36.5%): MASLD 31.3% (95% CI 29.2%–33.4%), MetALD 2.2% (95%CI 1.6–2.9%), ALD 0.7% (95%CI 0.5–0.9%) and etiology-specific or cryptogenic SLD 0.03% (95% CI 0.01%–0.08%)”
> “In this national study, we estimate the prevalence of SLD to be 34.2% (ie, > 90 million US adults), with MASLD accounting for the majority (31.3%)”

Source: [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11232657/)

<a id="topic-2.2.1.2.2-8"></a>

###### US adults with SLD and MASLD, age-adjusted, and advanced fibrosis in SLD, NHANES 2017 to 2023

> “Using the recent National Health and Nutrition Examination Survey from 2017 to 2023, we analyzed data from 12,199 participants (≥18 years) who completed transient elastography.”
> “The age-adjusted prevalence of SLD (cut-off: 285 dB/m) was 35.0% (95% confidence interval [CI] 33.4–36.7). Within this category, the age-adjusted prevalence for MASLD was 31.9% (95% CI 30.4–33.4), MetALD 2.2% (95% CI 1.8–2.6), and ALD 0.8% (95% CI 0.6–1.1).”
> “In contrast, the prevalence of advanced fibrosis in SLD was significantly higher during the COVID-19 era, at 9.8% for 285 dB/m and 7.8% for 263 dB/m, compared to 7.4% (P=0.039) and 6% (P=0.041) in the pre-COVID-19 era.”

Source: [Kim et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12016658/)

<a id="topic-2.2.1.2.2-9"></a>

###### US general population with MASLD and MASLD-related cirrhosis, NHANES 2017 to 2020

> “The prevalence of chronic liver disease etiologies was ALD 0.85%, MetALD 3.38%, CHB 0.23%, CHC 0.73%, ALD + viral hepatitis 0.16%, and MASLD 33.05%.”
> “In the general population, the prevalence of ALD-cirrhosis was 0.08%, MetALD-cirrhosis 0.19%, CHB-cirrhosis 0.01%, CHC-cirrhosis 0.10%, MASLD-cirrhosis 1.27%, ALD + viral hepatitis-cirrhosis 0.08%, and other cirrhosis 0.87%.”
> “Individuals with MASLD comprise the majority of US residents with cirrhosis.”

Source: [Younossi et al. (2025c)](https://pubmed.ncbi.nlm.nih.gov/39879587/)

<a id="topic-2.2.1.2.2-10"></a>

###### US adults with NAFLD and NASH: prevalence and clinically significant fibrosis in AASLD 2023 guidance

> “The prevalence of NAFLD in adults is estimated to be 25%–30% in the general population”
> “The prevalence of NASH in the general population is challenging to determine with certainty; however, NASH was identified in 14% of asymptomatic patients undergoing colon cancer screening.”
> “This study also highlights that since the publication of a prior prospective prevalence study,”
> “the prevalence of clinically significant fibrosis (stage 2 or higher fibrosis) has increased > 2-fold.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.2.2-11"></a>

###### US NAFLD and NASH cases with F3 to F4 fibrosis, 2015 and projected to 2030, Markov model

> “The total NAFLD population in 2015 was estimated at 83.1 million cases (Fig. 3A), with a prevalence rate of 30.0% among the population aged ≥15 years and 25.8% among all ages. By 2030, the NAFLD population was projected to increase 21% to 100.9 million cases.”
> “The number of NASH cases is projected to increase 63% from 16.52 million cases in 2015 to 27.00 million in 2030 (Fig. 3B).”
> “Among NASH cases in 2015, an estimated 20% have F3/F4 fibrosis or advanced liver disease, encompassing approximately 3.31 million cases (Fig. 4). By 2030, this number is expected to increase over 160% to 7.94 million cases and will account for 29% of NASH cases.”

Source: [Estes et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5767767/)

<a id="topic-2.2.1.2.2-12"></a>

###### US adults with MASLD, MASH, and MASH with F2 or higher fibrosis, projected 2020 to 2050, microsimulation model

> “The model predicted a steady increase in the prevalence of MASLD from 33.7% (86.3 million people) in 2020 to 41.4% (121.9 million people) by 2050. Cases of MASH would increase from 14.9 million (5.8% of US adults) in 2020 to 23.2 million (7.9% of US adults) by 2050. The number of cases of MASH and clinically significant fibrosis (ie, F≥F2, centrilobular and periportal fibrosis or more severe disease) were estimated to increase from 6.7 million to 11.7 million.”

Source: [Le et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11742522/)

<a id="topic-2.2.1.2.2-13"></a>

###### Global and North American NAFLD prevalence: meta-analysis of studies from 1990 to 2019

> “Across the study period (1990–2019), meta-analytic pooling of NAFLD prevalence estimates and ultrasound-defined NAFLD yielded an overall global prevalence of 30.05% (95% CI: 27.88%–32.32%) and 30.69% (28.4–33.09), respectively.”
> “Global NAFLD prevalence increased by +50.4% from 25.26% (21.59–29.33) in 1990–2006 to 38.00% (33.71–42.49) in 2016–2019 (p<0.001)”
> “Across the entire study period (1990–2019), analysis of the regional prevalence rates showed a prevalence of 31.20% in North America and Australia (95% CI: 25.86%–37.08%)”

Source: [Younossi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10026948/)

<a id="topic-2.2.1.2.2-14"></a>

###### Global and North American NASH prevalence: estimate from voluntarily biopsied NAFLD cohorts

> “Subsequently, the NASH prevalence in the general population was estimated by multiplying the prevalence of NASH in the “voluntary biopsied NAFLD” group with the prevalence of NAFLD in the general population.”
> “Our estimates suggest that the global NASH prevalence is 5.27% (SE: 2.63).”
> “North America [5.00% (2.50)]”
> “The prevalence of NASH among NAFLD patients is 16.02% (95% CI: 3.24%–52.08%).”

Source: [Younossi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10026948/)

<a id="topic-2.2.1.2.2-15"></a>

###### Global NAFLD prevalence in adults diagnosed by imaging: meta-analysis

> “The overall prevalence of NAFLD worldwide was estimated to be 32·4% (95% CI 29·9-34·9). Prevalence increased significantly over time, from 25·5% (20·1-31·0) in or before 2005 to 37·8% (32·4-43·3) in 2016 or later (p=0·013). Overall prevalence of NAFLD was significantly higher in men than in women (39·7% [36·6-42·8] vs 25·6% [22·3-28·8]; p<0·0001).”

Source: [Riazi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35798021/)

<a id="topic-2.2.1.2.2-16"></a>

###### Global NAFLD prevalence and metabolic comorbidities: meta-analysis of studies from 1989 to 2015

> “Global prevalence of NAFLD is 25.24% (95% CI: 22.10-28.65) with highest prevalence in the Middle East and South America and lowest in Africa.”
> “Metabolic comorbidities associated with NAFLD included obesity (51.34%; 95% CI: 41.38-61.20), type 2 diabetes (22.51%; 95% CI: 17.92-27.89), hyperlipidemia (69.16%; 95% CI: 49.91-83.46%), hypertension (39.34%; 95% CI: 33.15-45.88), and metabolic syndrome (42.54%; 95% CI: 30.06-56.05).”

Source: [Younossi et al. (2016a)](https://pubmed.ncbi.nlm.nih.gov/26707365/)

<a id="topic-2.2.1.2.2-17"></a>

###### Global NAFLD prevalence forecast to 2040, hierarchical Bayesian model

> “The forecasted 2040 prevalence was 55.7%, a three-fold increase since 1990 and a 43.2% increase from the 2020 prevalence of 38.9%.”

Source: [Le et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9597215/)

<a id="topic-2.2.1.2.2-18"></a>

###### UK Biobank participants with liver MRI: SLD, MASLD, and at-risk MASH

> “At-risk MASH was defined as PDFF≥5% and cT1 ≥875 ms”
> “Among 40,189 patients, 10,886 (27.0%) had a PDFF ≥5%, indicating SLD. Among patients with SLD, 1% had ALD, 89.0% had MASLD, 7.9% had MetALD and 2.2% had at-risk MASH. The at-risk MASH group, which included 0.6% of the general population, had the highest mean liver fat on MRI and the highest BMI.”

Source: [Schneider et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12285740/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Fibrosis stage as the primary predictor of outcomes, with higher risk from F2 (at-risk NASH)

> “Data from meta-analyses and pooled studies demonstrate that fibrosis and the presence of steatohepatitis are the primary predictors of disease progression.”
> “Nevertheless, patients with NASH and at least stage 2 fibrosis (F2), referred to as “at-risk” NASH, have a demonstrably higher risk of liver-related morbidity and mortality.”
> “The most common causes of death in patients with NAFLD overall are cardiovascular disease (CVD) and nonhepatic malignancy, followed by liver disease.”
> “Bridging fibrosis and cirrhosis are associated with an exponentially greater risk of liver-related morbidity and mortality than earlier stages of fibrosis.”
> “Among patients with cirrhosis, progression to clinical decompensation ranges from 3% to 20% per year.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.3-2"></a>

###### All-cause and liver-related mortality by fibrosis stage: meta-analysis of 14 articles, 17,301 participants with biopsy-proven NAFLD

> “Medline and Embase databases were searched to include cohort studies reporting survival outcomes by fibrosis stage in biopsy-proven NAFLD.”
> “A total of 14 articles involving 17,301 patients with NAFLD were included. All-cause mortality at 1, 5, and 10 years for stage 0 to 2 fibrosis was 0.1%, 3.3%, and 7.7% vs 0.3%, 20.6%, and 41.5% for stage 4 fibrosis.”
> “Compared with stage 0 fibrosis, all-cause mortality increased with fibrosis stage: stage 2; HR, 1.46 (95% confidence interval [CI], 1.08–1.98), stage 3; HR, 1.96 (95% CI, 1.41–2.72), and stage 4; HR, 3.66 (95% CI, 2.65–5.05).”
> “Risk for liver-related mortality increased exponentially as fibrosis stage increased: stage 2; HR, 4.07 (95% CI, 1.44–11.5), stage 3; HR, 7.59 (95% CI, 2.80–20.5), and stage 4; HR, 15.1 (95% CI, 5.27–43.4).”

Source: [Ng et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10792524/)

<a id="topic-2.2.1.3-3"></a>

###### Mortality rate ratios by fibrosis stage: meta-analysis of 5 cohorts, 1,495 participants with NAFLD

> “1,495 NAFLD patients with 17,452 patient years of follow-up were included.”
> “Compared to NAFLD patients with no fibrosis (stage 0), NAFLD patients with fibrosis were at an increased risk for all-cause mortality and this risk increased with increase in the stage of fibrosis: stage 1, MRR, 1.58 (95% CI 1.19–2.11); stage 2, MRR, 2.52 (95% CI 1.85–3.42); stage 3, MRR, 3.48 (95% CI 2.51–4.83), and stage 4, MRR, 6.40 (95% CI 4.11–9.95).”
> “The results were more pronounced as the risk of liver-related mortality increased exponentially with increase in the stage of fibrosis: stage 1, MRR, 1.41 (95% CI 0.17–11.95); stage 2, MRR, 9.57 (95% CI 1.67–54.93); stage 3, MRR, 16.69 (95% CI 2.92–95.36); and stage 4, MRR, 42.30 (95% CI 3.51–510.34).”

Source: [Dulai et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5397356/)

<a id="topic-2.2.1.3-4"></a>

###### Relative risk of mortality and liver events, stage 4 versus stage 0: meta-analysis of 13 studies, 4,428 participants with NAFLD

> “Our meta-analysis included 13 studies, comprising 4428 patients with NAFLD; 2875 of these were reported to have NASH.”
> “Compared with no fibrosis (stage 0), unadjusted risk increased with increasing stage of fibrosis (stage 0 vs 4): all-cause mortality RR, 3.42 (95% CI, 2.63-4.46); liver-related mortality RR, 11.13 (95% CI, 4.15-29.84); liver transplant RR, 5.42 (95% CI, 1.05-27.89); and liver-related events RR, 12.78 (95% CI, 6.85-23.85).”

Source: [Taylor et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32027911/)

<a id="topic-2.2.1.3-5"></a>

###### Death or liver transplantation and liver-related events by fibrosis stage: 619 participants with biopsy-diagnosed NAFLD, median 12.6 years

> “We performed a retrospective analysis of 619 patients diagnosed with NAFLD from 1975 through 2005 at medical centers in the United States, Europe, and Thailand.”
> “Over a median follow-up of 12.6 years (range 0.3–35.1), 193 of the patients (33.2%) died or underwent liver transplantation. Features of liver biopsies significantly associated with death or liver transplantation included fibrosis stage 1 (HR, 1.88; 95% CI, 1.28, 2.77), stage 2 (HR, 2.89; 95% CI, 1.93, 4.33), stage 3 (HR, 3.76; 95% CI, 2.40, 5.89), and stage 4 (HR, 10.9; 95% CI, 6.06, 19.62) compared with stage 0”
> “Twenty-six patients (4.2%) developed liver-related events; fibrosis stage 3 (HR 14.2 [95% CI 3.38, 59.68]) and stage 4 (HR 51.5 [95% CI 9.87, 269.2]) compared to stage 0, were significantly associated with the events.”

Source: [Angulo et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4516664/)

<a id="topic-2.2.1.3-6"></a>

###### Deaths and liver-related complications per 100 person-years by fibrosis stage: prospective NASH CRN cohort, 1,773 adults, median 4 years

> “A total of 1773 adults with NAFLD were followed for a median of 4 years. All-cause mortality increased with increasing fibrosis stages (0.32 deaths per 100 person-years for stage F0 to F2 [no, mild, or moderate fibrosis], 0.89 deaths per 100 persons-years for stage F3 [bridging fibrosis], and 1.76 deaths per 100 person-years for stage F4 [cirrhosis]).”
> “The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14).”
> “After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3).”

Source: [Sanyal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8881985/)

<a id="topic-2.2.1.3-7"></a>

###### Mortality by histologic stage versus matched controls: Swedish nationwide biopsy cohort, 10,568 participants, median 14.2 years

> “This nationwide, matched cohort study included all individuals in Sweden with biopsy-confirmed NAFLD (1966–2017; n=10,568).”
> “Over a median of 14.2 years, 4,338 NAFLD patients died.”
> “Compared to controls, significant excess mortality risk was observed with simple steatosis (8.3/1000PY, aHR=1.71, 95%CI=1.64–1.79), non-fibrotic NASH (13.4/1000PY, aHR=2.14, 95%CI=1.93–2.38), non-cirrhotic fibrosis (18.4/1000PY, aHR=2.44, 95%CI=2.22–2.69) and cirrhosis (53.6/1000PY, aHR=3.79, 95%CI=3.34–4.30)”
> “The excess mortality associated with NAFLD was primarily from extra-hepatic cancer (4.5/1000PY; aHR=2.16, 95%CI=2.03–2.30), followed by cirrhosis (2.7/1000PY; aHR=18.15, 95%CI=14.78–22.30), cardiovascular disease (1.4/1000PY; aHR=1.35, 95%CI=1.26–1.44) and hepatocellular carcinoma (HCC)(1.2/1000PY; aHR=11.12, 95%CI=8.65–14.30).”

Source: [Simon et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8185553/)

<a id="topic-2.2.1.3-8"></a>

###### Major adverse liver outcomes by fibrosis stage: Swedish cohort of 1,260 participants with non-cirrhotic NAFLD, median 13 years

> “Patients (n = 1,260) with NAFLD without cirrhosis were diagnosed through biopsy or radiology, and had fibrosis estimated through vibration-controlled transient elastography, biopsy, or FIB-4 score between 1974 and 2020 and followed up through 2020.”
> “MALO occurred in 111 (8.8%, incidence rate = 5.9/1,000 person-years) patients with NAFLD and 197 (1.6%, incidence rate = 1.0/1,000 person-years) reference individuals during a median follow up of 13 years.”
> “The 20-year cumulative incidences of MALO were 2% for the reference population, 3% for patients with F0, and 35% for F3.”
> “The adjusted hazard ratio (aHR) for F2, as determined by biopsy, was 2.9 (95% CI 1.5–5.5), and for F3 the aHR was 8.9 (95% CI 4.6–17.4), both compared with the reference group with F0–1.”

Source: [Akbari et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10827505/)

<a id="topic-2.2.1.3-9"></a>

###### Progression to cirrhosis and all-cause mortality in non-cirrhotic MASH F2 and F3: US TARGET-NASH cohort, 2,378 participants

> “Among the 2378 patients included in this analysis, 48% had MASH cirrhosis.”
> “Among the 1425 patients with non-cirrhotic MASH, there were 982 patients in the F0–F1 cohort, 281 patients in the F2 cohort, and 162 patients in the F3 cohort (Supplemental Fig. 2).”
> “Incidence rates of cirrhosis increased from 0.34/100PM in the F0–F1 cohort to 1.24/100PM in the F2 cohort and 6.62/100PM in the F3 cohort (Table 5). Unadjusted risk of progressing to cirrhosis was highest among those with F3 (HR, 95% CI; 18.66, 10.97–31.73) and 3.74 times higher with F2 (HR, 95% CI; 3.74, 2.00–6.98) versus F0–F1 (Fig. 3).”
> “All-cause mortality was associated with disease severity and incidence rates increased from 0.14/100PM in the F0–F1 cohort to 0.3/100PM in the F2 cohort, 0.42/100PM in the F3 cohort, 2.02/100PM in the compensated cirrhosis cohort and 4.62/100PM in the decompensated cirrhosis cohort (Table 5).”
> “This analysis was supported by Novo Nordisk Inc., Plainsboro, NJ.”

Source: [Luthra and Sheth (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11787050/)

<a id="topic-2.2.1.3-10"></a>

###### Fibrosis progression and regression rates and times by stage: meta-analysis of 54 paired biopsy or imaging studies

> “Time to progress by 1 fibrosis stage was 9.9, 10.3, 13.3 and 22.2 years for F0, F1, F2, and F3, respectively. Time to regress by 1 stage was 21.3, 12.5, 20.4, and 40.0 years for F4, F3, F2, and F1, respectively. Rates estimated from RCTs were higher than those from observational studies.”
> “In patients with F2, a similar proportion progressed, regressed, or remained stable (32%, 37%, and 31%, respectively) after 5 years. Patients with F3 regressed more often than progressed, 32% vs. 22%”
> “Pooled incidence of progression from F0, F1, F2, and F3 were 6.5, 6.9, 5.8, and 4.5/100 person-years, respectively (Table 3). Pooled incidence for regression from F1, F2, F3, and F4 were 2.5, 4.6, 6.0, and 4.7/100 person-years, respectively.”

Source: [Le et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9898457/)

<a id="topic-2.2.1.3-11"></a>

###### Fibrosis progression rate in NASH versus NAFL: meta-analysis of 11 paired biopsy cohorts, 411 participants

> “We identified 11 cohort studies including 411 patients with biopsy-proven NAFLD (150 with NAFL and 261 with NASH).”
> “Over 2145.5 person-years of follow up, 33.6% had fibrosis progression, 43.1% had stable fibrosis, and 22.3% had improvement in fibrosis stage.”
> “These findings correspond to 1 stage of progression over14.3 years for patients with NAFL (95% CI, 9.1–50.0 years) and 7.1 years for patients with NASH (95% CI, 4.8–14.3 years).”

Source: [Singh et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4208976/)

<a id="topic-2.2.1.3-12"></a>

###### Fibrosis progression in NASH and mortality rates in NAFLD and NASH: global meta-analysis

> “Fibrosis progression proportion, and mean annual rate of progression in NASH were 40.76% (95% CI: 34.69-47.13) and 0.09 (95% CI: 0.06-0.12).”
> “Liver-specific mortality and overall mortality among NAFLD and NASH were 0.77 per 1,000 (range, 0.33-1.77) and 11.77 per 1,000 person-years (range, 7.10-19.53) and 15.44 per 1,000 (range, 11.72-20.34) and 25.56 per 1,000 person-years (range, 6.29-103.80).”

Source: [Younossi et al. (2016a)](https://pubmed.ncbi.nlm.nih.gov/26707365/)

<a id="topic-2.2.1.3-13"></a>

###### All-cause and cause-specific mortality among adults with NAFLD: global meta-analysis

> “Among the NAFLD population, the pooled mortality rate (n=3) in studies that had used ultrasound or serum diagnostic method was 12.60 per 1000 PY (6.68–23.67) for all-cause mortality; 4.20 per 1000 PY (1.34–7.05) for cardiac-specific mortality; 2.83 per 1000 PY (0.78–4.88) for extrahepatic cancer-specific mortality; and 0.92 per 1000 PY (0.00–2.21) for liver-specific mortality (Table 4).”

Source: [Younossi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10026948/)

<a id="topic-2.2.1.3-14"></a>

###### Progression from steatosis to steatohepatitis, effect of type 2 diabetes, and cause-specific mortality by histologic stage

> “It has been estimated that approximately 10–30% of persons with isolated steatosis progress to steatohepatitis and advanced liver disease, but the risk is much higher in the presence of T2D (42-65% have steatosis).”
> “In a Swedish population-based cohort of 10,568 adults with biopsy-confirmed MASLD and 49,925 matched general population comparators, mortality rates from cirrhosis and HCC were modestly elevated in simple steatosis (absolute rate differences, 1.2 and 0.7/1,000 person-years [PY], respectively), but these rates increased progressively in MASH without fibrosis (3.0 and 1.3/1,000 PY, respectively), non-cirrhotic fibrosis (5.5 and 2.5/1,000 PY, respectively) and cirrhosis (22.3 and 5.5/1,000 PY, respectively).”
> “in a study on 447 adult participants with MASLD and paired liver biopsies >1 year apart, individuals with T2D had a significantly higher cumulative incidence of fibrosis progression at 4 years (24% vs. 20%), 8 years (60% vs. 50%), and 12 years (93% vs. 76%) (p <0.005)”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.1.3-15"></a>

###### US NAFLD-related decompensated cirrhosis, hepatocellular carcinoma, and liver deaths, projected 2015 to 2030, Markov model

> “Incident decompensated cirrhosis is forecasted to increase by 168%, from 39,320 cases annually in 2015 to 105,430 cases in 2030”
> “incident HCC cases are expected to increase by 137% from 5,160 to 12,240 in 2030 (Fig. 5).”
> “Liver deaths are projected at 78,300 in 2030, an increase of 178% from 2015 (Fig. 5).”

Source: [Estes et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5767767/)

<a id="topic-2.2.1.3-16"></a>

###### US MASLD-related decompensated cirrhosis, liver cancer, and liver transplant, projected 2020 to 2050, microsimulation model

> “After 30 years, prevalent cases of decompensated cirrhosis would more than triple, while incident cases of liver cancer would almost double and liver transplant would almost quadruple.”

Source: [Le et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11742522/)

<a id="topic-2.2.1.3-17"></a>

###### US deaths from chronic liver disease and cirrhosis of all causes, 2024

| Measure | Value |
| --- | --- |
| Number of deaths | “52,274” |
| Deaths per 100,000 population | “15.4” |
| Cause of death rank | “9” |

Source: [CDC FastStats chronic liver disease and cirrhosis (2026)](https://www.cdc.gov/nchs/fastats/liver-disease.htm)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Substrate overload and lipotoxicity

> “In defining pathogenic drivers of NAFL and NASH, a useful conceptual framework is that the liver’s capacity to handle the primary metabolic energy substrates, carbohydrates and fatty acids, is overwhelmed, leading to accumulation of toxic lipid species”
> “These metabolites induce hepatocellular stress, injury and death, leading to fibrogenesis and genomic instability that predispose to cirrhosis and hepatocellular carcinoma.”
> “When fatty acids are either supplied in excess or their disposal is impaired, they may serve as substrates for the generation of lipotoxic species that provoke ER stress and hepatocellular injury.”

Source: [Friedman et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6553468/)

> “The presence and severity of NAFL and NASH are substantially determined by factors that govern the supply and disposition of fatty acids, diacylglycerols, ceramides, cholesterol, phospholipids, and other intrahepatic lipids.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.4-2"></a>

###### Insulin resistance and adipose tissue dysfunction

> “Insulin resistance is nearly universal in patients with NAFLD and is present in the liver, adipose tissue, and muscle.”
> “Adipose tissue insulin resistance is characterized by increased release of free fatty acids from adipocytes (lipolysis) in the fasting state”
> “A primary disease driver may be an oversupply of fat to adipocytes such that their ability to store triglyceride without inducing cell stress is exceeded, which activates inflammatory pathways and causes insulin resistance.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.4-3"></a>

###### Hepatic de novo lipogenesis and dietary sugars

> “The metabolic mechanisms leading to NAFLD reflect an imbalance of energy metabolism in the liver: excess energy, mostly in the form of carbohydrates and fat, entering the liver relative to the ability of the liver to oxidize this energy to CO2 or export it as very-low-density lipoproteins (VLDLs) (Figure 3).”
> “Although excess consumption of any food can lead to development of NAFLD, mono- and disaccharides, especially fructose, sucrose, and high-fructose corn syrup, which is ubiquitous in processed foods, can activate programs of hepatic de novo lipogenesis that further exacerbate NAFLD.”
> “Skeletal muscle insulin resistance, one of the earliest defects associated with metabolic syndrome and prediabetes”

Source: [Loomba et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12168897/)

<a id="topic-2.2.1.4-4"></a>

###### Hepatocellular injury, inflammation, and macrophage activation

> “Hepatocellular injury in NASH is characterized by endoplasmic reticulum (ER) stress”
> “likely modulate the hepatocyte’s development of lipotoxic stress, injury and inflammation. The relative contribution of these defects in individuals with NASH is not clarified yet and likely varies among individuals.”

Source: [Friedman et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6553468/)

> “The response of the liver to lipotoxic injury includes activation and recruitment of resident macrophages, which further contributes to hepatocellular injury and stellate cell activation as part of a complex interplay among hepatic cell types.”
> “Additional factors such as hepatocyte uric acid production, exposure to products derived from the gut microbiome, and perhaps low hepatic magnesium levels, may also contribute to the NASH phenotype.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.4-5"></a>

###### Fibrogenesis through hepatic stellate cell activation

> “The accumulation of extracellular matrix in the liver, which leads to progressive fibrosis, cirrhosis, portal HTN and liver failure, is the major cause of liver-related death in patients with NAFLD. Fibrogenesis is driven by signaling from stressed or injured hepatocytes and activated macrophages (Kupffer cells in the liver), leading to activation of resident hepatic stellate cells into myofibroblasts to produce matrix proteins faster than they are degraded”
> “Another NASH-specific pathway is through the PNPLA3-I148M variant’s effects directly on stellate cell fibrogenesis”

Source: [Friedman et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6553468/)

<a id="topic-2.2.1.4-6"></a>

###### Genetic modifiers of hepatocyte lipid handling

> “Although in some patients, the development and progression of NASH are driven by substrate overload and insulin resistance, in other patients, disease progression is heavily influenced by genetic factors impacting hepatocyte lipid handling.”
> “The I148M polymorphism of PNPLA3 impairs lipolysis of triglyceride in lipid droplets,”
> “Recently, lossof-function variants in HSD17B13, a gene that encodes an enzyme that also localizes to lipid droplets in hepatocytes, have been linked to protection against NASH, progressive fibrosis, and HCC.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.4-7"></a>

###### PPAR-mediated pathways as therapeutic targets: adipocyte insulin sensitivity, fatty acid oxidation, and inflammation

> “improve adipocyte insulin sensitivity [eg, peroxisome proliferator-activated receptor (PPAR)γ ligands]”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

> “For example, peroxisome proliferator–activated receptor gamma (PPARγ) ligands (for example, pioglitazone), a specialized type of nuclear receptor ligand, enhance adipocyte storage of fat and improve NASH, albeit at the expense of increased peripheral fat stores and weight gain, as shown in clinical trials of these drugs in patients with type 2 diabetes”
> “The PPARα component increases fatty acid oxidation, whereas the PPARδ component has anti-inflammatory effects.”
> “PPARγ ligands (for example, pioglitazone, a member of the family of thiazolidinedione class of drugs) have been studied in several trials and improve steatosis, inflammation and hepatocellular ballooning as well as hepatic fibrosis”

Source: [Friedman et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6553468/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Liver biopsy: reference standard for grading and staging, AASLD 2023 practice guidance

> “Although liver biopsy assessment remains the reference standard for the grading and staging of NASH, it has important limitations related to risk, cost, and resource utilization. Therefore, liver biopsies for grading and staging of NASH are not consistently performed in clinical practice and should be reserved for specific clinical scenarios (Figure 2).”
> “Liver biopsy should be considered when NITs suggest significant fibrosis (≥ F2), especially if additional evaluation suggests the presence of “at-risk” NASH (eg, using FAST, MEFIB, MAST, or cT1), NIT assessment is indeterminate, aminotransferases are persistently elevated (> 6 mo), or additional/alternate diagnoses are suspected.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.5-2"></a>

###### Liver biopsy: required for a definite diagnosis of steatohepatitis, EASL-EASD-EASO 2024 guideline

> “In most cases, liver biopsy is not required for clinical management of individuals with MASLD; however, liver biopsy is still required for the definite diagnosis of steatohepatitis and can help to rule out alternative causes of liver disease (LoE 1, strong consensus).”
> “None of these non-invasive methods can assess relevant microscopic features of MASLD such as ballooning or lobular inflammation (LoE 2, strong consensus).”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.1.5-3"></a>

###### Liver biopsy: only reliable means to diagnose NASH, AGA clinical care pathway

> “A liver biopsy is currently the only reliable means to diagnose NASH and is the reference standard for fibrosis staging. However, liver biopsy may not be feasible to obtain in a significant number of patients.”

Source: [Kanwal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8819923/)

<a id="topic-2.2.1.5-4"></a>

###### Liver biopsy: reserved to the specialist, ADA Standards of Care 2026

> “While liver biopsy remains the gold standard for the diagnosis of MASH, its indication is reserved to the discretion of the specialist within an interprofessional team approach due to high costs and potential for morbidity associated with this procedure.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.1.5-5"></a>

###### Primary risk assessment with FIB-4: thresholds, AASLD 2023 practice guidance

> “When the fibrosis-4 index (FIB-4) is <1.3, patients can be followed in the primary care setting and reassessed periodically.”
> “In patients older than age 65, a FIB-4 cutoff of > 2.0 should be used. FIB-4 has low accuracy in those under age 35; thus, secondary assessment should be considered in those <35 with increased metabolic risk or elevated liver chemistries.”
> “In patients with FIB4 ≥ 1.3, a secondary assessment should be done [preferentially vibration-controlled elastography (VCTE) or Enhanced Liver Fibrosis (ELF) initially] or the patient referred for further risk stratification (if being seen in a nongastroenterology/hepatology setting). Direct referral to gastroenterology/hepatology should be considered in those with aminotransferases persistently (> 6 mo) above normal to exclude other causes of liver disease or when FIB4 > 2.67 due to the increased risk of clinically significant fibrosis.”
> “In addition, a change in FIB-4 status category from low risk (< 1.3) to intermediate risk (1.3–2.67) to high risk (> 2.67) may be used to assess clinical progression.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.5-6"></a>

###### Primary risk assessment with FIB-4: thresholds and false negatives, EASL-EASD-EASO 2024 guideline

> “If FIB-4 is below 1.3, these individuals can be assumed to be at low risk of advanced fibrosis and may be re-assessed every 1-3 years. However, despite the high negative predictive value, clinicians should recognise that FIB-4 will miss around 10% of individuals with advanced fibrosis, and it has not been formally demonstrated that repeating FIB-4 over time is effective in picking up the remaining individuals.”
> “If FIB-4 is >1.3 (or >2.0 in individuals aged >65), the risk for advanced fibrosis is increased.”
> “One option is that individuals proceed to liver elastography (e.g. VCTE) as a second step to clarify the stage of fibrosis; this option is particularly suggested in individuals with FIB-4 values close to 2.67 or in high-risk conditions.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.1.5-7"></a>

###### Primary risk assessment with FIB-4: thresholds, AGA clinical care pathway

> “Previous studies have shown that FIB-4 score <1.3 (<2.0 in those older than 65 years) can reliably exclude advanced fibrosis in patients with NAFLD, with a negative predictive value of ≥90%.”
> “Patients with FIB-4 score >2.67 are at high risk for advanced fibrosis,”
> “The remaining 30%-40% of patients with an FIB-4 test would likely have values in the indeterminate range (ie, 1.3–2.67).”

Source: [Kanwal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8819923/)

<a id="topic-2.2.1.5-8"></a>

###### Screening with FIB-4 in type 2 diabetes or prediabetes: ADA Standards of Care 2026

> “4.22a Screen adults with type 2 diabetes or with prediabetes, particularly those with obesity or other cardiometabolic risk factors or established cardiovascular disease, for their risk of having or developing cirrhosis related to metabolic dysfunction–associated steatohepatitis (MASH) using a calculated fibrosis-4 index (FIB-4)”
> “4.23 Adults with type 2 diabetes or prediabetes with a FIB-4 ≥ 1.3 should have additional risk stratification by liver stiffness measurement with transient elastography, or, if unavailable, the enhanced liver fibrosis (ELF) test. B”
> “A value of <1.3 is considered low risk of having advanced fibrosis (F3–F4) and for developing adverse liver outcomes, while ≥1.3 is considered as having a higher probability of at-risk MASH clinically significant fibrosis (≥F2) and increased risk of adverse liver outcomes. A value of >2.67 confers a high risk of having advanced fibrosis (F3–F4), and referral to the liver specialist is warranted without additional testing.”
> “In individuals with diabetes ≥65 years of age, higher cutoffs for FIB-4 have been recommended (1.9–2.0 rather than ≥1.3)”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.1.5-9"></a>

###### Aminotransferases: frequently normal in clinically significant fibrosis

> “Aminotransferase levels are frequently normal in patients with advanced liver disease due to NASH and should not be used in isolation to exclude the presence of NASH with clinically significant fibrosis”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

> “A screening strategy relying on elevated plasma aminotransferases >40 units/L would miss most individuals with MASH in these settings, as at-risk MASH with clinically significant fibrosis (≥F2) is frequently observed with plasma aminotransferases below the commonly used cutoff of 40 units/L”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.1.5-10"></a>

###### Vibration-controlled transient elastography: liver stiffness thresholds, AASLD 2023 practice guidance

> “A recent meta-analysis suggested that a VCTE-derived liver stiffness measurement (LSM) <8 kPa can be used to rule out advanced fibrosis, especially if used sequentially after FIB-4.”
> “LSMs by VCTE between 8 and 12 kPa may be associated with fibrotic NASH, and LSM > 12 kPa is associated with a high likelihood of advanced fibrosis, although the positive predictive value is low (range: 0.34–0.71).”
> “In identifying patients with cirrhosis, a sequential approach with a FIB-4 > 3.48 and LSM by VCTE ≥ 20 kPa had a specificity of 90%.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.5-11"></a>

###### Vibration-controlled transient elastography: liver stiffness thresholds, AGA clinical care pathway

> “In a study of 450 consecutive adults who underwent liver biopsy and FibroScan for suspected NAFLD at 7 centers, the Youden cutoff value for F≥F2 was 8.2 kPa.”
> “A value of >12.1 kPa on VCTE indicates that clinically significant fibrosis is likely, with positive predictive values of 76% and 88% in patients seen in diabetes and hepatology clinic populations, respectively, although the positive predictive value can be low in primary care populations.”
> “We recommend that patients with discordant or indeterminate LSM results (ie, 8.0–12.0 kPa) in primary care and endocrine clinics be referred to hepatology where, like high-risk patients, they might need to undergo either a liver biopsy or MRE for further diagnostic evaluation.”

Source: [Kanwal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8819923/)

<a id="topic-2.2.1.5-12"></a>

###### Vibration-controlled transient elastography and ELF: thresholds in type 2 diabetes or prediabetes, ADA Standards of Care 2026

> “An LSM value of <8.0 kPa has a good negative predictive value to exclude advanced fibrosis (≥F3–F4)”
> “If the LSM is ≥8.0 kPa, the risk for advanced fibrosis (≥F3-F4) is higher and such individuals should be referred to the hepatologist”
> “Individuals with ELF ≥9.8 are considered at high risk of having MASH with advanced liver fibrosis (≥F3–F4) and therefore are at risk for adverse liver outcomes”
> “An ELF <9.8 suggests an individual is at low risk of advanced liver fibrosis and may be followed in the nonspecialty clinic with repeat testing in ≥2 years but may need repeat testing more often if ELF is between 9.2 and 9.7.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.1.5-13"></a>

###### Enhanced Liver Fibrosis test: thresholds, AASLD 2023 practice guidance

> “The ELF panel is a proprietary blood test consisting of three elements involved in matrix turnover: hyaluronic acid, tissue inhibitor of metalloproteinase-1, and N-terminal procollagen III peptide. An ELF score of ≥ 9.8 reliably identifies patients with NAFLD at increased risk of progression to cirrhosis and liver-related clinical events.”
> “Note that in patients with confirmed or suspected advanced fibrosis, an ELF ≥ 11.3 is a predictor of future liver-related events and is approved for this purpose; use of other ELF cutoffs in secondary risk assessment is based on expert option.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.5-14"></a>

###### Magnetic resonance elastography: accuracy and thresholds, AASLD 2023 practice guidance

> “MRE is more sensitive than VCTE in the detection of fibrosis stage ≥ 2”
> “Although MRE is not a first-line approach to risk stratification in a patient with NAFLD, it can be an important tool if clinical uncertainty exists, if there is a need for concomitant cross-sectional imaging, or when other elastography techniques are unavailable.”
> “An LSM by MRE ≥ 5 kPa is suggestive of cirrhosis”
> “Note that the units for LSM by VCTE and MRE are both kilopascals, but the scales are different.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.5-15"></a>

###### Rule-out and rule-in cut-offs of non-invasive tests for fibrosis and at-risk MASH, EASL-EASD-EASO 2024 guideline

| Non-invasive test | Rule-out cut-off | Rule-in cut-off |
| --- | --- | --- |
| FIB-4 | “F3: 1.3” | “F3: 2.67” |
| ELF | “F3: 7.7” | “F3: 9.8” |
| VCTE liver stiffness | “F3: 8 kPa” | “F3: 12 kPa” |
| MEFIB (MRE combined with FIB-4) | “F2: MRE <3.3 kPa and FIB-4 <1.6” | “F2: MRE ≥3.3 kPa and FIB-4 ≥1.6” |

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.1.5-16"></a>

###### FibroScan-AST score for at-risk NASH: rule-out and rule-in cut-offs

> “The most predictive model combined LSM, CAP, and AST, and was designated FAST (FibroScan-AST).”
> “Cutoff for sensitivity (≥0·90) was 0·35 and for specificity (≥0·90) was 0·67 in the derivation cohort”

Source: [Newsome et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7066580/)

<a id="topic-2.2.1.5-17"></a>

###### Selection of resmetirom candidates with non-invasive tests: AASLD 2024 guidance update

> “There are no FDA-approved noninvasive tests to diagnose MASH with F2-F3 or to monitor response to pharmacotherapy.”
> “Notably, the FDA-approved label does not require liver biopsy to confirm the diagnosis of fibrotic MASH. While MASH can only be definitively diagnosed by histologic examination, patient selection in practice is based on evidence of steatosis and fibrosis as determined by NILDA methodologies among persons with cardiometabolic risk factors without other causes of steatosis, notably alcohol consumption of more than 20 g/d for women and more than 30 g/d for men.”
> “In general, imaging-based NILDAs, such as liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) or magnetic resonance elastography (MRE),”
> “In the MAESTRO-NASH trial, participants were screened with VCTE and those with LSM >8.5 kPa in whom liver histology demonstrated MASH with F2-F3 were enrolled. Among enrolled participants, the median (interquartile range) LSM by VCTE was 12 kPa (10-15 kPa) and the mean LSM by MRE was 3.5 kPa. The median (interquartile range) of the enhanced liver fibrosis score was 9.7 (9.2-10.4).”
> “For example, 50% of participants with biopsy-proven F2-F3 in the MAESTRO-NASH trial had LSM by VCTE that was outside the interquartile range of 10 kPa to 15 kPa.”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

<a id="topic-2.2.1.5-18"></a>

###### Selection of semaglutide candidates with non-invasive tests: AASLD 2025 guidance update

> “Semaglutide (Wegovy) candidates should have MASH with stages 2–3 fibrosis, identified using non-invasive tests (NITs) such as VCTE (8–15 kPa), MRE (3.1–4.4 kPa), or ELF (9.2–10.5), rather than liver biopsy, which is impractical and unnecessary for most patients. In those with VCTE (15–20 kPa), MRE (4.4–5 kPa), or ELF (10.5–11.3), an individualized decision to treat should be based on exclusion of cirrhosis with another confirmatory NIT, or cross-sectional imaging excluding nodular-appearing liver contour and signs of portal hypertension, or a platelet count of <150,000/mm3.”
> “Semaglutide is not approved as an indication for patients with MASH cirrhosis (VCTE >20 kPa, MRE >5.0 kPa, ELF >11.3, and/or evidence of portal hypertension).”
> “A FIB-4 score below 1.3 excludes advanced fibrosis (F3 or greater) in 99% of all patients and 95% of patients with multiple cardiometabolic risks in the primary care setting.”
> “To be clear, FIB-4 should not be used as a single rule-in or rule-out test for semaglutide eligibility for patients with MASLD/MASH.”
> “The recommended range of 8–15 kPa included ~50% of the study population, while up to 19% of participants had LSM <8 kPa, and up to 32.5% of participants had LSM ≥15 kPa.”

Source: [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated)

<a id="topic-2.2.1.5-19"></a>

###### Diagnosis rate of noncirrhotic NASH with moderate to advanced fibrosis: US population calculator for resmetirom eligibility

> “Published analyses suggest a diagnosis rate of ~ 10% (range 3.3–14.3%) and ~ 16% year-over-year growth in the treatment-eligible population.”
> “Estimation of the treatment-eligible population for resmetirom depends importantly on NASH diagnosis rates, which are predicted to be < 15% in the 3 years after drug approval.”
> “First, from additional analysis of NHANES data, it is estimated that 14.3% of prevalent patients with F2/F3 NASH have received a diagnosis of liver disease in a clinical setting (based on survey responses)”

Source: [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/)

<a id="topic-2.2.1.5-20"></a>

###### Prevalence of diagnosed NASH: US adults, National Health and Wellness Survey 2016

> “Data came from the 2016 National Health and Wellness Survey, a nationally representative patient-reported outcomes survey conducted in the United States.”
> “The 2016 prevalence of diagnosed NASH among the US adult population was 0.15%.”

Source: [Tapper et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10077759/)

<a id="topic-2.2.1.5-21"></a>

###### Self-reported liver disease awareness: US adults with MASLD and with liver stiffness 8 to 15 kPa, NHANES 2017 to 2023

> “This study utilized the NHANES data cycle 2017–2020 and 2021–2023, a nationally representative survey of the noninstitutionalized U.S. population conducted by the National Center for Health Statistics (NCHS), which included vibration-controlled transient elastography (VCTE) data.”
> “Individuals with MASLD and LS 8–15 kPa were considered resmetirom-eligible in this study.”
> “Awareness of liver disease among individuals with MASLD remained low, with 5.8% (95% CI: 4.5%–7.2%) pre-pandemic and 6.7% (95% CI: 5.4%–8.1%) late-pandemic reporting awareness (p=0.36). Among those eligible for resmetirom, awareness was 12.1% (95% CI: 5.4%–18.8%) pre-pandemic and 10.3% (95% CI: 6.4%–14.2%) late-pandemic (p=0.63).”

Source: [Alp et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12520227/)

<a id="topic-2.2.1.5-22"></a>

###### Underdiagnosis of at-risk MASH in type 2 diabetes or prediabetes

> “Clinicians underestimate the prevalence of at-risk MASH and do not consistently implement appropriate screening strategies in people with prediabetes or type 2 diabetes, thus missing a chance to establish an early diagnosis. This pattern of underdiagnosis is compounded by sparse referral to specialists and inadequate prescription of medications with potential efficacy in MASH”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

Additional sources: [Sterling et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/38489523/); [Sterling et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/38489518/); [Cusi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35569886/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Asymptomatic course: detection by imaging or liver chemistries

> “In most patients, NAFLD is asymptomatic or associated with vague symptoms, often leaving patients undiagnosed.”
> “Patients with NAFLD are most commonly referred with incidentally noted hepatic steatosis on imaging or elevated liver chemistries.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

> “Unless specific testing is done to identify NAFLD, the condition is typically silent until advanced and potentially irreversible liver impairment occurs. For this reason, the majority of patients with NAFLD are unaware of having this serious condition.”

Source: [Duell et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35418240/)

> “MASH is commonly symptomatic only during later stages of the disease and symptoms can be highly non-specific, making diagnosis challenging for physicians.”

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

<a id="topic-2.2.1.6-2"></a>

###### Physician-reported signs and symptoms survey: US adults with MASH, 2019 and 2022

> “We assessed work productivity burden in a real-world population with suspected/confirmed MASH, comparing work productivity and symptoms across subgroups (risk status, age, BMI, and comorbidities) in the USA using secondary data from Adelphi Real World MASH Disease Specific Programmes™, cross-sectional surveys of physicians and consulting patients in 2019 and 2022.”
> “Fourteen prespecified individual physician-reported features of MASH were evaluated by the survey: fatigue, sleep disturbance, insomnia, general weakness, unexplained weight loss, hair loss, changes to personality, memory loss, jaundice, aching/discomfort in upper right abdomen, itchy skin, swelling in the legs/ankles/feet, tendency to bleed and bruise more easily, and swelling of the abdomen.”
> “These risk categories were: low-risk MASH (liver biopsy fibrosis stages F0–2, VCTE <8.0 kPa; FIB-4 <1.3); indeterminate (liver biopsy n/a, VCTE >8.0–12.0 kPa; FIB-4 n/a); and high-risk MASH (liver biopsy fibrosis stages F3–4, VCTE >12 kPa; FIB-4 ≥1.3).”
> “Of the 14 reported signs and symptoms, 11 were significantly associated with both physician-stated fibrosis stage and/or AASLD-derived risk category.”

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

| Physician-reported sign or symptom, n (%) | Overall (n = 424) | AASLD-derived low risk (n = 141) | AASLD-derived indeterminate risk (n = 30) | AASLD-derived high risk (n = 82) |
| --- | --- | --- | --- | --- |
| None | “167 (39.4)” | “58 (41.1)” | “6 (20.0)” | “9 (11.0)” |

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

<a id="topic-2.2.1.6-3"></a>

###### Constitutional symptoms: fatigue, sleep disturbance, and general weakness

| Physician-reported sign or symptom, n (%) | Overall (n = 424) | AASLD-derived low risk (n = 141) | AASLD-derived indeterminate risk (n = 30) | AASLD-derived high risk (n = 82) |
| --- | --- | --- | --- | --- |
| Fatigue | “230 (54.2)” | “71 (50.4)” | “22 (73.3)” | “70 (85.4)” |
| Sleep disturbance | “100 (23.6)” | “27 (19.1)” | “8 (26.7)” | “39 (47.6)” |
| Insomnia | “37 (8.7)” | “13 (9.2)” | “3 (10.0)” | “11 (13.4)” |
| General weakness | “68 (16.0)” | “19 (13.5)” | “6 (20.0)” | “29 (35.4)” |

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

> “Non-specific symptoms of fatigue, sleep disturbance, and general weakness associated with MASH and other conditions predicted work impact in low-risk MASH.”

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

> “Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and patients with MASH in Canada, France, Germany, and Italy between January 2024 and June 2024.”
> “In all patients, fatigue was the most reported symptom (48.1%, n = 1,268/2,636) followed by sleep disturbance (25.3%, n = 667/2,636), and general weakness (23.7%, n = 625/2,636; Table S3).”

Source: [Marquardt et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13019595/)

<a id="topic-2.2.1.6-4"></a>

###### Fatigue and pruritus: adults with bridging fibrosis or compensated cirrhosis due to NASH, STELLAR 3 and 4 baseline

> “Specifically, PROs (Short Form–36, Chronic Liver Disease Questionnaire–NASH, Euro‐Qol 5 Dimension, and Work Productivity and Activity Impairment instruments) were assessed at baseline in patients with histologically confirmed bridging fibrosis (F3) or compensated cirrhosis (F4) due to NASH enrolled in STELLAR 3 and 4.”
> “Among the included 1,669 patients with advanced NASH (mean age = 58 ± 9 years, 48% F3, 42% with psychiatric comorbidities), 33% and 27% had fatigue and pruritus, respectively.”
> “The median pruritus score was 6 (interquartile range [IQR] 4‐7) and did not differ between patients with bridging fibrosis and compensated cirrhosis (P = 0.55).”
> “Conclusion: Clinically significant fatigue and pruritus are common in patients with advanced NASH, and these symptoms negatively affect PROs.”

Source: [Younossi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7603531/)

<a id="topic-2.2.1.6-5"></a>

###### Fatigue, pruritus, and sleep disorders: adults with MASLD in the Global NAFLD/MASLD Registry

> “Patients with MASLD were prospectively enrolled into the Global NAFLD/MASLD Registry.”
> “A total of 8034 patients with MASLD from 39 countries (age 54±12 years, 46% male, 50% type 2 diabetes, 39% advanced fibrosis) were included. At baseline, 25% reported significant pruritus, 35% significant fatigue, and 34% sleep disorders, and 10% had all 3 symptoms.”
> “At 1-year follow-up, over half of the patients with baseline symptoms continued to experience them, and 14% to 18% developed de novo symptoms.”

Source: [Younossi et al. (2026c)](https://pubmed.ncbi.nlm.nih.gov/42925568/)

<a id="topic-2.2.1.6-6"></a>

###### Abdominal and skin symptoms: right upper quadrant discomfort, pruritus, and jaundice

> “MASH has been associated with symptoms such as fatigue, abdominal pain, and poor sleep quality.”

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

| Physician-reported sign or symptom, n (%) | Overall (n = 424) | AASLD-derived low risk (n = 141) | AASLD-derived indeterminate risk (n = 30) | AASLD-derived high risk (n = 82) |
| --- | --- | --- | --- | --- |
| Aching/discomfort in upper right abdomen | “43 (10.1)” | “15 (10.6)” | “2 (6.7)” | “23 (28.0)” |
| Itchy skin | “35 (8.3)” | “13 (9.2)” | “5 (16.7)” | “10 (12.2)” |
| Jaundice | “14 (3.3)” | “3 (2.1)” | “1 (3.3)” | “8 (9.8)” |

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

<a id="topic-2.2.1.6-7"></a>

###### Cognitive symptoms: memory loss and changes to personality

> “Obesity and cognitive impairment are also common in individuals with MASH.”

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

| Physician-reported sign or symptom, n (%) | Overall (n = 424) | AASLD-derived low risk (n = 141) | AASLD-derived indeterminate risk (n = 30) | AASLD-derived high risk (n = 82) |
| --- | --- | --- | --- | --- |
| Memory loss | “11 (2.6)” | “3 (2.1)” | “0 (0.0)” | “7 (8.5)” |
| Changes to personality | “9 (2.1)” | “4 (2.8)” | “0 (0.0)” | “4 (4.9)” |

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

> “Patients were grouped as: early fibrosis (stage 0–2) without additional CVRM comorbidities (EFnoC); early fibrosis with additional CVRM comorbidities (EFwC); or advanced fibrosis (stage 3–4) with additional CVRM comorbidities (AFwC).”
> “Patients with AFwC had significantly higher symptom burden compared with those with EFnoC across multiple symptoms (fatigue, p = 0.0006; itchy skin, p = 0.0191; emotional impact, p = 0.0073; activity limitations, p <0.0001; cognitive symptoms, p = 0.0012; and social impact, p = 0.0007; Table 1).”

Source: [Marquardt et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13019595/)

<a id="topic-2.2.1.6-8"></a>

###### Psychiatric symptoms: anxiety and depression in adults with diagnosed NASH

> “After adjusting for baseline demographics and characteristics, NASH (N = 136) compared to the matched general population cohort (N = 544), reported significantly lower (worse) mental (MCS 43.19 vs. 46.22, p = 0.010) and physical (PCS 42.04 vs. 47.10, p < 0.001) status, higher % with anxiety (37.5% vs 25.5%, p = 0.006) and depression (43.4% vs 30.1%, p = 0.004),”
> “More NASH patients reported anxiety (37.5% vs. 25.5%, p = 0.006) and depression (43.4% vs. 30.1%, p = 0.004), but sleep difficulties did not differ between cohorts (Fig. 2).”

Source: [Tapper et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10077759/)

<a id="topic-2.2.1.6-9"></a>

###### Physical examination: features of insulin resistance and of advanced liver disease

> “Body fat distribution (eg, android vs. gynoid, lipodystrophic), features of insulin resistance (eg, dorsal-cervical fat pad, acanthosis nigricans), features of advanced liver disease (eg, firm liver, splenomegaly, prominent abdominal veins, ascites, gynecomastia, spider angiomata, palmar erythema)”
> “Initial evaluation of such patients should include screening for metabolic comorbidities, assessment of alcohol intake, and exclusion of other causes of liver disease as well as physical examination to identify signs of insulin resistance and advanced liver disease (Table 1).”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.6-10"></a>

###### Signs of fluid retention, bleeding, and hepatic decompensation

| Physician-reported sign or symptom, n (%) | Overall (n = 424) | AASLD-derived low risk (n = 141) | AASLD-derived indeterminate risk (n = 30) | AASLD-derived high risk (n = 82) |
| --- | --- | --- | --- | --- |
| Swelling in legs, ankles, feet | “42 (9.9)” | “11 (7.8)” | “1 (3.3)” | “20 (24.4)” |
| Swelling of abdomen | “26 (6.1)” | “1 (0.7)” | “0 (0.0)” | “16 (19.5)” |
| Tendency to bleed and bruise more easily | “9 (2.1)” | “1 (0.7)” | “0 (0.0)” | “6 (7.3)” |

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

> “The principal outcomes included death from any cause, hepatic decompensation (clinically apparent ascites, overt encephalopathy, or variceal hemorrhage),”
> “Encephalopathy (in 30 patients) and ascites (in 19) were the most common new decompensation events.”

Source: [Sanyal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8881985/)

Additional sources: [Huang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40050362/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Cirrhosis: prevalence in US adults with MASLD, NHANES 2017 to 2020

> “We used National Health and Nutrition Examination Surveys (NHANES 2017-2020) to estimate the prevalence of cirrhosis and clinically significant (CS)-portal hypertension in alcohol-associated liver disease (ALD), MetALD, viral hepatitis to include chronic hepatitis B (CHB) and chronic hepatitis C (CHC), and metabolic dysfunction-associated steatotic liver disease (MASLD).”
> “In the general population, the prevalence of ALD-cirrhosis was 0.08%, MetALD-cirrhosis 0.19%, CHB-cirrhosis 0.01%, CHC-cirrhosis 0.10%, MASLD-cirrhosis 1.27%, ALD + viral hepatitis-cirrhosis 0.08%, and other cirrhosis 0.87%.”
> “The prevalence of cirrhosis in the United States is 2.6% while the prevalence of CS-portal hypertension is 0.98%. Individuals with MASLD comprise the majority of US residents with cirrhosis.”

Source: [Younossi et al. (2025c)](https://pubmed.ncbi.nlm.nih.gov/39879587/)

<a id="topic-2.2.1.7-2"></a>

###### Cirrhosis: progression to clinical decompensation

> “Those with cirrhosis require biannual screening for HCC as well as screening for varices and monitoring for signs or symptoms of decompensation.”
> “Among patients with cirrhosis, progression to clinical decompensation ranges from 3% to 20% per year.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.7-3"></a>

###### Hepatic decompensation and hepatocellular cancer by fibrosis stage: adults with biopsy-confirmed NAFLD, NASH CRN NAFLD Database 2

> “A total of 1773 adults with NAFLD were followed for a median of 4 years.”
> “The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14).”
> “After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3).”
> “The study included adults who had liver biopsies that could be evaluated and that revealed NAFLD and who had at least one follow-up visit after 48 weeks.”

Source: [Sanyal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8881985/)

<a id="topic-2.2.1.7-4"></a>

###### Projected decompensated cirrhosis and hepatocellular carcinoma: US NAFLD population, 2015 to 2030 model

> “Incidence of decompensated cirrhosis will increase 168% to 105,430 cases by 2030, while incidence of HCC will increase by 137% to 12,240 cases.”
> “Projected changes in NAFLD‐related cirrhosis, advanced liver disease, and liver‐related mortality were quantified through 2030.”

Source: [Estes et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5767767/)

<a id="topic-2.2.1.7-5"></a>

###### Hepatocellular carcinoma: incidence in US veterans with NAFLD

> “We compared 296,707 NAFLD patients with 296,707 matched controls. During 2,382,289 person-years [PY] of follow-up, 490 NAFLD patients developed HCC (0.21/1000 PY). HCC incidence was significantly higher among NAFLD patients vs. controls (0.02/1000 PY; hazard ratio, 7.62, 95% confidence interval=5.76–10.09). Among patients with NAFLD, those with cirrhosis had the highest annual incidence of HCC (10.6 /1000 PY).”
> “In medical record reviews, 20% of NAFLD patients with HCC had no evidence of cirrhosis.”
> “We conducted a retrospective cohort study from a total of 130 facilities in the Veterans Health Administration.”

Source: [Kanwal et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6279617/)

<a id="topic-2.2.1.7-6"></a>

###### Hepatocellular carcinoma without cirrhosis: systematic review and meta-analysis of NAFLD-related HCC

> “Of 3631 records identified, 61 studies (done between January, 1980, and May, 2021; 94 636 patients) met inclusion criteria.”
> “A higher proportion of patients with NAFLD-related hepatocellular carcinoma did not have cirrhosis (38·5%, 95% CI 27·9–50·2) compared with patients with hepatocellular carcinoma secondary to other causes (14·6%, 8·7–23·4; p<0·0001).”

Source: [Tan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9718369/)

<a id="topic-2.2.1.7-7"></a>

###### Hepatocellular carcinoma risk with F3 fibrosis and surveillance recommendations

> “In adults with non-cirrhotic MASLD or MASH in the absence of severe fibrosis (i.e. those with fibrosis stage <F3) assessed by non-invasive markers or liver biopsy, surveillance for early detection of hepatocellular carcinoma is currently not recommended (LoE 3, weak recommendation, consensus).”
> “In adults with non-cirrhotic MASLD or MASH in the presence of severe fibrosis (F3) assessed by non-invasive markers or liver biopsy, surveillance may be considered based on an individual risk assessment (LoE 4, weak recommendation, strong consensus).”
> “Individuals with F3 fibrosis have an intermediate risk of developing HCC that is lower than that of individuals with cirrhosis, but not negligible.”
> “In the national Veterans Affairs study, a FIB-4 >2.67, suggestive of advanced fibrosis (F3/F4), was associated with an increased risk of HCC (0.39/1,000 vs. 0.04/1,000 PY in individuals with persistently low FIB-4) in the absence of cirrhosis.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.1.7-8"></a>

###### Liver transplantation: NASH/MASH share of US and European transplant recipients, 2000 to 2022

> “Data from 2 large LT registries: the US Scientific Registry of Transplant Recipients (SRTR) and the European Liver Transplant Registry (ELTR), years 2000-2022, were compared.”
> “NASH/MASH also increased: SRTR 9%-28%, ELTR 5%-12%. From SRTR, NASH/MASH was the common etiology by 2022;”
> “ALD and NASH/MASH are now leading indications for liver transplantation in 2 large global regions.”

Source: [Younossi et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/40674288/)

<a id="topic-2.2.1.7-9"></a>

###### Liver transplantation: MASH share of the US waitlist for steatotic liver disease, 2010 to 2023

> “Steatotic liver disease (SLD) is the leading indication for liver transplantation (LT) among U.S. adults.”
> “We identified 65,675 adults on the LT waitlist secondary to SLD (median age 57 years old [IQR 50–64], 65.1% men, 74.9% NHW, 3.2% AA, 17.9% Hispanic, 2.5% API, 1.1% AI/AN, and 0.5% multiracial) from 2010 to 2023 (Table 1). Overall, 44.5% had MASH (vs 55.5% ALD) while 17.2% had HCC (vs 82.8% non-HCC).”

Source: [Patel et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11869966/)

<a id="topic-2.2.1.7-10"></a>

###### Cardiovascular disease: risk of fatal and non-fatal events by severity of NAFLD, meta-analysis

> “We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of incident CVD events.”
> “NAFLD was associated with a moderately increased risk of fatal or non-fatal CVD events (pooled random-effects HR 1·45, 95% CI 1·31-1·61;”
> “This risk markedly increased across the severity of NAFLD, especially the stage of fibrosis (pooled random-effects HR 2·50, 95% CI 1·68-3·72;”
> “CVD risk is further increased with more advanced liver disease, especially with higher fibrosis stage.”

Source: [Mantovani et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34555346/)

<a id="topic-2.2.1.7-11"></a>

###### Cardiovascular disease: principal cause of death, American Heart Association scientific statement

> “In addition to these serious complications, NAFLD is a risk factor for atherosclerotic cardiovascular disease, which is the principal cause of death in patients with NAFLD.”

Source: [Duell et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35418240/)

<a id="topic-2.2.1.7-12"></a>

###### Cardiovascular disease: atherosclerosis, heart failure, and arrhythmia

> “The most common causes of death in patients with NAFLD overall are cardiovascular disease (CVD) and nonhepatic malignancy, followed by liver disease.”
> “A strong association exists between NAFLD and atherosclerotic heart disease, heart failure, and arrhythmias, particularly atrial fibrillation.”
> “Furthermore, in a large prospectively studied observational cohort, the incidence of cardiac events was the same across all fibrosis stages; however, the number of cardiac events was relatively low.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

> “Overall, individuals with MASLD have a higher risk of non-fatal cardiovascular disease (HR 1.40),”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.1.7-13"></a>

###### Chronic kidney disease: risk of incident CKD, meta-analysis

> “We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of incident CKD.”
> “NAFLD was associated with a moderately increased risk of incident CKD (n=10 studies; random-effects HR 1.43, 95% CI 1.33 to 1.54;”
> “All risks were independent of age, sex, obesity, hypertension, diabetes and other conventional CKD risk factors.”

Source: [Mantovani et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/33303564/)

<a id="topic-2.2.1.7-14"></a>

###### Chronic kidney disease: higher prevalence with advanced fibrosis

> “A meta-analysis of 20 cross-sectional studies (n = 28,000 individuals) found that NAFLD was associated with a 2-fold increased prevalence of CKD.”
> “Recently published data from the NASH CRN demonstrate a higher prevalence of CKD in patients with advanced fibrosis compared with lower fibrosis stages.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

> “Emerging evidence suggests that MASLD increases the risk of CKD in people with type 2 diabetes, particularly when liver fibrosis is present”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.1.7-15"></a>

###### New-onset nonhepatic outcomes: adults with biopsy-confirmed NAFLD, NASH CRN NAFLD Database 2

> “New-onset hypertension (7.8 events per 100 person-years) was the most common new nonhepatic outcome, followed by type 2 diabetes (4.8 events per 100 person-years), chronic kidney disease (2.5 events per 100 person-years), cardiac events (0.8 events per 100 person-years), nonhepatic cancer (0.8 events per 100 person-years), and cerebrovascular events (0.4 events per 100 person-years).”
> “As compared with patients with stage F0 to F2 fibrosis, patients with stage F4 fibrosis also had a higher incidence of type 2 diabetes (7.53 vs. 4.45 events per 100 person-years) and a decrease of more than 40% in the estimated glomerular filtration rate (2.98 vs. 0.97 events per 100 person-years). The incidence of cardiac events and nonhepatic cancers were similar across fibrosis stages.”

Source: [Sanyal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8881985/)

<a id="topic-2.2.1.7-16"></a>

###### Type 2 diabetes: incident diabetes in NAFLD

> “The presence of NAFLD is associated with a 2- to 5-fold risk of incident diabetes,”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.7-17"></a>

###### Extrahepatic cancer: risk of incident extrahepatic cancers, meta-analysis

> “We performed a meta-analysis of observational studies to quantify the magnitude of the association between non-alcoholic fatty liver disease (NAFLD) and risk of extrahepatic cancers.”
> “NAFLD was significantly associated with a nearly 1.5-fold to twofold increased risk of developing GI cancers (oesophagus, stomach, pancreas or colorectal cancers). Furthermore, NAFLD was associated with an approximately 1.2-fold to 1.5-fold increased risk of developing lung, breast, gynaecological or urinary system cancers.”

Source: [Mantovani et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/33685968/)

<a id="topic-2.2.1.7-18"></a>

###### Extrahepatic cancer: leading contributor to excess mortality in biopsy-confirmed NAFLD, Sweden

> “This nationwide, matched cohort study included all individuals in Sweden with biopsy-confirmed NAFLD (1966–2017; n=10,568).”
> “The excess mortality associated with NAFLD was primarily from extra-hepatic cancer (4.5/1000PY; aHR=2.16, 95%CI=2.03–2.30), followed by cirrhosis (2.7/1000PY; aHR=18.15, 95%CI=14.78–22.30), cardiovascular disease (1.4/1000PY; aHR=1.35, 95%CI=1.26–1.44) and hepatocellular carcinoma (HCC)(1.2/1000PY; aHR=11.12, 95%CI=8.65–14.30).”

Source: [Simon et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8185553/)

> “In the general population, MASLD is not associated with increased overall cancer-related mortality,”
> “but it is associated with higher risk of HCC and certain extrahepatic cancers, mostly thyroid and gastrointestinal.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### SF-36 component scores, anxiety, and depression in 136 US adults with physician-diagnosed NASH versus matched general population and type 2 diabetes cohorts, 2016 National Health and Wellness Survey

> “Data came from the 2016 National Health and Wellness Survey, a nationally representative patient-reported outcomes survey conducted in the United States. Respondents with physician-diagnosed NASH, physician-diagnosed T2DM, and respondents from the general population were compared.”
> “After adjusting for baseline demographics and characteristics, NASH (N = 136) compared to the matched general population cohort (N = 544), reported significantly lower (worse) mental (MCS 43.19 vs. 46.22, p = 0.010) and physical (PCS 42.04 vs. 47.10, p < 0.001) status, higher % with anxiety (37.5% vs 25.5%, p = 0.006) and depression (43.4% vs 30.1%, p = 0.004)”
> “NASH cohort did not differ from matched T2DM cohort (N = 272) on mental or work-related WPAI scores, but had significantly worse physical status (PCS 40.52 vs. 44.58, p = 0.001), higher % with anxiety (39.9% vs 27.8%, p = 0.043)”

Source: [Tapper et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10077759/)

<a id="topic-2.2.1.8.1-2"></a>

###### SF-36 physical and mental health by fibrosis stage in 713 adults with NAFLD, NASH Clinical Research Network

> “QOL data were collected from adults with NAFLD enrolled in the NASH Clinical Research Network using the SF-36 survey and scores were compared to normative U.S. population scores.”
> “A total of 713 subjects with NAFLD (M=269, F=444) were included. Mean age of subjects was 48.3 years; 61% had definite NASH, and 28% had bridging fibrosis or cirrhosis.”
> “Subjects with NAFLD had worse physical (mean=45.2) and mental health scores (mean=47.6) compared to the U.S. population with (mean=50) and without (physical: 55.8, mental: 52.5) chronic illness.”
> “Subjects with cirrhosis had significantly (P<0.001) poorer physical health scores (38.4) vs. subjects with no (47.6), mild (46.2), moderate (44.6) or bridging fibrosis (44.6).”
> “Mental health scores did not differ between participants with and without NASH or by degree of fibrosis.”

Source: [David et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2692572/)

<a id="topic-2.2.1.8.1-3"></a>

###### Physical health-related patient-reported outcomes in 72 adults with biopsy-proven NASH and F2 or F3 fibrosis, as summarized in a systematic review

> “Biopsy-proven NASH with stage F2/F3 fibrosis (72)”
> “At baseline, physical health-related PROs of patients with NASH were lower than established general population levels, regardless of fibrosis stage (F3: p <0.05 for physical functioning, role-physical, general health, and PCS of SF-36; F2: p <0.05 for general health and PCS of SF-36)”
> “Health-related work productivity and activity impairment scores at baseline were significantly greater than 0 (p <0.05 except for absenteeism)”

Source: [Younossi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9418497/)

<a id="topic-2.2.1.8.1-4"></a>

###### Patient-reported outcomes in 1667 adults with NASH and F3 or F4 fibrosis versus the general population, STELLAR trial baseline

> “We analyzed data from 1667 patients (58 ± 9 years, 40% male, 52% with cirrhosis, 74% with diabetes) with NASH and bridging fibrosis or compensated cirrhosis (metavir scores, F3 or F4) enrolled in the phase 3 STELLAR trials of selonsertib (NCT03053050 and NCT03053063) who completed PRO questionnaires (SF-36, CLDQ-NASH, EQ-5D, or WPAI:SHP) before treatment initiation.”
> “Mean physical health-related PRO scores were significantly lower than those of the general population: patients with F4 fibrosis had score reductions of 4.4% to 12.9% in 6/8 SF-36 domains and patients with F3 fibrosis had score reductions of 3.9% to 11.7% in 4/8 domains (P < .01).”
> “In multivariate regression analysis, factors independently associated with lower PRO scores included having cirrhosis, female sex, higher body mass index, history of smoking, and diabetes or other comorbidities (P < .01).”

Source: [Younossi et al. (2019b)](https://pubmed.ncbi.nlm.nih.gov/30779990/)

<a id="topic-2.2.1.8.1-5"></a>

###### Fatigue and pruritus in 1,669 adults with NASH and bridging fibrosis or compensated cirrhosis, STELLAR 3 and 4 baseline

> “were assessed at baseline in patients with histologically confirmed bridging fibrosis (F3) or compensated cirrhosis (F4) due to NASH enrolled in STELLAR 3 and 4.”
> “Among the included 1,669 patients with advanced NASH (mean age = 58 ± 9 years, 48% F3, 42% with psychiatric comorbidities), 33% and 27% had fatigue and pruritus, respectively.”
> “All PRO scores of patients with fatigue were significantly impaired (mean up to −31% of a PRO range size in comparison to patients without fatigue).”
> “All PROs were impaired (by up to −19% of a range size, all P < 0.01) in patients with NASH with pruritus.”
> “The median pruritus score was 6 (interquartile range [IQR] 4‐7) and did not differ between patients with bridging fibrosis and compensated cirrhosis (P = 0.55).”
> “Although patients with bridging fibrosis had higher median fatigue scores (indicative of less fatigue) than those with cirrhosis (5.0 [IQR 4.0‐5.8] vs. 4.7 [3.5‐5.7]; P = 0.0028), the difference does not meet the threshold of a minimal clinically important difference for domain scores of the CLDQ‐NASH (approximately 0.5 points).”

Source: [Younossi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7603531/)

<a id="topic-2.2.1.8.1-6"></a>

###### Patient-reported outcomes and fibrosis improvement in 392 adults with NASH and bridging fibrosis or compensated cirrhosis, phase 2 trial NCT03449446

> “Patients with NASH with bridging fibrosis or compensated cirrhosis were enrolled in a phase 2, randomized, placebo‐controlled study of selonsertib, firsocostat, or cilofexor, alone or in two‐drug combinations (NCT03449446).”
> “A total of 392 patients with NASH (mean ± SD, 60 ± 9 years old; 35% men; 89% white; 72% diabetes; and 56% compensated cirrhosis) were included.”
> “Baseline Physical Functioning (PF) and Bodily Pain of SF‐36 and Fatigue and Worry of CLDQ‐NASH were significantly lower in patients with cirrhosis (total CLDQ‐NASH score mean ± SD, 4.91 ± 1.06 with cirrhosis vs. 5.16 ± 1.14 without cirrhosis; P < 0.05).”
> “After 48 weeks of treatment, patients with ≥1‐stage fibrosis improvement without worsening of NASH experienced improvement in EQ‐5D and five out of six CLDQ‐NASH domains (P < 0.05).”
> “Fibrosis regression was independently associated with greater improvements in PF and EQ‐5D scores, while NAS improvement was associated with improvement in fatigue and pruritus (all P < 0.05).”

Source: [Younossi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8279457/)

<a id="topic-2.2.1.8.1-7"></a>

###### CLDQ-MASH domain scores by histologic fibrosis stage (F3 to F4 versus F0 to F2) in adults with MASH

> “There were 4,213 MASH patients included: age 56 ± 11 years, 44% male, 65% type 2 diabetes, 69% advanced fibrosis (F3–F4).”
> “After item reduction and exploratory factor analysis with the training set (>90% variance), the CLDQ-MASH contained 35 items and seven domains.”
> “Notably, in the context of liver disease severity, the CLDQ-MASH was able to discriminate individuals with vs. without histologic advanced fibrosis (p <0.05 for three domains and the total score)”

Source: [Younossi et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11835563/)

| CLDQ-MASH score (mean ± SD; 1 to 7, higher is better) | Histologic F3–F4 (n = 1,917) | Histologic F0–F2 (n = 868) | p value |
| --- | --- | --- | --- |
| Total CLDQ-MASH | “5.10 ± 1.14” | “5.19 ± 1.18” | “0.0281” |
| Activity | “5.33 ± 1.46” | “5.41 ± 1.55” | “0.0316” |
| Fatigue | “4.50 ± 1.46” | “4.55 ± 1.49” | “0.28” |
| Systemic symptoms | “4.91 ± 1.33” | “5.05 ± 1.33” | “0.0091” |
| Worry | “5.11 ± 1.53” | “5.31 ± 1.52” | “0.0002” |

Source: [Younossi et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11835563/)

<a id="topic-2.2.1.8.1-8"></a>

###### CLDQ-NAFLD disease-specific instrument: 36 items in six domains

> “Thus, the resulting Chronic Liver Disease Questionnaire-Non-Alcoholic Fatty Liver Disease version instrument had 36 items grouped into six domains: Abdominal Symptoms, Activity, Emotional, Fatigue, Systemic Symptoms, and Worry.”
> “The domains' correlations with the most relevant domains of Short Form-36 exceeded 0.70.”

Source: [Younossi et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28211165/)

<a id="topic-2.2.1.8.1-9"></a>

###### EQ-5D and CLDQ-NAFLD index by early (F0 to F2) and advanced (F3 to F4) fibrosis in adults with NASH, United States and five European countries, GAIN study

> “The Global Assessment of the Impact of NASH (GAIN) study is a prevalence-based burden of illness study across Europe (France, Germany, Italy, Spain, and the UK) and the USA.”
> “Of the patients, 767 (20%) provided information on indirect costs and health-related quality of life using the EuroQOL 5-D (EQ-5D; n = 749) and Chronic Liver Disease Questionnaire – Non-Alcoholic Fatty Liver Disease (CLDQ-NAFLD) (n = 723).”
> “All patients were categorised as having early (F0–F2) or advanced (F3–F4) fibrosis stage.”
> “In general, there was a clear pattern of decreasing HRQoL score with worsening fibrosis score in all countries, with the exception of France, where similar scores were seen in both early and advanced fibrosis.”
> “The average CLDQ-NAFLD index was 4.9, with France having the highest score at 5.7 and the USA having the lowest score of 4.4 (Table 3).”

Source: [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/)

| Index and population, mean (SD) | Early (F0–F2) | Advanced (F3–F4) | Overall |
| --- | --- | --- | --- |
| EQ-5D index, United States (n = 58, 36, 94) | “0.80 (0.19)” | “0.67 (0.23)” | “0.75 (0.22)” |
| EQ-5D index, all countries (n = 531, 218, 749) | “0.80 (0.2)” | “0.62 (0.33)” | “0.75 (0.26)” |
| CLDQ-NAFLD index, USA (n = 55, 36, 91) | “4.7 (1.05)” | “4.0 (1.12)” | “4.4 (1.12)” |
| CLDQ-NAFLD index, all countries (n = 513, 210, 723) | “5.2 (1.1)” | “4.4 (1.4)” | “4.9 (1.2)” |

Source: [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/)

<a id="topic-2.2.1.8.1-10"></a>

###### EQ-5D-5L by fibrosis stage and cardiovascular, renal, and metabolic comorbidity in adults with MASH, Canada, France, Germany, and Italy, 2024

> “Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and patients with MASH in Canada, France, Germany, and Italy between January 2024 and June 2024.”
> “Patients were grouped as: early fibrosis (stage 0–2) without additional CVRM comorbidities (EFnoC); early fibrosis with additional CVRM comorbidities (EFwC); or advanced fibrosis (stage 3–4) with additional CVRM comorbidities (AFwC).”
> “Mean EQ-5D-5L scores were lower for EFwC patients (0.85 ± 0.16 [n = 524]) and AFwC patients (0.81 ± 0.18 [n = 113]) compared with EFnoC patients (0.90 ± 0.12 [n = 48], p <0.05 and p <0.001, respectively).”
> “Patients with AFwC experienced greater cognitive and emotional impairment, required professional caregivers more often, and had increased rates of hospitalization compared with those with EFwC.”

Source: [Marquardt et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13019595/)

<a id="topic-2.2.1.8.1-11"></a>

###### Baseline mapped EQ-5D utility by fibrosis stage in 800 adults with biopsy-confirmed MASH and F2 or F3 fibrosis, ESSENCE trial part 1

> “Adults with biopsy-confirmed MASH and fibrosis stage F2 or F3 were randomized 2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo plus standard of care.”
> “A total of 800 participants were included in this analysis (semaglutide 2.4 mg n = 534; placebo n = 266).”
> “31.3% of participants had stage 2 fibrosis, 68.8% had stage 3 fibrosis, and 55.9% had type 2 diabetes.”
> “Across the study population, the baseline mapped health utility (∼0.78, Table 1) was lower than that reported in the literature for a similar patient population (0.84).”

Source: [Augusto et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13651485/)

| Baseline group | Baseline EQ-5D utility, mean (SD) |
| --- | --- |
| Fibrosis stage 2, semaglutide (n = 169) | “0.783 (0.186)” |
| Fibrosis stage 2, placebo (n = 81) | “0.789 (0.190)” |
| Fibrosis stage 3, semaglutide (n = 365) | “0.792 (0.176)” |
| Fibrosis stage 3, placebo (n = 185) | “0.769 (0.194)” |

Source: [Augusto et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13651485/)

<a id="topic-2.2.1.8.1-12"></a>

###### Pruritus, fatigue, and sleep disorders in 8034 adults with MASLD, Global NAFLD/MASLD Registry

> “Patients with MASLD were prospectively enrolled into the Global NAFLD/MASLD Registry.”
> “A total of 8034 patients with MASLD from 39 countries (age 54±12 years, 46% male, 50% type 2 diabetes, 39% advanced fibrosis) were included. At baseline, 25% reported significant pruritus, 35% significant fatigue, and 34% sleep disorders, and 10% had all 3 symptoms.”
> “All 3 conditions, especially fatigue, were independently associated with significantly impaired HRQL and work productivity loss.”

Source: [Younossi et al. (2026c)](https://pubmed.ncbi.nlm.nih.gov/42925568/)

<a id="topic-2.2.1.8.1-13"></a>

###### SF-6D health utility in noncirrhotic and cirrhotic NAFLD, 89 outpatients

> “There were 89 patients with the spectrum of NAFLD completed the SF-36 questionnaire: 59 with non-cirrhotic NAFLD and 30 with cirrhosis.”
> “Patients with NAFLD had significantly lower quality of life and health utility scores than the general population (all p<0.0001).”
> “Furthermore, patients with cirrhosis had lower quality of life and utility scores than non-cirrhotic NAFLD patients: SF-6D 0.660±0.107 in non-cirrhotic NAFLD vs 0.551±0.138 in cirrhotic NAFLD (p=0.0003).”

Source: [Sayiner et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5013331/)

<a id="topic-2.2.1.8.1-14"></a>

###### Health-related quality of life in NASH: systematic review of 23 studies

> “Twenty-five publications covering 23 unique studies were identified. Overall, the data showed a substantial impact of NASH on HRQoL, particularly in terms of physical functioning and fatigue, with deterioration of physical and mental health as NASH progresses.”
> “Prevalent symptoms, including fatigue, abdominal pain, anxiety/depression, cognition problems, and poor sleep quality, adversely impact patients’ ability to work and perform activities of daily living and the quality of relationships.”
> “Most studies were rated ‘moderate’ at quality assessment, and all evaluable studies had inadequate control of confounders.”

Source: [Younossi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9418497/)

<a id="topic-2.2.1.8.1-15"></a>

###### Fibrosis stage and quality of life: meta-analysis of 13 cohort studies

> “Our meta-analysis included 13 studies, comprising 4428 patients with NAFLD; 2875 of these were reported to have NASH.”
> “Three studies examined the effects of increasing fibrosis on quality of life had inconsistent findings.”
> “Further studies are needed to assess the association between fibrosis stage and patient quality of life and establish that change in liver fibrosis stage is a valid endpoint for use in clinical trials.”

Source: [Taylor et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32027911/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Annual direct medical costs of NAFLD in the United States, steady-state prevalence model

> “We constructed a steady-state prevalence model to quantify this burden in the United States and Europe.”
> “In the United States, over 64 million people are projected to have NAFLD, with annual direct medical costs of about $103 billion ($1,613 per patient).”
> “Costs are highest in patients aged 45-65. The burden is significantly higher when societal costs are included.”

Source: [Younossi et al. (2016b)](https://pubmed.ncbi.nlm.nih.gov/27543837/)

<a id="topic-2.2.1.8.2-2"></a>

###### Lifetime direct costs of NASH and advanced NASH in US adults, Markov model, 2017

> “We constructed lifetime Markov models for all stages of NASH and a separate model to specifically identify the increased burden of advanced NASH (fibrosis stage >3).”
> “Costs included inpatient, outpatient, professional services, emergency department, and drug costs, which were obtained from the Center for Medicare and Medicaid Services Fee Schedule 2017 and published data.”
> “Lifetime costs of all NASH patients in the United States in 2017 will be $222.6 billion, and the cost of the advanced NASH population will be $95.4 billion.”

Source: [Younossi et al. (2019a)](https://pubmed.ncbi.nlm.nih.gov/30180285/)

<a id="topic-2.2.1.8.2-3"></a>

###### Direct medical and indirect costs by early (F0 to F2) and advanced (F3 to F4) fibrosis in adults with NASH, United States and five European countries, GAIN study, 2018

> “In total, 3,754 patients found to have NASH on liver biopsy were stratified by fibrosis score and by biomarkers as either early or advanced fibrosis.”
> “All patients were categorised as having early (F0–F2) or advanced (F3–F4) fibrosis stage.”
> “For 2018, the mean total annual per patient cost of NASH was €2,763, €4,917, and €5,509 for direct medical, direct non-medical, and indirect costs, respectively. National per-patient cost was highest in the USA and lowest in France. Costs increased with fibrosis and decompensation, driven by hospitalisation and comorbidities. Indirect costs were driven by work loss.”
> “Overall, costs for patients with advanced fibrosis were higher (€3,983) than for those with early-stage fibrosis (€2,224).”
> “A major share of indirect costs resulted from early retirement or stopping working (74%), followed by time off work in the previous 12 months (26%).”
> “Patient indirect or productivity-related costs correlated positively with NASH severity, because patients with relatively more severe disease had to stop working (12% vs. 5% in patients with early-stage disease) or cited that their retirement was the result of NASH (13% vs. 5% in patients with early-stage disease)”

Source: [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/)

| Mean annual cost per patient (SD) | Early fibrosis | Advanced fibrosis | USA |
| --- | --- | --- | --- |
| NASH-related direct medical (physician-reported, n = 2,604, 1,150, 1,221) | “€2,224 (19,956)” | “€3,983 (23,788)” | “€4,881 (42,077)” |
| Total direct medical, NASH-related and non-NASH | “€3,883 (20,634)” | “€6,727 (25,052)” | “€7,258 (36,704)” |
| Indirect (patient-reported, n = 546, 221, 97) | “€5,939 (15,989)” | “€12,642 (21,813)” | “€13,435 (29,493)” |

Source: [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/)

<a id="topic-2.2.1.8.2-4"></a>

###### Annual non-drug costs by fibrosis stage and liver health state in a US cost-effectiveness model, based on US estimates from the GAIN study

> “We used NASH-specific costs for early and advanced fibrosis based on the US estimates from the GAIN study where direct medical resource utilization information was collected on web-based case record forms by specialists. These estimates were then adjusted to an annual time period.”

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

| Health state | Annual cost, base case | Lower value | Upper value |
| --- | --- | --- | --- |
| F0 to F2 | “$7,063” | “$5,650” | “$8,475” |
| F3 | “$8,423” | “$6,738” | “$10,108” |
| Compensated cirrhosis | “$34,275” | “$27,420” | “$41,131” |
| Decompensated cirrhosis | “$158,480” | “$126,784” | “$190,176” |
| Hepatocellular carcinoma | “$115,002” | “$92,001” | “$138,002” |

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

<a id="topic-2.2.1.8.2-5"></a>

###### Annual direct medical cost by liver health state, 2025 US dollars, payer-perspective model funded by a diagnostics manufacturer

> “Our study was conducted from a health-care payer perspective and included direct medical costs associated with each health state (Table 2), including inpatient and outpatient, medications, and procedures.”
> “All costs were sourced from published literature using a combination of micro-costing and gross-costing methods, adjusted using the Consumer Price Index, and reported in 2025 United States dollars.”
> “This study was funded by Siemens Healthcare Diagnostics Inc, Tarrytown, NY, USA who contributed to conceptualization, design, data collection, analysis, decision to publish, and preparation of the article.”

Source: [Chen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087396/)

| Health state | Direct medical cost, 2025 USD per year, base value | Range |
| --- | --- | --- |
| F0-1 | “500” | “480–510” |
| F2-3 | “1180” | “640–1720” |
| Compensated cirrhosis | “23,360” | “18,210–28,510” |
| Decompensated cirrhosis | “36,290” | “30,190–42,390” |
| Hepatocellular carcinoma | “85,840” | “60,900–110,790” |

Source: [Chen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087396/)

<a id="topic-2.2.1.8.2-6"></a>

###### All-cause annual costs by FIB-4 category in 6,743 US adults with NASH, linked electronic health record and claims data, 2016 to 2020

> “Adults with NASH were identified in the Veradigm Health Insights Electronic Health Record Database and linked Komodo claims data. The index date was the earliest coded NASH diagnosis between 1 January 2016 and 31 December 2020 with valid FIB-4 and ≥6 months of database activity and continuous enrollment pre- and post-index.”
> “Among 6,743 qualifying patients, index FIB-4 was ≤0.95 for 2,345 patents, 0.95-2.67 for 3,289 patients, 2.67-4.12 for 571 patients, and >4.12 for 538 patients (mean age 55.8 years; 62.9% female).”
> “Mean age, comorbidity burden, cardiovascular disease risk, and healthcare utilization increased with increasing FIB-4. Mean ± SD annual costs increased from $16,744±$53,810 to $34,667±$67,691 between the lowest and highest FIB-4 cohorts”
> “A one-unit increase in FIB-4 at index was associated with a 3.4% (95%CI: 1.7%-5.2%) increase in mean total annual cost and an 11.6% (95%CI: 8.0%-15.3%) increased likelihood of hospitalization.”

Source: [Tapper et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36866575/)

<a id="topic-2.2.1.8.2-7"></a>

###### Health care costs after identification of FIB-4-defined F3 or F4 fibrosis in 251,725 commercially insured US adults with NAFLD or NASH, 2008 to 2016

> “Using the Optum Research Database, a retrospective cohort study was conducted among 251,725 commercially insured adult patients with ≥1 NAFLD/NASH diagnosis from January 1, 2008, to August 31, 2016, and laboratory data required to calculate FIB‐4 scores.”
> “The prevalence of FIB‐4‐based F3 and F4 fibrosis was 0.40%‐2.72% and 1.03%‐1.61%, respectively. Almost 50% of patients identified with FIB‐4‐based F3 or F4 had type 2 diabetes, cardiovascular disease, or renal impairment.”
> “Total all‐cause health care costs increased significantly from pre‐index to post‐index for patients with FIB‐4‐based F3 fibrosis across most criteria (17%‐29% increase) and patients with FIB‐4‐based F4 fibrosis across all criteria (47%‐48% increase). Inpatient costs were the primary drivers of this increment.”

Source: [Gordon et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7327220/)

<a id="topic-2.2.1.8.2-8"></a>

###### Annual all-cause costs by advanced liver disease stage in 485,774 commercially insured US adults with NAFLD or NASH, 2016 US dollars

> “Adult NAFLD/NASH patients were identified retrospectively from MarketScan Commercial claims (2006-2016). Following initial NAFLD/NASH diagnosis, advanced liver diseases were identified using the first diagnosis as their index date. Mean annual all-cause HRU and costs (2016 USD) were reported.”
> “Within the database, 485,774 NAFLD/NASH patients met eligibility criteria.”
> “Compared with NAFLD/NASH without advanced liver diseases (adjusted costs: $23,860), the annual cost of CC, DCC, LT, and HCC were 1.22, 5.64, 8.27, and 4.09 times higher [adjusted costs: $29,078, $134,448, $197,392, and $97,563 (P<0.0001)]. Inpatient admissions significantly drove increasing HRU.”

Source: [Wong et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8500367/)

<a id="topic-2.2.1.8.2-9"></a>

###### Inpatient and outpatient charges and payments in Medicare beneficiaries with NAFLD, with and without cirrhosis, 2010

> “Medicare beneficiaries (January 1, 2010 to December 31, 2010) with NAFLD diagnosis by International Classification of Diseases, Ninth Revision codes in the absence of other liver diseases were selected.”
> “A total of 976 inpatients and 4742 outpatients with NAFLD were included—87% were white, 36% male, 30% had cardiovascular disease (CVD) or metabolic syndrome conditions, and 12% had cirrhosis.”
> “For inpatients, median total hospital charge was $36,289. NAFLD patients with cirrhosis had higher charges and payments than noncirrhotic NAFLD patients ($61,151 vs. $33,863 and $18,804 vs. $10,146, P<0.001).”
> “For outpatients, median total charge was $9,011. NAFLD patients with cirrhosis had higher charges and payments than noncirrhotic NAFLD patients ($12,049 vs. $8,830 and $2,586 vs. $1,734, P<0.001).”

Source: [Sayiner et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5300028/)

<a id="topic-2.2.1.8.2-10"></a>

###### Health care resource use and work impairment in 136 US adults with NASH versus matched general population, 2016 National Health and Wellness Survey

> “Data came from the 2016 National Health and Wellness Survey, a nationally representative patient-reported outcomes survey conducted in the United States.”
> “After adjusting for baseline demographics and characteristics, NASH (N = 136) compared to the matched general population cohort (N = 544)”
> “In terms of HRU, there were more visits to an HCP (8.43 vs. 5.17, p < 0.001), ER visits (0.73 vs. 0.38, p = 0.021), and hospitalizations (0.43 vs. 0.21, p = 0.024) for NASH compared to the matched general population cohort (Fig. 3) and NASH patients reported more specialty visits (p’s < 0.05), for example, more general/family medicine provider visits (1.49 vs. 1.14, p = 0.040), hepatologist visits (0.10 vs. 0.02, p = 0.022), and gastroenterologist visits (0.38 vs. 0.12 p < 0.001)”
> “Impairment of work and activity on WPAI was significantly higher for NASH patients compared to matched general population cohort, including absenteeism (17.0% vs. 9.2%, p = 0.041) and presenteeism (32.9% vs. 22.2%, p = 0.019), as well as overall work impairment (39.6% vs. 26.2%, p = 0.011), and activity impairment (44.7% vs. 30.8%, p < 0.001)”

Source: [Tapper et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10077759/)

<a id="topic-2.2.1.8.2-11"></a>

###### Work productivity and activity impairment by fibrosis risk category in 429 US adults with MASH, 2019 and 2022 physician and patient surveys

> “We assessed work productivity burden in a real-world population with suspected/confirmed MASH, comparing work productivity and symptoms across subgroups (risk status, age, BMI, and comorbidities) in the USA using secondary data from Adelphi Real World MASH Disease Specific Programmes™, cross-sectional surveys of physicians and consulting patients in 2019 and 2022.”
> “These risk categories were: low-risk MASH (liver biopsy fibrosis stages F0–2, VCTE <8.0 kPa; FIB-4 <1.3); indeterminate (liver biopsy n/a, VCTE >8.0–12.0 kPa; FIB-4 n/a); and high-risk MASH (liver biopsy fibrosis stages F3–4, VCTE >12 kPa; FIB-4 ≥1.3).”
> “In total, 87 physicians and 429 individuals with MASH provided data. The impact of MASH on activities was greater in high-versus low-risk MASH (activity impairment score: high risk, 30.8%; low risk, 17%; p <0.001 across all risk categories). Overall work impairment scores were 18.8% in low-risk and 19.9% in high-risk MASH.”
> “This analysis was funded by Eli Lilly and Company.”

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

<a id="topic-2.2.1.8.2-12"></a>

###### Hospitalization and work impairment by fibrosis stage in adults with MASH, Canada, France, Germany, and Italy, 2024

> “Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and patients with MASH in Canada, France, Germany, and Italy between January 2024 and June 2024.”
> “AFwC patients also experienced greater impairment while working compared with EFnoC patients (29.7 ± 26.5 [n = 35] vs. 16.1 ± 21.3 [n = 28], p = 0.0271).”
> “On average, the overall hospitalization rate was low in the 12 months before data collection (mean: 0.1 ± 1.1 times). However, those with AFwC were significantly more likely to be hospitalized because MASH comorbidities compared with those with EFnoC (p <0.0001; Table S7).”

Source: [Marquardt et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13019595/)

<a id="topic-2.2.1.8.2-13"></a>

###### Modeled US health care costs averted by a hypothetical therapy halting fibrosis progression in MASLD with moderate to advanced fibrosis

> “The US MASLD disease burden model is a Markov model which forecasts disease progression and the impact of diagnosis and treatment. Diagnostic costs for all patients and direct costs for patients with MASLD-related liver disease were also incorporated.”
> “The scenarios in which a hypothetical therapy halts fibrosis progression resulted in reductions in cases of decompensated cirrhosis (11-39%), hepatocellular carcinoma (10-34%), and liver-related deaths (8-31%), a 9-31% reduction in cumulative DALYs, and $40.5 to $99.1B incremental healthcare costs averted.”
> “Increasing diagnosis and treatment for the MASLD population with moderate-to-advanced fibrosis will prevent advanced liver disease and death and will result in reducing the associated direct healthcare costs.”

Source: [Wallace et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39832655/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Informal and professional caregiver costs by fibrosis stage in adults with NASH, United States and five European countries, GAIN study

> “The secondary objective was to estimate the total annualised cost of the disease, including all health-related items and non-health and indirect costs accrued by patients and their families.”
> “The overall direct non-medical cost per patient was €4,917 (Table 5). Professional (34%) and informal (48%) caregivers accounted for most of these costs and these percentages increased with disease severity (fibrosis stage).”
> “Caregivers, whether professional or informal, accounted for the greatest proportion of direct non-medical costs.”
> “The remaining direct non-medical costs resulted from transport, disability allowances, alternative therapies, home alteration, and OTC remedies.”

Source: [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/)

| Mean annual direct non-medical cost per patient (SD), patient-reported | Early fibrosis (n = 546) | Advanced fibrosis (n = 221) | USA (n = 97) |
| --- | --- | --- | --- |
| Non-medical | “€1,704 (5,785)” | “€4,661 (9,839)” | “€3,243 (7,685)” |

Source: [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Fibrosis staging required for coverage of resmetirom or semaglutide: liver biopsy, VCTE, MRE, or ELF test, national commercial prior authorization policy

> “Patient has stage F2 or F3 fibrosis prior to initiating treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet [documentation required] identified by ONE of the following (a, b, c, or d):”
> “Liver biopsy performed within the 3 years preceding treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet [documentation required]; OR”
> “Vibration-controlled transient elastography (VCTE) performed within the 6 months preceding treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet [documentation required]; OR”
> “Magnetic resonance elastography (MRE) performed within the 6 months preceding treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet [documentation required]; OR”
> “Enhanced Liver Fibrosis™ (ELF) test performed within the 6 months preceding treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet [documentation required] with a score of ≥ 9.2 to ≤ 10.5 [documentation required]”

Source: [Cigna Rezdiffra prior authorization policy (2026)](https://a.static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_852_coveragepositioncriteria_hepatology_rezdiffra_pa.pdf)

<a id="topic-2.2.1.8.4-2"></a>

###### Unit costs of the ELF test, transient elastography, imaging, and liver biopsy in hepatology workup, 2025 US dollars, model funded by a diagnostics manufacturer

> “Hepatology workup costs comprised of specialist consultation and fibrosis staging, which reflected standard practice using a combination of liver biopsy, ELF, and imaging-based modalities (TE, MRE, or liver ultrasound). Resource use frequencies for each staging component were estimated from the same real-world cohort and are reported in Table 2.”
> “All costs were sourced from published literature using a combination of micro-costing and gross-costing methods, adjusted using the Consumer Price Index, and reported in 2025 United States dollars.”
> “This study was funded by Siemens Healthcare Diagnostics Inc, Tarrytown, NY, USA who contributed to conceptualization, design, data collection, analysis, decision to publish, and preparation of the article.”

Source: [Chen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087396/)

| Test or service, 2025 USD | Cost | Resource use in hepatology workup |
| --- | --- | --- |
| ELF test, one-time screening cost (range) | “200” (“170–230”) | Not applicable |
| FIB-4 test, one-time screening cost | “0” | Not applicable |
| Hepatology consultation | “257” | “100” |
| ELF test in hepatology workup | “185” | “25” |
| Transient elastography | “32” | “25” |
| Ultrasound liver | “136” | “200” |
| MRI or CT abdomen or liver | “323” | “5” |
| Liver biopsy | “354” | “15” |

Source: [Chen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087396/)

<a id="topic-2.2.1.8.4-3"></a>

###### Lifetime costs of FIB-4 and ELF screening strategies with resmetirom treatment of F2 to F3 fibrosis in high-risk US primary care patients, model funded by a diagnostics manufacturer

> “We developed a decision-analytic model for MASLD natural history and treatment to compare 6 noninvasive test strategies using Fibrosis-4 (FIB-4) and/or enhanced liver fibrosis (ELF) tests at varying cutoffs. Patients identified with significant fibrosis were referred for hepatology staging (biopsy and/or imaging-based), and eligible individuals were considered for Resmetirom ($47,400/y; mean duration: 1.6–1.8 year).”
> “Sequential screening with ELF (cutoff 9.80) following indeterminate FIB-4 (1.3–2.67) was the most cost-effective, yielding 8.610 QALYs and $96,990 in lifetime costs at a $100,000/QALY threshold. ELF-alone screening at a 9.00 cutoff maximized QALYs and individuals treated but increased unnecessary referrals.”
> “Resmetirom treatment costs were obtained from Centers for Medicare & Medicaid Services ($47,400/y at the time of analysis) and applied exclusively to individuals with F2-3 fibrosis.”
> “This study was funded by Siemens Healthcare Diagnostics Inc, Tarrytown, NY, USA who contributed to conceptualization, design, data collection, analysis, decision to publish, and preparation of the article.”

Source: [Chen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087396/)

<a id="topic-2.2.1.8.4-4"></a>

###### Costs of FIB-4 followed by VCTE or ELF screening strategies for high-risk MASLD in US primary care, with resmetirom treatment of F2 or F3 fibrosis

> “Six screening strategies were assessed, using either vibration-controlled transient elastography (VCTE) or the enhanced liver fibrosis (ELF) test as a second-line test following an initial Fibrosis-4 (FIB-4) assessment as the first line NIT. The model included treatment effects of resmetirom for metabolic dysfunction-associated steatohepatitis (MASH) patients with F2 or F3 fibrosis.”
> “All screening strategies for high-risk MASLD in US incurred additional costs compared to no screening, ranging from $13 587 to $14 730 per patient with T2D and $14 274 to $15 661 per patient with obesity.”
> “ICERs ranged from $26 913 to $27 884 per QALY for T2D patients and $23 265 to $24  992 per QALY for patients with obesity. While ICERs were influenced by VCTE availability, they remained cost-effective when using ELF as the second-line test.”

Source: [Younossi et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39373093/)

<a id="topic-2.2.1.8.4-5"></a>

###### Five-year direct costs of FIB-4 followed by ELF or VCTE screening of all US adults living with diabetes, 2026 to 2030, study funded by test and drug manufacturers

> “This study aimed to estimate the direct healthcare costs of two MASLD and MASH screening strategies among all people living with diabetes in Brazil, Germany, Japan, the Kingdom of Saudi Arabia (KSA), Spain and the United States (US), from 2026 to 2030.”
> “The Fibrosis‐4 (FIB‐4) index was used as the first line test, followed by the Enhanced Liver Fibrosis (ELF) test or vibration‐controlled transient elastography (VCTE) for confirmatory assessment.”
> “Over 5 years, the estimated costs of Strategy 1 ranged from R$0.7–1.3 billion for Brazil, €346–617 million for Germany, ¥80–172 billion for Japan, SAR 3.7–6.0 billion for the KSA, €591–949 million for Spain and $2.7–15.2 billion for the US.”
> “Strategy 2 resulted in higher costs, ranging from R$1.2–2.0 billion for Brazil, €528–940 million for Germany, ¥121–262 billion for Japan, SAR 5.7–9.2 billion for the KSA, €0.9–1.4 billion for Spain and $4.1–23 billion for the US.”
> “This study was funded by Boehringer Ingelheim, Echosens and Novo Nordisk.”

Source: [Lazarus et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12589856/)

<a id="topic-2.2.1.8.4-6"></a>

###### Number of VCTE examinations needed under the current FIB-4-based algorithm for 75.8 million US adults with MASLD, NHANES 2017 to 2020

> “Current guidelines recommend using the Fibrosis-4 score for initial identification of subjects at risk of future complications.”
> “We interrogated the National Health and Nutrition Examination Survey data, 2017–20, in which a sample of subjects representative of US civilian population underwent vibration-controlled transient elastography (VCTE).”
> “In the survey data, 2,691 subjects, projecting to 75.8 million US adults, were found to have MASLD, of whom 11% had LSM 8–12 kPa and 6% LSM ≥12 kPa. When the current guideline was applied, 18.1 million VCTEs would be needed to diagnose 3.5 million subjects with LSM ≥8 kPa and 1.7 million subjects with LSM ≥12 kPa.”
> “would detect 4.9 million with LSM ≥8 kPa and 2.5 million subjects with LSM ≥12 kPa (37% and 45% improvement over the current guideline, respectively), while requiring 5.0 million fewer VCTEs (28% reduction).”

Source: [Kim et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12832100/)

<a id="topic-2.2.1.8.4-7"></a>

###### Confirmatory fibrosis testing needed after FIB-4 screening of 8,366 US primary care patients with type 2 diabetes or prediabetes, 2022 to 2024

> “This cross-sectional study evaluated primary care patients with T2DM or prediabetes and a FIB-4 score between 2022 and 2024.”
> “Of 8,366 patients with T2DM and prediabetes, 2,064 (25%) had FIB-4s in need of confirmatory risk assessment. The expanded FIB-4 fibrosis screening for T2DM and prediabetes increased the number of patients needing confirmatory fibrosis risk assessment by 9.1 times compared to those with diagnoses of MASLD (n=228).”
> “Expanded screening for advanced liver fibrosis would substantially increase the number of patients who need confirmatory testing for liver fibrosis, increasing cost and straining access.”
> “Second, we only included patients from a single academic healthcare system in the southeastern United States”

Source: [Patel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094816/)

<a id="topic-2.2.1.8.4-8"></a>

###### Use of liver biopsy and transient elastography in US and European NASH practice, GAIN study

> “Key differences in practice between the EU5 countries and USA were that imaging techniques were less frequently used in the USA: 618 (51%) patients received an ultrasound compared with an average of 76% in EU5 countries; and only a minority received transient elastography: 157 (13%) compared with a total of 1,071 (42%) in EU5 countries.”
> “The reported rate of liver biopsy was lowest in Spain (130 patients, 25%), and highest in the USA (697, 57%).”
> “For instance, in the USA, the main sources of data were the Medicaid National Average Drug Acquisition Cost database for drug costs, the Centre for Medicare and Medicaid services for test procedures and surgeries, and the American Medical Association for consultations.”

Source: [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/)

<a id="topic-2.2.1.8.4-9"></a>

###### Number of diagnostic tests and biopsy confirmation rate by fibrosis stage in adults with MASH, Canada, France, Germany, and Italy, 2024

> “Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and patients with MASH in Canada, France, Germany, and Italy between January 2024 and June 2024.”
> “However, only 22.9% (n = 532/2,319) of patients had their MASH diagnosis confirmed by liver biopsy. Non-invasive diagnostic techniques were reported for 97.3% of patients (n = 2,513/2,584).”
> “To diagnose MASH, a mean of 19.6 ± 11.29 tests were conducted in total. The most common test type was comorbidity assessments (5.5 ± 4.1). On average, significantly more diagnostic tests were required for patients with EFwC (19.7 ± 11.3, p = 0.0054) and AFwC (23.8 ± 11.9, p <0.0001) compared with those with EFnoC (17.4 ± 10.1).”
> “In addition, patients with AFwC required significantly more imaging scans to monitor MASH in the 2 years before data collection compared with those with EFnoC (p <0.0001).”

Source: [Marquardt et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13019595/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Lifestyle Intervention and Weight Loss

<a id="topic-2.2.2.1.1-1"></a>

###### EASL-EASD-EASO guideline recommendations: weight loss targets, diet quality, and physical activity in adults with MASLD

> “In adults with MASLD, dietary and behavioural therapy-induced weight loss should be recommended to improve liver injury, as assessed histologically or non-invasively (LoE 1, strong recommendation, strong consensus).”
> “In adults with MASLD and overweight, dietary and behavioural therapy-induced weight loss should aim at a sustained reduction of ≥5% to reduce liver fat, 7-10% to improve liver inflammation, and ≥10% to improve fibrosis (LoE 2, strong recommendation, strong consensus).”
> “In adults with MASLD, improving diet quality (similar to the Mediterranean dietary pattern), limiting the consumption of ultra-processed food (rich in sugars and saturated fat) and avoiding sugar-sweetened beverages should be recommended to improve histologically or non-invasively assessed liver injury (LoE 2, strong recommendation, strong consensus).”
> “In adults with MASLD, physical activity and exercise should be recommended to reduce steatosis, tailored to the individual’s preference and ability (preferably >150 min/week of moderate or 75 min/week of vigorous-intensity physical activity) (LoE 1, strong recommendation, strong consensus).”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.1-2"></a>

###### EASL-EASD-EASO guideline: achievement and maintenance of weight loss

> “However, a limited proportion of individuals achieve a weight reduction of ≥5%”
> “In addition, long-term adherence to behavioural changes is often insufficient, as seen in obesity trials”
> “Only a few studies have performed 12-24 month follow-ups, showing a maximal weight loss at 6 months, followed by a gradual weight regain to a net weight loss of about 5% at 12-24 months and partial regain of liver lipid content and stiffness”
> “Further follow-up studies are needed to determine the long-term effectiveness of dietary and behavioural therapy-induced weight loss (including its magnitude) on clinical liver-related outcomes and liver-related mortality (LoE 3, strong consensus).”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.1-3"></a>

###### AASLD practice guidance statements: caloric deficit and physical activity

> “Thus, actionable statements rather than formal recommendations are provided herein.”
> “Patients with NAFLD who are overweight or obese should be prescribed a diet that leads to a caloric deficit. When possible, diets with limited carbohydrates and saturated fat and enriched with high fiber and unsaturated fats (eg, Mediterranean diet) should be encouraged due to their additional cardiovascular benefits”
> “Patients with NAFLD should be strongly encouraged to increase their activity level to the extent possible. Individualized prescriptive exercise recommendations may increase sustainability and have benefits independent of weight loss”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.2.1.1-4"></a>

###### AASLD practice guidance: magnitude of weight loss and its maintenance

> “Weight loss of 3%–5% improves steatosis, but greater weight loss (> 10%) is generally required to improve NASH and fibrosis”
> “Few patients (≤ 10%) achieve effective weight loss despite structured interventions at 1 year, and fewer than half of these maintain the weight lost 5 years after intervention”
> “Weight loss improves hepatic steatosis, NASH, and hepatic fibrosis in a dose-dependent manner.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.2.1.1-5"></a>

###### ADA Standards of Care recommendation 4.25: lifestyle change in adults with type 2 diabetes or prediabetes and MASLD

> “Adults with type 2 diabetes or prediabetes, particularly with overweight or obesity, who have metabolic dysfunction–associated steatotic liver disease (MASLD) should be recommended lifestyle changes using an interprofessional approach that promotes weight loss, ideally within a structured nutrition plan and physical activity program for cardiometabolic benefits B and histological improvement. C”
> “There is consensus that a minimum weight loss goal of 5%, preferably ≥10%, is needed to improve liver histology”
> “Individualized, structured weight loss and exercise programs offer greater benefit than standard counseling in people with MASLD”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.2.1.1-6"></a>

###### AASLD updates on resmetirom and semaglutide: lifestyle modification alongside pharmacotherapy

> “Regardless of resmetirom treatment status, best practices in metabolic dysfunction-associated steatotic liver disease (MASLD) management should include comprehensive lifestyle modification (nutrition, exercise, and behavior modification) and optimal control of comorbid metabolic conditions”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

> “Lifestyle modification remains the cornerstone of MASLD/MASH management alongside semaglutide.”

Source: [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated)

<a id="topic-2.2.2.1.1-7"></a>

###### Weight loss and histology in biopsy-proven NASH: prospective cohort in Havana, Cuba, 293 participants, 261 with paired biopsies at week 52

> “We conducted a prospective study of 293 patients with histologically proven NASH who were encouraged to adopt recommended lifestyle changes to reduce their weight over 52 weeks, from June 2009 through May 2013, at a tertiary medical center in Havana, Cuba.”
> “Paired liver biopsies were available from 261 patients.”
> “At week fifty-two, 88 subjects (30%) had lost ≥5% of their weight.”
> “All patients who lost ≥10% of their weight had reductions NAS, 90% had resolution of NASH, and 45% had regression of fibrosis.”

Source: [Vilar-Gomez et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25865049/)

<a id="topic-2.2.2.1.1-8"></a>

###### Intensive lifestyle intervention: randomized trial in 31 overweight or obese adults with biopsy-proven NASH, 48 weeks

> “Thirty one overweight or obese individuals (Body mass index 25-40 kg/m2) with biopsy proven NASH were randomized in a 2:1 ratio to receive intensive lifestyle intervention (LS) or structured education (control).”
> “After 48 weeks of intervention, participants assigned to LS lost an average of 9.3% of their weight vs 0.2% in the control group (p=0.003).”
> “A higher proportion of participants in the LS group had a reduction of NAS ≥ 3 points or had post treatment NAS ≤ 2 as compared to the control group (72% vs 30%, p=0.03).”
> “Post intervention liver biopsy was completed in 28/31 (90%) of participants, 18/21 (86%) in the lifestyle intervention group and 10/10 (100%) in the control group.”

Source: [Promrat et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2799538/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Thyroid Hormone Receptor-beta Agonists

<a id="topic-2.2.2.1.2-1"></a>

###### FDA-approved indication and dosage: resmetirom

> “REZDIFFRA® is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).”
> “This indication is approved under accelerated approval based on improvement of MASH and fibrosis”
> “Avoid use of REZDIFFRA in patients with decompensated cirrhosis”
> “The recommended dosage of REZDIFFRA is based on actual body weight.”
> “<100 kg, the recommended dosage is 80 mg orally once daily.”
> “≥100 kg, the recommended dosage is 100 mg orally once daily.”

Source: [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf)

<a id="topic-2.2.2.1.2-2"></a>

###### MAESTRO-NASH week 52 primary end points: 966-patient primary analysis population

> “We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3”
> “Overall, 966 patients formed the primary analysis population (322 in the 80-mg resmetirom group, 323 in the 100-mg resmetirom group, and 321 in the placebo group).”
> “NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group and 29.9% of those in the 100-mg resmetirom group, as compared with 9.7% of those in the placebo group (P<0.001 for both comparisons with placebo).”
> “Fibrosis improvement by at least one stage with no worsening of the NAFLD activity score was achieved in 24.2% of the patients in the 80-mg resmetirom group and 25.9% of those in the 100-mg resmetirom group, as compared with 14.2% of those in the placebo group (P<0.001 for both comparisons with placebo).”
> “Diarrhea and nausea were more frequent with resmetirom than with placebo.”

Source: [Harrison et al. (2024)](https://www.nejm.org/doi/full/10.1056/NEJMoa2309000)

<a id="topic-2.2.2.1.2-3"></a>

###### EASL-EASD-EASO guideline recommendations: resmetirom in non-cirrhotic MASH with significant fibrosis

> “If approved locally and dependent on the label, adults with non-cirrhotic MASH with significant liver fibrosis (stage ≥2) should be considered for treatment with resmetirom as a MASH-targeted therapy, as this treatment demonstrated histological efficacy on steatohepatitis and fibrosis in a large phase III registrational trial with an acceptable safety and tolerability profile (LoE 2, strong recommendation, consensus).”
> “Treatment with resmetirom, if approved locally, may be considered for individuals with MASLD who are non-cirrhotic and with documentation of either: (A) advanced fibrosis; (B) at-risk steatohepatitis with significant fibrosis (by liver biopsy, when available, or by non-invasive panels validated for that purpose); or (C) risk of adverse liver-related outcomes (e.g. by elastography- or biomarker-defined thresholds) (LoE 3, open recommendation, consensus).”
> “No MASH-targeted pharmacotherapy can currently be recommended for adults with MASH at the cirrhotic stage (LoE 5, weak recommendation, strong consensus).”
> “For individuals with MASLD undergoing therapy with resmetirom, data on sustainability of histological benefits, individual prediction of response, liver-related outcomes and long-term safety are not currently available (LoE 5, strong consensus).”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.2-4"></a>

###### EASL-EASD-EASO guideline: response rates, duration of therapy, and use with GLP-1 receptor agonists

> “Similarly, there is currently no evidence to provide confident guidance on when to stop treatment, particularly considering that about 70-80 % of participants did not respond to treatment according to histological criteria.”
> “Therefore, it appears reasonable to use resmetirom according to the same criteria in individuals already receiving GLP1RA treatment.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.2-5"></a>

###### AASLD update to the practice guidance: resmetirom patient selection and exclusions

> “This article serves as an update to the 2023 AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease”
> “Resmetirom can be considered for treatment of adults with MASH and moderate to advanced liver fibrosis (consistent with F2-F3).”
> “Noninvasive liver disease assessment—preferably imaging-based test results—consistent with MASH with F2-F3, or”
> “Historical liver biopsy demonstrating MASH with F2-F3 (and without evidence of concomitant, histologically active autoimmune liver disease).”
> “Resmetirom is not recommended for persons with compensated or decompensated cirrhosis, concomitant uncontrolled active liver diseases (such as autoimmune hepatitis and primary biliary cholangitis), or ongoing alcohol consumption greater than 20 g/d for women or greater than 30 g/d for men.”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

<a id="topic-2.2.2.1.2-6"></a>

###### AASLD update to the practice guidance: continuation or discontinuation of resmetirom at 12 months

> “The decision to continue treatment beyond 12 months should be based on assessing whether a patient has evidence of improvement, worsening or treatment failure, or disease stabilization.”
> “Continuation of resmetirom treatment in persons with significant fibrosis improvement is recommended.”
> “Among persons with evidence of worsening liver disease at 12 months of treatment, discontinuation of resmetirom should be considered.”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

<a id="topic-2.2.2.1.2-7"></a>

###### AASLD update to the practice guidance: resmetirom in persons already receiving other therapies with potential MASH benefit

> “The MAESTRO-NASH trial notably excluded individuals who initiated or dose-modified drugs with GLP-1 receptor agonist activity, thiazolidinediones, or vitamin E within 6 months of randomization”
> “Among persons already taking any of these medications with potential efficacy for treating MASH, data are insufficient to guide prescribers about whether or when to initiate resmetirom therapy.”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

<a id="topic-2.2.2.1.2-8"></a>

###### ADA Standards of Care recommendation 4.28: referral for thyroid hormone receptor-β agonist treatment in adults with type 2 diabetes or prediabetes

> “For consideration of treatment with a thyroid hormone receptor-β agonist in adults with type 2 diabetes or prediabetes with MASLD with moderate (F2) or advanced (F3) liver fibrosis on liver histology, or by a validated imaging-based or blood-based test, refer to a gastroenterologist or hepatologist with expertise in MASLD management. A”
> “Given complexities associated with selection of an individual for therapy, drug cost, and treatment monitoring, therapy should be individualized and initiated by a hepatologist or gastroenterologist with expertise in MASH within an interprofessional team.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Incretin-based Therapies

<a id="topic-2.2.2.1.3-1"></a>

###### FDA-approved indication and dosage: semaglutide 2.4 mg injection for noncirrhotic MASH

> “WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity:”
> “For the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis”
> “The recommended maintenance dosage of WEGOVY injection for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults is 2.4 mg injected subcutaneously once weekly. If patients do not tolerate the maintenance dosage of 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly.”

Source: [Novo Nordisk WEGOVY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf)

<a id="topic-2.2.2.1.3-2"></a>

###### ESSENCE part 1 primary end points: planned interim analysis of the first 800 patients at week 72

> “In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks. The results of a planned interim analysis conducted at week 72 involving the first 800 patients are reported here (part 1).”
> “Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001).”
> “A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001).”
> “Gastrointestinal adverse events were more common in the semaglutide group.”

Source: [Sanyal et al. (2025)](https://www.nejm.org/doi/full/10.1056/NEJMoa2413258)

<a id="topic-2.2.2.1.3-3"></a>

###### AASLD update to the practice guidance on semaglutide: indication, patient selection, and cirrhosis

> “This practice recommendation serves as an update to the 2023 AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction–associated steatotic liver disease (MASLD), and provides implementable guidance on patient selection for treatment, consideration of comorbidities, and monitoring of treatment safety and efficacy of semaglutide.”
> “Semaglutide (Wegovy) candidates should have MASH with stages 2–3 fibrosis, identified using non-invasive tests (NITs) such as VCTE (8–15 kPa), MRE (3.1–4.4 kPa), or ELF (9.2–10.5), rather than liver biopsy, which is impractical and unnecessary for most patients.”
> “Semaglutide is not approved as an indication for patients with MASH cirrhosis (VCTE >20 kPa, MRE >5.0 kPa, ELF >11.3, and/or evidence of portal hypertension).”

Source: [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated)

<a id="topic-2.2.2.1.3-4"></a>

###### AASLD update to the practice guidance on semaglutide: combination with resmetirom

> “Combination use with resmetirom at the dose of 2.4 mg/week has not been studied.”
> “However, semaglutide and resmetirom have not been studied as a combination therapy for MASH, nor have they been compared for relative efficacy.”

Source: [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated)

<a id="topic-2.2.2.1.3-5"></a>

###### ADA Standards of Care recommendations 4.26 and 4.27a: GLP-1 RA and dual GIP and GLP-1 RA in adults with type 2 diabetes and MASLD

> “In adults with type 2 diabetes, MASLD, and overweight or obesity, consider using a glucagon-like peptide 1 receptor agonist (GLP-1 RA) with demonstrated benefits in MASH A or a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA with potential benefits in MASH B for the treatment of obesity as an adjunctive therapy to lifestyle interventions for weight loss.”
> “In adults with type 2 diabetes and biopsy-proven MASH or those at high risk for liver fibrosis (based on noninvasive tests), a GLP-1 RA is preferred for glycemic management due to beneficial effects on MASH. A Pioglitazone B or a dual GIP and GLP-1 RA B can be considered for glycemic management due to potential beneficial effects on MASH.”
> “Semaglutide is currently the only glucose-lowering or obesity medication that is FDA approved for the treatment of MASH.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.2.1.3-6"></a>

###### EASL-EASD-EASO guideline recommendations on GLP-1 receptor agonists, issued while the semaglutide phase 3 trial was ongoing

> “In the absence of a formal demonstration of histological improvement in large, well conducted, phase III trials, glucagon-like peptide 1 receptor agonists (GLP1RA) cannot currently be recommended as MASH-targeted therapies (LoE 5, strong recommendation, strong consensus).”
> “GLP1RAs are safe to use in MASH (including compensated cirrhosis) and should be used for their respective indications, namely type 2 diabetes and obesity, as their use improves cardiometabolic outcomes (LoE 2, strong recommendation, strong consensus).”
> “In case of substantial weight loss induced by GLP1RAs, a hepatic histological benefit could be expected, although this has not been extensively documented so far (LoE 2, strong consensus).”
> “A large registrational, phase III study with semaglutide is ongoing.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.3-7"></a>

###### AASLD practice guidance statement on semaglutide for its approved indications, issued before any GLP-1 RA was approved for NASH

> “Although several GLP-1RAs are approved for treatment of T2DM, none has been approved for treatment of NASH.”
> “Semaglutide can be considered for its approved indications (T2DM/obesity) in patients with NASH as it confers a cardiovascular benefit and improves NASH”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.2.1.3-8"></a>

###### Tirzepatide: SYNERGY-NASH phase 2 trial in MASH with F2 or F3 fibrosis, 190 randomized participants with missing week 52 biopsies imputed

> “We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks.”
> “Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group.”
> “The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons).”
> “The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42).”
> “Larger and longer trials are needed to further assess the efficacy and safety of tirzepatide for the treatment of MASH.”

Source: [Loomba et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38856224/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Pioglitazone and Vitamin E

<a id="topic-2.2.2.1.4-1"></a>

###### AASLD practice guidance statements: pioglitazone and vitamin E

> “Pioglitazone improves NASH and can be considered for patients with NASH in the context of patients with T2DM”
> “Vitamin E can be considered in select individuals as it improves NASH in some patients without diabetes”
> “Available data on semaglutide, pioglitazone, and vitamin E do not demonstrate an antifibrotic benefit, and these compounds have not been carefully studied in patients with cirrhosis”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.2.1.4-2"></a>

###### AASLD update to the practice guidance on resmetirom: regulatory status of pioglitazone and vitamin E for MASH

> “AASLD guidance previously recognized that in the absence of approved therapy, pharmacologic treatment with semaglutide, pioglitazone, and vitamin E could be considered in appropriate patients.”
> “Although not FDA approved for the treatment of MASH, vitamin E and pioglitazone may also improve steatohepatitis.”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

<a id="topic-2.2.2.1.4-3"></a>

###### EASL-EASD-EASO guideline recommendations: pioglitazone and vitamin E not recommended as MASH-targeted therapies

> “Where available, pioglitazone is safe to use in adults with non-cirrhotic MASH but given the lack of robust demonstration of histological efficacy on steatohepatitis and liver fibrosis in large phase III trials, pioglitazone cannot be recommended as a MASH-targeted therapy (LoE 2, weak recommendation, consensus).”
> “Given the lack of robust demonstration of histological efficacy on steatohepatitis and liver fibrosis derived from large phase III trials and potential long-term risks, vitamin E cannot be recommended as a MASH-targeted therapy (LoE 2, weak recommendation, strong consensus).”
> “However, no large, international, phase III trial has been conducted and pioglitazone has been withdrawn from the market in several European countries.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.4-4"></a>

###### ADA Standards of Care recommendations 4.27a, 4.27b, and 4.30a: pioglitazone in adults with type 2 diabetes and MASH

> “In adults with type 2 diabetes and biopsy-proven MASH or those at high risk for liver fibrosis (based on noninvasive tests), a GLP-1 RA is preferred for glycemic management due to beneficial effects on MASH. A Pioglitazone B or a dual GIP and GLP-1 RA B can be considered for glycemic management due to potential beneficial effects on MASH.”
> “Combination therapy with pioglitazone plus GLP-1 RA can be considered for the treatment of hyperglycemia in adults with type 2 diabetes with biopsy-proven MASH or those at high risk of liver fibrosis (identified with noninvasive tests) because of potential beneficial effects on MASH. B”
> “In adults with type 2 diabetes and MASLD, use of glucose-lowering therapies other than pioglitazone or GLP-1 RAs may be continued as clinically indicated, but these therapies lack evidence of benefit in MASH. B”
> “In the context of treating hyperglycemia in individuals with type 2 diabetes with MASLD, where the low cost of pioglitazone and any liver improvement would be an added benefit to glycemic management, these plans would be potentially cost-effective for the treatment of MASLD”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.2.1.4-5"></a>

###### ADA Standards of Care: vitamin E with and without type 2 diabetes

> “Vitamin E may be beneficial for the treatment of MASH in individuals without diabetes”
> “However, in individuals with type 2 diabetes, vitamin E monotherapy was found to be ineffective in a small RCT”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.2.1.4-6"></a>

###### PIVENS: pioglitazone 30 mg or vitamin E 800 IU vs placebo in 247 adults without diabetes, 96 weeks, intention-to-treat primary analysis

> “We randomly assigned 247 adults with nonalcoholic steatohepatitis and without diabetes to receive pioglitazone at a dose of 30 mg daily (80 subjects), vitamin E at a dose of 800 IU daily (84 subjects), or placebo (83 subjects), for 96 weeks.”
> “The primary analysis was an intention-to-treat analysis in which the proportions of subjects in each active-treatment group (pioglitazone and vitamin E) in whom there was improvement in nonalcoholic steatohepatitis were compared with the proportion of subjects in the placebo group in whom there was improvement.”
> “Vitamin E therapy, as compared with placebo, was associated with a significantly higher rate of improvement in nonalcoholic steatohepatitis (43% vs. 19%, P = 0.001), but the difference in the rate of improvement with pioglitazone as compared with placebo was not significant (34% and 19%, respectively; P = 0.04).”
> “both agents were associated with reductions in hepatic steatosis (P = 0.005 for vitamin E and P<0.001 for pioglitazone) and lobular inflammation (P = 0.02 for vitamin E and P = 0.004 for pioglitazone) but not with improvement in fibrosis scores (P = 0.24 for vitamin E and P = 0.12 for pioglitazone).”

Source: [Sanyal et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2928471/)

<a id="topic-2.2.2.1.4-7"></a>

###### PIVENS: resolution of steatohepatitis with pioglitazone, as summarized in the AASLD practice guidance

> “In the PIVENS trial, pioglitazone treatment did not meet the a priori primary endpoint of a ≥2-point reduction NAS without worsening of fibrosis, although 47% had NASH resolution compared with 21% of participants receiving placebo (p <0.001)”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.2.1.4-8"></a>

###### Pioglitazone 45 mg/d for 18 months in 101 randomized participants with NASH and prediabetes or type 2 diabetes

> “Patients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from the general population and outpatient clinics.”
> “All patients were prescribed a hypocaloric diet (500-kcal/d deficit from weight-maintaining caloric intake) and then randomly assigned to pioglitazone, 45 mg/d, or placebo for 18 months, followed by an 18-month open-label phase with pioglitazone treatment.”
> “Among patients randomly assigned to pioglitazone, 58% achieved the primary outcome (treatment difference, 41 percentage points [95% CI, 23 to 59 percentage points]) and 51% had resolution of NASH (treatment difference, 32 percentage points [CI, 13 to 51 percentage points]) (P < 0.001 for each).”
> “Pioglitazone treatment also was associated with improvement in individual histologic scores, including the fibrosis score (treatment difference, -0.5 [CI, -0.9 to 0.0]; P = 0.039)”
> “The overall rate of adverse events did not differ between groups, although weight gain was greater with pioglitazone (2.5 kg vs. placebo).”
> “Single-center study.”

Source: [Cusi et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27322798/)

<a id="topic-2.2.2.1.4-9"></a>

###### Pioglitazone safety: weight gain, heart failure, fractures, and bladder cancer in guideline texts

> “Potential side effects associated with pioglitazone include weight gain, osteoporosis in postmenopausal women, a debated risk of bladder cancer, and potential risk for worsening heart failure in those with preexisting cardiac dysfunction”
> “its use in clinical practice has been overtaken by the increasing use of newer antidiabetic agents such as glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium glucose cotransporter-2 (SGLT-2) inhibitors (SGLT-2i) with pleiotropic metabolic benefits, most notably weight loss and reduction in cardiovascular mortality”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

> “Pioglitazone causes dose-dependent weight gain (15 mg/day, mean weight gain of 1–2%; 45 mg/day, mean weight gain of 3–5%), which can be blunted or reversed if combined with SGLT2 inhibitors or GLP-1 RAs”
> “Pioglitazone increases fracture risk, may promote heart failure if used in individuals with preexisting congestive heart failure, and may increase the risk of bladder cancer, although this remains controversial”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

> “but the side effect profile (weight gain, pedal oedema, haemodilution, bone loss in post-menopausal women and a debate around the risk of bladder cancer) has limited its development for MASH”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.4-10"></a>

###### Pioglitazone safety: boxed warning for congestive heart failure in the FDA label

> “Thiazolidinediones, including ACTOS, cause or exacerbate congestive heart failure in some patients”
> “ACTOS is not recommended in patients with symptomatic heart failure.”
> “Initiation of ACTOS in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated”

Source: [Takeda Pharmaceuticals ACTOS prescribing information (2017)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021073s049lbl.pdf)

<a id="topic-2.2.2.1.4-11"></a>

###### Pioglitazone safety in PIVENS: weight gain at week 96 and cardiovascular events

> “There was a significant improvement in insulin resistance only in the pioglitazone group, but that group was also the only group that had a significant mean weight gain (a mean increase of 4.7 kg at week 96, P<0.001 for the comparison with placebo)”
> “A similar number of cardiovascular events occurred among subjects taking placebo (12 events), those taking vitamin E (12), and those taking pioglitazone (10). No cases of congestive heart failure were reported.”

Source: [Sanyal et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2928471/)

<a id="topic-2.2.2.1.4-12"></a>

###### Vitamin E safety and advanced fibrosis outcomes in the AASLD practice guidance

> “Although no study has demonstrated that vitamin E meaningfully reduces fibrosis, a retrospective study of 236 patients with NASH and advanced fibrosis showed that vitamin E use was associated with lower rates of hepatic decompensation (37% vs. 62%, p = 0.04) and higher transplant free survival (78% vs. 49%, p < 0.01)”
> “Concern about the risks of vitamin E on bleeding and specifically hemorrhagic stroke has been raised, but prospective data are needed to confirm this observation.”
> “In addition, data demonstrating a relationship between vitamin E and prostate cancer are conflicting”
> “Such potential risks should be discussed with patients before initiation of long-term high-dose (eg, 800 IU daily) vitamin E therapy.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

Additional sources: [Cusi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35569886/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Sodium-glucose Cotransporter-2 Inhibitors and Other Off-label Therapies

<a id="topic-2.2.2.1.5-1"></a>

###### EASL-EASD-EASO recommendation on SGLT2 inhibitors and metformin as MASH-targeted therapy

> “There is insufficient evidence to recommend the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors or metformin as MASH-targeted therapies; however, they are safe to use in MASLD and should be used for their respective indications, namely type 2 diabetes, heart failure and chronic kidney disease (LoE 3, strong recommendation, strong consensus).”
> “Controlled clinical trials with liver histological endpoints are currently not available.”
> “Currently, there is no evidence that metformin alone can improve histology in MASH.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.5-2"></a>

###### EASL-EASD-EASO statement on statins, fibrates, ezetimibe, and silymarin as MASH treatment

> “Nonetheless the efficacy of statins, specifically for treating MASH, cannot be established, since there are no large RCTs of statins with histological endpoints. The same holds true for fibrates and ezetimibe.”
> “Silymarin (an extract of milk thistle) may improve liver enzymes but the few, small, RCTs available”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.5-3"></a>

###### ADA Standards of Care 2026: glucose-lowering therapies other than pioglitazone and GLP-1 RAs in adults with type 2 diabetes and MASLD

> “In adults with type 2 diabetes and MASLD, use of glucose-lowering therapies other than pioglitazone or GLP-1 RAs may be continued as clinically indicated, but these therapies lack evidence of benefit in MASH.”
> “reduce hepatic steatosis, but their effects on steatohepatitis remain unknown.”
> “However, these agents have either failed to improve steatohepatitis in paired-biopsy studies (metformin) or have no RCTs with liver histological end points (i.e., sulfonylureas, glitinides, dipeptidyl peptidase 4 inhibitors, or acarbose).”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.2.1.5-4"></a>

###### AASLD 2023 practice guidance on SGLT2 inhibitors, metformin, ursodeoxycholic acid, DPP-4 inhibitors, statins, and silymarin

> “Available studies evaluating the role of SGLT-2i in the treatment of NAFLD/NASH are limited by relatively small sample sizes and lack of histological outcomes.”
> “Within these limitations, available data suggest SGLT-2i improve hepatic steatosis; however, the therapeutic impact of SGLT-2i on liver histology needs to be better defined.”
> “Metformin, ursodeoxycholic acid, dipeptidylpeptidase-4, statins, and silymarin are well studied in NASH and should not be used as a treatment for NASH as they do not offer a meaningful histological benefit.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.2.1.5-5"></a>

###### Dapagliflozin phase 3 trial (DEAN): design, population, and setting

> “Multicentre, double blind, randomised, placebo controlled trial.”
> “Six tertiary hospitals in China from 23 November 2018 to 28 March 2023.”
> “154 adults with biopsy diagnosed MASH, with or without type 2 diabetes.”
> “All participants were randomly assigned to receive 10 mg orally of dapagliflozin or matching placebo once daily for 48 weeks.”
> “A total of 33% participants (51/154) had stage F1 fibrosis, 45% (70/154) had stage F2, and 19% (29/154) had stage F3.”

Source: [Lin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12135075/)

<a id="topic-2.2.2.1.5-6"></a>

###### Dapagliflozin phase 3 trial (DEAN): histologic results at 48 weeks, intention-to-treat analysis

> “Analyses used the intention-to-treat dataset.”
> “MASH improvement without worsening of fibrosis was reported in 53% (41/78) of participants in the dapagliflozin group and 30% (23/76) in the placebo group (risk ratio 1.73 (95% confidence interval (CI) 1.16 to 2.58); P=0.006).”
> “MASH resolution without worsening of fibrosis occurred in 23% (18/78) of participants in the dapagliflozin group and 8% (6/76) in the placebo group (risk ratio 2.91 (95% CI 1.22 to 6.97); P=0.01). Fibrosis improvement without worsening of MASH was reported in 45% (35/78) of participants in the dapagliflozin group, as compared with 20% (15/76) in the placebo group (risk ratio 2.25 (95% CI 1.35 to 3.75); P=0.001).”

Source: [Lin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12135075/)

<a id="topic-2.2.2.1.5-7"></a>

###### Dapagliflozin phase 3 trial (DEAN): limitations stated by the authors

> “Firstly, our primary endpoint was MASH improvement without worsening of liver fibrosis instead of MASH resolution without worsening of fibrosis or fibrosis improvement without worsening of MASH according to the guidance of FDA”
> “Secondly, the current trial was conducted in a Chinese population, which limits the broader generalisability of the conclusion.”
> “Finally, because of the scarcity of major adverse liver outcomes (eg, cirrhosis and hepatocellular carcinoma), large scale and long term trials are needed to further confirm these effects.”

Source: [Lin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12135075/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Bariatric and Metabolic Surgery

<a id="topic-2.2.2.1.6-1"></a>

###### AASLD 2023 practice guidance on bariatric surgery

> “Bariatric surgery should be considered as a therapeutic option in patients who meet criteria for metabolic weight loss surgery, as it effectively resolves NAFLD or NASH in the majority of patients without cirrhosis and reduces mortality from CVD and malignancy.”
> “The type, safety, and efficacy of bariatric surgery in patients with well-compensated NASH cirrhosis is not established and requires a careful benefit–risk assessment by a multidisciplinary team of experts that includes a hepatologist.”
> “Failure to achieve substantial weight loss following bariatric surgery is associated with persistent NASH.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.2.1.6-2"></a>

###### EASL-EASD-EASO recommendation on bariatric surgery in non-cirrhotic MASLD

> “In adults with non-cirrhotic MASLD who have an approved indication, bariatric surgery should be considered, because it can induce long-term beneficial effects on the liver and is associated with remission of type 2 diabetes and improvement of cardiometabolic risk factors (LoE 3, strong recommendation, strong consensus).”
> “Metabolic/bariatric endoscopic procedures require further validation as MASH-targeted therapy and cannot currently be recommended (LoE 4, weak recommendation, strong consensus).”
> “However, in a study with control biopsies after surgery, advanced fibrosis (bridging fibrosis or cirrhosis) persisted in 47% of individuals sometimes even 5 years or more post-surgery and despite significant weight loss.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.6-3"></a>

###### ADA Standards of Care 2026: metabolic surgery in adults with type 2 diabetes and MASH

> “Consider metabolic surgery in appropriate candidates as an option to treat MASH in adults with type 2 diabetes and obesity”
> “Meta-analyses report that 70–80% of people have improvement in hepatic steatosis, 50–75% of people have improvement in inflammation and hepatocyte ballooning (necrosis), and 30–40% of people have improvement in fibrosis”
> “It is important to note that currently metabolic surgery is not indicated solely for treatment of MASH.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.2.1.6-4"></a>

###### BRAVES randomized trial: Roux-en-Y gastric bypass or sleeve gastrectomy vs lifestyle modification plus best medical care, 1-year histology

> “We did a multicentre, open-label, randomised trial at three major hospitals in Rome, Italy. We included participants aged 25-70 years with obesity (BMI 30-55 kg/m2), with or without type 2 diabetes, with histologically confirmed NASH.”
> “The primary endpoint of the study was histological resolution of NASH without worsening of fibrosis at 1-year follow-up.”
> “In the intention-to-treat analysis, the percentage of participants who met the primary endpoint was significantly higher in the Roux-en-Y gastric bypass group (54 [56%]) and sleeve gastrectomy group (55 [57%]) compared with lifestyle modification (15 [16%]; p<0·0001).”
> “Severe adverse events occurred in ten (6%) participants who had bariatric-metabolic surgery, but these participants did not require re-operations and severe adverse events were resolved with medical or endoscopic management.”

Source: [Verrastro et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37088093/)

<a id="topic-2.2.2.1.6-5"></a>

###### BRAVES randomized trial: fibrosis improvement at 1 year and fibrosis stage of participants

> “In this open-label RCT, fibrosis improvement by ≥1 stage without worsening of MASH after 1 year was achieved in 37% and 39% of patients after Roux-en-Y gastric bypass and sleeve gastrectomy, respectively, vs. 23% after lifestyle modification. However, the majority of study participants had mild fibrosis.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.6-6"></a>

###### Prospective cohort of 180 adults with severe obesity and biopsy-proven NASH: histology 5 years after bariatric surgery

> “We performed a prospective study of 180 severely obese patients with biopsy-proven NASH, defined by the NASH clinical research network histologic scores.”
> “At 5 years after bariatric surgery, NASH was resolved, without worsening fibrosis, in samples from 84% of patients (n = 64; 95% confidence interval, 73.1%-92.2%). Fibrosis decreased, compared with baseline, in samples from 70.2% of patients (95% CI, 56.6%-81.6%). Fibrosis disappeared from samples from 56% of all patients (95% CI, 42.4%-69.3%) and from samples from 45.5% of patients with baseline bridging fibrosis.”

Source: [Lassailly et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32553765/)

<a id="topic-2.2.2.1.6-7"></a>

###### SPLENDOR cohort: major adverse liver outcomes and cardiovascular events at 10 years after bariatric surgery in fibrotic NASH without cirrhosis

> “In this retrospective cohort study of 1158 patients (including 650 patients who underwent bariatric surgery and 508 patients in the nonsurgical control group) with biopsy-proven fibrotic nonalcoholic steatohepatitis without cirrhosis, bariatric surgery was significantly associated with a lower risk of major adverse liver outcomes (adjusted absolute 10-year risk difference of 12.4%) and major adverse cardiovascular events (adjusted absolute 10-year risk difference of 13.9%).”
> “Among the patients analyzed with overlap weighting methods, the cumulative incidence of major adverse liver outcomes at 10 years was 2.3% (95% CI, 0%-4.6%) in the bariatric surgery group and 9.6% (95% CI, 6.1%-12.9%) in the nonsurgical group (adjusted absolute risk difference, 12.4% [95% CI, 5.7%-19.7%]; adjusted hazard ratio, 0.12 [95% CI, 0.02-0.63]; P = .01).”
> “Within the first year after bariatric surgery, 4 patients (0.6%) died from surgical complications, including gastrointestinal leak (n = 2) and respiratory failure (n = 2).”

Source: [Aminian et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8587225/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

###### Summary

Resmetirom and semaglutide 2.4 mg are approved for noncirrhotic MASH with moderate to advanced liver fibrosis, both under accelerated approval based on improvement of MASH and fibrosis. In the MAESTRO-NASH primary analysis population of 966 patients, NASH resolution with no worsening of fibrosis occurred in 25.9% (resmetirom 80 mg) and 29.9% (100 mg) compared with 9.7% (placebo), and fibrosis improvement by at least one stage in 24.2% and 25.9% compared with 14.2%. The EASL guideline states that evidence is limited to 52-week histological data, that about 70-80 % of participants did not respond according to histological criteria, and that there is no evidence to guide when to stop treatment. In the ESSENCE interim analysis of the first 800 patients at week 72, resolution of steatohepatitis occurred in 62.9% with semaglutide and 34.3% with placebo, and reduction in fibrosis in 36.8% and 22.4%; the AASLD semaglutide update states that 37.1% of treated participants did not resolve MASH and 63.2% did not have a reduction in fibrosis, and that available data do not identify predictors of response. No FDA-approved noninvasive test diagnoses MASH with F2 to F3 or monitors response to pharmacotherapy. Resmetirom and semaglutide have not been studied in combination or compared. Among 6837 resmetirom initiators, 37.2% had a recorded incretin prescription. The EASL guideline states that agents receiving accelerated approval must demonstrate beneficial effects on clinical outcomes and that no MASH-targeted pharmacotherapy can currently be recommended at the cirrhotic stage.

Other options have limits. Few patients (≤ 10%) achieve effective weight loss with structured interventions at 1 year, and fewer than half of these maintain it at 5 years; in one cohort, 88 of 293 participants (30%) lost 5% or more of their weight at week 52. Pioglitazone and vitamin E are not FDA approved for MASH, the EASL guideline does not recommend either as a MASH-targeted therapy, and in a 96-week trial in 247 adults without diabetes neither was associated with improvement in fibrosis scores; pioglitazone was associated with a mean weight gain of 4.7 kg at week 96, and its label states that thiazolidinediones cause or exacerbate congestive heart failure in some patients. The EASL guideline finds insufficient evidence to recommend SGLT2 inhibitors or metformin as MASH-targeted therapies. Metabolic surgery is not indicated solely for treatment of MASH, advanced fibrosis persisted in 47% of individuals in one post-surgery biopsy study, and in a cohort of 650 surgical patients with fibrotic NASH, 4 (0.6%) died from surgical complications within the first year.

Access and persistence are also limited. A diagnosis rate of ~10% (range 3.3% to 14.3%) of the treatment-eligible population has been estimated. In one cohort, 129 of 137 patients prescribed resmetirom (94.2%) required prior authorization, 33 (24.1%) prior authorization denials required appeal, and resmetirom was dispensed on average 22.7 days after prescription; in another cohort, 13 patients (16%) discontinued resmetirom after an average of 25.5 days, 11 because of adverse events. In company market research with 100 US MASH treaters, 85% of specialists described the greatest unmet needs as lack of effective, liver-directed therapies.

Source: [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf); [Novo Nordisk WEGOVY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf); [Harrison et al. (2024)](https://www.nejm.org/doi/full/10.1056/NEJMoa2309000); [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext); [Sanyal et al. (2025)](https://www.nejm.org/doi/full/10.1056/NEJMoa2413258); [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated); [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated); [Papadimopoulos et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43039875/); [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/); [Vilar-Gomez et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25865049/); [Sanyal et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2928471/); [Takeda Pharmaceuticals ACTOS prescribing information (2017)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021073s049lbl.pdf); [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/); [Aminian et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8587225/); [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/); [Shuaibi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12271776/); [Ravela et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11970881/); [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.2.2.1.7-2"></a>

###### Resmetirom: histologic nonresponse, 52-week data, and absence of stopping rules (EASL-EASD-EASO)

> “Importantly, evidence is currently limited to 52-week histological outcome data. This raises uncertainty as to whether responses will be sustained in the long-term. Similarly, there is currently no evidence to provide confident guidance on when to stop treatment, particularly considering that about 70-80 % of participants did not respond to treatment according to histological criteria.”
> “For individuals with MASLD undergoing therapy with resmetirom, data on sustainability of histological benefits, individual prediction of response, liver-related outcomes and long-term safety are not currently available (LoE 5, strong consensus).”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.7-3"></a>

###### Semaglutide: histologic nonresponse at week 72 in ESSENCE and absence of predictors of response (AASLD)

> “In the ESSENCE trial, 37.1% of participants treated with semaglutide did not resolve MASH, and 63.2% did not have a reduction in fibrosis without worsening of steatohepatitis by week 72. At the current time, we do not have data from the ESSENCE trial to reliably identify patients who are unlikely to resolve MASH or regress liver fibrosis with 72 weeks of semaglutide treatment.”
> “Publicly available data from the ESSENCE trial do not allow an assessment of blood tests and other NITs that predict response to treatment (and this is generally an unmet need in clinical trials of MASH pharmacotherapy).”

Source: [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated)

<a id="topic-2.2.2.1.7-4"></a>

###### No FDA-approved noninvasive test for selection or monitoring (AASLD)

> “There are no FDA-approved noninvasive tests to diagnose MASH with F2-F3 or to monitor response to pharmacotherapy.”
> “Since the FDA-approved resmetirom prescribing information”
> “does not include implementable guidance for practicing clinicians about whom to treat and how to monitor for response and safety”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

<a id="topic-2.2.2.1.7-5"></a>

###### Unverified clinical benefit of accelerated approvals, untested combinations, and no therapy for MASH cirrhosis (EASL-EASD-EASO research needs)

> “With the registration of resmetirom and potentially other agents in the future, it is important to define non-response and stopping rules as well as to ascertain their long-term metabolic (e.g. bone density, endocrine functions), cardiovascular and oncological (e.g. extrahepatic malignancy) safety. The potential additive or synergistic effects of combining drugs intended to treat MASH and/or cardiometabolic comorbidities needs to be prospectively assessed. All pharmacological agents receiving accelerated approval for the treatment of MASH must demonstrate beneficial effects on clinical outcomes (i.e. mortality, decompensation, liver transplantation, HCC) in the extended period of phase III clinical trials and real-world studies. In addition, it is important to develop effective pharmacological treatments for individuals with MASH-related cirrhosis.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.7-6"></a>

###### Combined resmetirom and semaglutide: not studied (AASLD and real-world US cohort)

> “However, semaglutide and resmetirom have not been studied as a combination therapy for MASH, nor have they been compared for relative efficacy.”

Source: [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated)

> “Resmetirom and semaglutide 2.4 mg are approved for metabolic dysfunction-associated steatohepatitis but have not been tested together.”
> “Because more than one-third of resmetirom initiators had a recorded incretin prescription, mostly before initiation, trials of combined treatment are needed.”

Source: [Papadimopoulos et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43039875/)

<a id="topic-2.2.2.1.7-7"></a>

###### Diagnosis rate of the treatment-eligible US population (Madrigal-funded population calculator)

> “Published analyses suggest a diagnosis rate of ~ 10% (range 3.3–14.3%) and ~ 16% year-over-year growth in the treatment-eligible population.”
> “Estimation of the treatment-eligible population for resmetirom depends importantly on NASH diagnosis rates, which are predicted to be < 15% in the 3 years after drug approval.”

Source: [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/)

<a id="topic-2.2.2.1.7-8"></a>

###### Real-world resmetirom access: prior authorization, denials, and dispensing delays at a US tertiary center

> “Among the 137 patients prescribed resmetirom, 129 patients (94.2%) required insurance prior authorization. A total of 33 (24.1%) insurance prior authorization denials were seen, which required an appeal for insurance approval.”
> “Appeals were denied due to unmet biopsy requirements, expired noninvasive fibrosis testing, or complete plan exclusions. On average, resmetirom was dispensed 22.7 days after being prescribed, with a delay of 12.5 days after insurance approval.”
> “Despite insurance approvals, access challenges persisted, with 5 patients discontinuing treatment prematurely due to cost concerns when nonprofit foundation grants were unavailable or logistical issues with specialty pharmacy dispensing.”

Source: [Shuaibi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12271776/)

<a id="topic-2.2.2.1.7-9"></a>

###### Real-world resmetirom discontinuation in a US hepatology prescription pathway

> “Thirteen patients (16%) discontinued resmetirom after an average of 25.5 days (range: 2–68 d), with 11 patients discontinuing due to adverse events.”
> “One in 6 patients discontinued resmetirom, primarily due to side effects.”

Source: [Ravela et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11970881/)

<a id="topic-2.2.2.1.7-10"></a>

###### Unmet need reported by US MASH treaters (Inventiva market research)

> “Despite the emergence of new treatment options, US HCPs feel that unmet need in MASH remains significant”
> “Without a prompt 85% of specialists in the US described the greatest unmet needs as lack of effective, liver directed therapies”
> “Global Primary Quant Patient Journey Market Research Jul. - Sep. ’25 (n=100). All HCPs were US MASH treaters”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

Lanifibranor is an investigational medicine that has not been approved by any regulatory authority. It is being evaluated in the phase 3 NATiV3 trial in patients with MASH with moderate and advanced fibrosis, and the manufacturer expects to report topline results in the fourth quarter of 2026. In the EASL guideline, management of MASLD consists of lifestyle modification and optimal management of comorbidities, including incretin-based therapies for type 2 diabetes or obesity, with resmetirom, if approved locally, considered as a MASH-targeted therapy for non-cirrhotic MASH with fibrosis stage 2 or higher; no MASH-targeted pharmacotherapy is recommended for the cirrhotic stage. The same guideline describes a phase IIb trial of lanifibranor with dose-dependent histological improvement of steatohepatitis and fibrosis and side effects of a 2.5% increase in weight, pedal oedema, and mild anaemia. For adults with type 2 diabetes and biopsy-proven MASH or high risk of liver fibrosis, the American Diabetes Association prefers a GLP-1 RA for glycemic management, allows pioglitazone plus a GLP-1 RA, and advises referral to a gastroenterologist or hepatologist for consideration of a thyroid hormone receptor-β agonist.

The American Diabetes Association states that MASH therapy should be individualized and initiated by a hepatologist or gastroenterologist with expertise in MASH within an interprofessional team, and the Cigna prior authorization policy for Rezdiffra requires prescribing by or in consultation with an endocrinologist, gastroenterologist, or hepatologist. About 14% of MAESTRO-NASH participants were receiving a GLP-1 RA, and the EASL guideline considers it reasonable to use resmetirom by the same criteria in these individuals; the AASLD resmetirom update states that data are insufficient to guide whether or when to start resmetirom in persons already taking therapies with potential MASH efficacy. Combination use of semaglutide 2.4 mg/week with resmetirom has not been studied, and another publication did not recommend upfront combination therapy and supported treatment consideration with resmetirom or semaglutide for noncirrhotic MASLD with liver stiffness of 10 to 20 kPa or ELF of 9.2 to 11.3. Among 6837 resmetirom initiators, 37.2% had a recorded incretin prescription, mostly before resmetirom (33.8%), and 231 of the remaining 4524 (5.1%) were co-initiators.

The manufacturer describes lanifibranor as a once-daily oral therapy, plans to demonstrate its value as monotherapy and in combination, and states that NATiV3 assesses lanifibranor in combination with GLP-1 and SGLT2 inhibitors. The manufacturer's Form 20-F states that weight gain with lanifibranor may lead patients to prefer a GLP-1 agent for the treatment of MASH.

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf); [Inventiva Paris MASH 2026 abstracts release (2026)](https://inventivapharma.com/wp-content/uploads/INVENTIVA-Paris-MASH-Poster-Presentations-EN-9.8.26.pdf); [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext); [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/); [Cigna Rezdiffra prior authorization policy (2026)](https://a.static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_852_coveragepositioncriteria_hepatology_rezdiffra_pa.pdf); [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated); [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated); [Younossi et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/41950980/); [Papadimopoulos et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43039875/); [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf); [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.2.2.2-2"></a>

###### EASL-EASD-EASO treatment algorithm: lifestyle, comorbidity management, and resmetirom for non-cirrhotic MASH with fibrosis stage 2 or higher

> “In adults with MASLD, lifestyle modification – including weight loss, dietary changes, physical exercise and discouraging alcohol consumption – as well as optimal management of comorbidities – including use of incretin-based therapies (e.g. semaglutide, tirzepatide) for T2D or obesity, if indicated – is advised. Bariatric surgery is also an option in individuals with MASLD and obesity.”
> “If approved locally and dependent on the label, adults with non-cirrhotic MASH with significant liver fibrosis (stage ≥2) should be considered for treatment with resmetirom as a MASH-targeted therapy, as this treatment demonstrated histological efficacy on steatohepatitis and fibrosis in a large phase III registrational trial with an acceptable safety and tolerability profile (LoE 2, strong recommendation, consensus).”
> “No MASH-targeted pharmacotherapy can currently be recommended for the cirrhotic stage.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.2-3"></a>

###### EASL-EASD-EASO guideline on lanifibranor: phase 2b results and ongoing phase 3 trial

> “A phase IIb trial showed a dose-dependent histological improvement of steatohepatitis and fibrosis with the pan-PPAR agonist lanifibranor”
> “though side effects were reminiscent of PPARγ agonists, namely a 2.5% increase in weight, pedal oedema and mild anaemia. A large registrational, phase III trial is ongoing.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.2-4"></a>

###### ADA Standards of Care 2026: GLP-1 RA, pioglitazone, and THR-β agonist placement in adults with type 2 diabetes and MASH

> “In adults with type 2 diabetes and biopsy-proven MASH or those at high risk for liver fibrosis (based on noninvasive tests), a GLP-1 RA is preferred for glycemic management due to beneficial effects on MASH.”
> “Combination therapy with pioglitazone plus GLP-1 RA can be considered for the treatment of hyperglycemia in adults with type 2 diabetes with biopsy-proven MASH or those at high risk of liver fibrosis (identified with noninvasive tests) because of potential beneficial effects on MASH.”
> “For consideration of treatment with a thyroid hormone receptor-β agonist in adults with type 2 diabetes or prediabetes with MASLD with moderate (F2) or advanced (F3) liver fibrosis on liver histology, or by a validated imaging-based or blood-based test, refer to a gastroenterologist or hepatologist with expertise in MASLD management.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.2.2-5"></a>

###### Care setting: specialist initiation of MASH-targeted therapy (ADA Standards of Care 2026)

> “Given complexities associated with selection of an individual for therapy, drug cost, and treatment monitoring, therapy should be individualized and initiated by a hepatologist or gastroenterologist with expertise in MASH within an interprofessional team.”
> “Treatment initiation and monitoring should be individualized and within the context of an interprofessional team that includes a gastroenterologist or hepatologist, consideration of individual preferences, and a careful shared-decision cost-benefit discussion.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.2.2-6"></a>

###### Care setting: prescriber specialty required by a national formulary prior authorization policy for resmetirom

> “The medication is prescribed by or in consultation with an endocrinologist, gastroenterologist, or hepatologist”
> “The medication will be used in combination with appropriate diet and exercise therapy”

Source: [Cigna Rezdiffra prior authorization policy (2026)](https://a.static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_852_coveragepositioncriteria_hepatology_rezdiffra_pa.pdf)

<a id="topic-2.2.2.2-7"></a>

###### Resmetirom in patients already receiving a GLP-1 RA (EASL-EASD-EASO)

> “Many individuals who may be eligible for treatment with resmetirom will already be receiving other pharmacological treatments, e.g. GLP1RA, which raises the question of how to integrate resmetirom into combination treatments. About 14% of participants in the MAESTRO-NASH trial were on GLP1RA treatment, with stable dosage in the 6 months and stable body weight in the 3 months preceding screening liver biopsy.”
> “Therefore, it appears reasonable to use resmetirom according to the same criteria in individuals already receiving GLP1RA treatment.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.2-8"></a>

###### Sequencing of resmetirom with incretin therapy, pioglitazone, or vitamin E (AASLD October 2024 update)

> “Among persons already taking any of these medications with potential efficacy for treating MASH, data are insufficient to guide prescribers about whether or when to initiate resmetirom therapy. Decisions may be made based on the patient’s comorbidity profile, response (if any) to the ongoing therapy, and the fibrosis stage and concern for further liver disease progression.”
> “This is not to be construed as an endorsement of off-label therapy for MASH but rather an acknowledgement of uncertainty about comparative efficacy of these drugs in light of the MAESTRO-NASH exclusion criteria.”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

<a id="topic-2.2.2.2-9"></a>

###### Combined semaglutide and resmetirom (AASLD November 2025 update)

> “There is minimal information about the combined use of semaglutide and resmetirom.”
> “GLP-1 RA treated patients showed similar rates of MASH resolution and fibrosis improvement in combination with resmetirom as patients not on these therapies and no notable differences in safety and tolerability were observed.”
> “Lifestyle modification remains the cornerstone of MASLD/MASH management alongside semaglutide. Combination use with resmetirom at the dose of 2.4 mg/week has not been studied.”

Source: [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated)

<a id="topic-2.2.2.2-10"></a>

###### Updated global consensus 2026: treatment initiation, upfront combination, and selection between resmetirom and semaglutide

> “Treatment consideration with resmetirom or semaglutide was supported for noncirrhotic MASLD with liver stiffness measurement values of 10 to 20 kPa or ELF values of 9.2 to 11.3, after exclusion of cirrhosis. Upfront combination therapy with both drugs was not recommended. Selection of pharmacologic therapy was to be determined through shared decision-making between patient and provider and individualized according to the patient's cardiometabolic profile.”

Source: [Younossi et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/41950980/)

<a id="topic-2.2.2.2-11"></a>

###### International expert panel 2026 on resmetirom and semaglutide: individualizing, switching, and combining agents

> “The two agents act through complementary mechanisms: resmetirom as a liver-directed thyroid hormone receptor-beta agonist and semaglutide as a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a broad spectrum of metabolic effects.”
> “We offer practical recommendations for individualising therapy by patient phenotype, managing patients already receiving GLP-1 RAs and defining response, non-response and criteria for switching or combining agents.”

Source: [Mironova et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42728029/)

<a id="topic-2.2.2.2-12"></a>

###### Real-world incretin exposure and co-initiation among US resmetirom initiators

> “Of 6837 initiators, 76.6% had overweight/obesity (code or body mass index [BMI] ≥ 30 kg/m2), 44.0% Type 2 diabetes and 16.8% a cirrhosis code. An incretin prescription was recorded in 37.2%, mostly before resmetirom (33.8%; excluded from the comparison). Of the remaining 4524, 231 (5.1%) were co-initiators.”

Source: [Papadimopoulos et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43039875/)

<a id="topic-2.2.2.2-13"></a>

###### Inventiva positioning: once-daily oral therapy, monotherapy and combination use, and background incretin therapy

> “We believe lanifibranor is uniquely positioned to deliver on physician and patient needs”
> “Once-daily, oral administration reduces patient burden, especially for those already on injectables”
> “Demonstrate lanifibranor’s value as monotherapy and in combination to secure broad and rapid market access”
> “Patients with MASH will be on medication at diagnosis”
> “MASH drug selection will be on this background”
> “Potential synergy between pan-PPAR and GLP-1 reduces metabolic burden and fibrogenic drive”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.2.2.2-14"></a>

###### Inventiva positioning: combination with GLP-1 RAs and SGLT2 inhibitors in NATiV3 and backbone therapy

> “NATiV3 uniquely positioned to assess lanifibranor in combination with GLP-1 and SGLT2 inhibitors: Reflecting the evolving treatment paradigm and supporting its potential as a backbone therapy.”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.2.2.2-15"></a>

###### Inventiva positioning: patients with or without type 2 diabetes, September 2026

> “Phase 1 and Phase 2 clinical data showed lanifibranor improves metabolic profile and cardiovascular risk factors in patients with MASH with or without type 2 diabetes”
> “Lanifibranor is currently being evaluated in the Phase 3 NATiV3 clinical trial for the treatment of patients with MASH with moderate and advanced fibrosis, with topline results expected in the fourth quarter of this year.”

Source: [Inventiva Paris MASH 2026 abstracts release (2026)](https://inventivapharma.com/wp-content/uploads/INVENTIVA-Paris-MASH-Poster-Presentations-EN-9.8.26.pdf)

> “The data we have generated in our Phase 2b clinical trials gives us deep conviction in lanifibranor's potential as a differentiated oral therapy for patients living with MASH.”

Source: [Inventiva debt and equity financing release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Debt-and-Equity-EN-06-02-2026.pdf)

<a id="topic-2.2.2.2-16"></a>

###### Inventiva risk factors: competition with approved therapies and patient preference for a GLP-1 agent

> “For example, lanifibranor has caused weight gain in certain patients and the potential for this side effect may, if approved, lead patients to prefer a GLP-1 agent for the treatment of MASH.”
> “We may lose lanifibranor’s Fast Track Designation if the FDA concludes that Rezdiffra and/or Wegovy addresses the unmet medical need for patients with MASH. We may also lose the FDA’s Breakthrough Therapy Designation if the FDA concludes that lanifibranor does not demonstrate substantial improvement over Rezdiffra or Wegovy on one or more clinically significant endpoints.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### NATIVE: histologic response in participants with type 2 diabetes

> “A total of 103 patients who underwent randomization had type 2 diabetes mellitus; the mean age of these patients was 56 years, the mean body-mass index was 33, 62 (60%) were women, 83 (81%) had significant or advanced fibrosis, and 84 (82%) had an NAS of 6 or greater.”
> “The patients with diabetes had improvements in histologic features of NASH that were similar to those in the full analysis population, and they had more pronounced reductions in fasting levels of glucose, insulin, and glycated hemoglobin than those observed in the full analysis population.”
> “Lanifibranor appeared to improve histologic features in patients regardless of diabetes status.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-2.2.2.3-2"></a>

###### NATIVE: race of participants and applicability to other racial and ethnic groups

> “The mean age of the patients was 54 years, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 33; 144 (58%) were female, 232 (94%) were White, and 103 (42%) had type 2 diabetes mellitus.”
> “The majority of patients in this 24-week trial were White. To assess whether longer treatment would result in similar efficacy and whether this efficacy would apply to other racial and ethnic groups, some of which have a greater predisposition to NASH than others, an appropriate phase 3 trial of longer duration and with more extensive assessments for efficacy and safety is needed.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-2.2.2.3-3"></a>

###### NATIVE: response by type 2 diabetes status and fibrosis stage F2 to F3 (company presentation)

> “Resolution of MASH and improvement of fibrosis: effect size is increased in F2/F3 patients as well as patients with T2D”
> “Fibrosis improvement and MASH resolution rates were higher in patients with T2D.”
> “With lanifibranor: 21% (800 mg) and 26% (1200 mg) in T2D vs 7% and 22% in non-T2D.”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.2.2.3-4"></a>

###### NATIVE and other phase 2 studies: metabolic response by type 2 diabetes status (descriptive comparison)

> “Metabolic benefits of lanifibranor were seen in these studies regardless of T2DM diagnosis”
> “Glycemic improvement scales with baseline burden and is greatest in established T2DM.”
> “Comparisons were descriptive, without statistical pooling.”
> “Absolute glycaemic gains are larger where baseline burden is higher (T2DM), while the adiponectin (PPARγ-engagement) response is essentially identical across strata.”

Source: [Holleboom et al. (2026)](https://inventivapharma.com/wp-content/uploads/Metabolic-Benefits-of-Lanifibranor-in-Patients-With-and-Without-Type-2-Diabetes_ParisMASH_poster.pdf)

<a id="topic-2.2.2.3-5"></a>

###### NATIVE retrospective analysis: response by PNPLA3 I148M genotype

> “Of these, 219 patients consented to genotyping for the PNPLA3 rs738409 SNP. Sixty five were II, 105 IM and 49 MM, which is highest risk for disease severity and progression.”
> “There was no significant difference in response to lanifibranor by PNPLA3 genotype, despite the fact that MM genotype patients had more activity on biopsy than the II or IM patients (82% NAS≥6, vs 74%, 70%), while there was no difference in fibrosis.”
> “The efficacy of lanifibranor on both liver histology and markers of cardiometabolic health appears to be independent of PNPLA3 status, despite MM genotype patients having more severe activity on liver biopsy.”

Source: [Griffel et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD23-PNPLA3_V1.0_20231013.pdf)

<a id="topic-2.2.2.3-6"></a>

###### NATIVE post hoc analysis: response by weight change during treatment

> “Patients were stratified by BL ADP level (< 5, 5–10, > 10 µg/mL) and by fold-change at EOT (< 1.5x, 1.5–4x, > 4x) and weight change (≤ 2.5%, 2.5–5% and > 5%).”
> “These effects were independent of body-weight change. Although modest weight gain was observed with lanifibranor, it did not prevent improvement in MASH, fibrosis, or cardiometabolic parameters.”

Source: [Rinella et al. (2026b)](https://inventivapharma.com/wp-content/uploads/ADP-and-Weight-Gain-Correlation-Poster_EASL2624.pdf)

<a id="topic-2.2.2.3-7"></a>

###### NATIVE biomarker analysis: serum signatures of histologic response to lanifibranor

> “Patients receiving lanifibranor were pooled, and those with liver biopsies were selected (n = 142).”
> “These signatures provided good accuracy for the noninvasive identification of histologic response under lanifibranor with area under the receiver operating characteristic curve at 0.81 ± 0.08 for E1 score, 0.80 ± 0.08 for E2 score, and 0.81 ± 0.08 for E3 score.”
> “These findings support utilizing a similar approach in a larger sample size (NATiV3, NCT03008070).”

Source: [Boursier et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40107637/)

<a id="topic-2.2.2.3-8"></a>

###### Comparator therapies: resmetirom response in participants receiving background GLP-1 RA therapy

> “GLP-1 RA treated patients showed similar rates of MASH resolution and fibrosis improvement in combination with resmetirom as patients not on these therapies and no notable differences in safety and tolerability were observed.”

Source: [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated)

<a id="topic-2.2.2.3-9"></a>

###### Comparator therapies: tirzepatide histologic response and metabolic change by type 2 diabetes status (SYNERGY-NASH post hoc analysis)

> “Few MASH studies have compared histological responses in participants with T2D with those who do not have T2D.”
> “In participants included in the present analyses, placebo-adjusted body weight reduction with tirzepatide 15 mg was nonsignificantly (P = 0.128 for interaction term) lower in participants with T2D (−14.5%) versus those without T2D (−22.5%).”
> “However, the association between fibrosis improvement response and changes in metabolic parameters such as HbA1c, body weight, and adiponectin were driven mainly by significant associations in the T2D group and were not observed in the non-T2D group.”

Source: [Caussy et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12635880/)

<a id="topic-2.2.2.3-10"></a>

###### Comparator therapies: dapagliflozin response by age and sex (DEAN)

> “Thirdly, a high proportion of male and relatively younger participants were recruited in this trial because they may be more willing to accept liver biopsy at screening. Although the results showed no age and sex differences of dapagliflozin on MASH improvement, female and the older patients were underrepresented in the current study.”

Source: [Lin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12135075/)

<a id="topic-2.2.2.3-11"></a>

###### Comparator therapies: bariatric surgery histologic response in Asian countries

> “Interestingly, the percentage of individuals with improved steatosis and hepatic fibrosis was higher in Asian countries.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Multidisciplinary care model across primary care, endocrinology, and hepatology (AASLD 2023)

> “Optimal care of the patient with NAFLD requires a multidisciplinary approach. The majority of patients are in the primary care/endocrine setting, in which management of medical comorbidities should be optimized, with preference given to treatments for type 2 diabetes mellitus, hypertension, or obesity that likely also have beneficial effects on NAFLD.”
> “The role of the gastroenterologist/hepatologist includes more comprehensive liver risk stratification, exclusion of other liver diseases, and a focus on liver-directed therapy.”
> “All patients should undergo dietary/nutritional assessment and a plan established for regular follow-up independent of gastroenterology/hepatology visits.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.2.4-2"></a>

###### Multidisciplinary management recommendation (EASL-EASD-EASO)

> “Given the multidirectional connections between MASLD and cardiometabolic comorbidities, a multidisciplinary approach is recommended to ensure all components are appropriately targeted to improve both liver-related and extrahepatic outcomes (LoE 3, strong recommendation, strong consensus).”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.4-3"></a>

###### AGA clinical care pathway: risk stratification in primary care and hepatologist-coordinated care for high-risk patients

> “As a result, FIB-4 provides a useful, inexpensive, first-line assessment of liver fibrosis for use in primary care.”
> “We recommend that these patients be managed by a multidisciplinary team closely coordinated by a hepatologist who can monitor for cirrhosis, HCC, and other cirrhosis-related complications. In these patients, we recommend aggressive lifestyle changes aimed at long-term weight loss.”

Source: [Kanwal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8819923/)

<a id="topic-2.2.2.4-4"></a>

###### ADA Standards of Care 2026: screening and referral of adults with type 2 diabetes or prediabetes

> “Adults with type 2 diabetes or prediabetes with a FIB-4 ≥ 1.3 should have additional risk stratification by liver stiffness measurement with transient elastography, or, if unavailable, the enhanced liver fibrosis (ELF) test.”
> “Refer adults with type 2 diabetes or prediabetes at higher risk for significant liver fibrosis (i.e., as indicated by FIB-4, liver stiffness measurement, or ELF) to a gastroenterologist or hepatologist for further evaluation and management.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.2.4-5"></a>

###### On-treatment monitoring and discontinuation criteria for resmetirom at 12 months (AASLD October 2024 update)

> “Hepatic function panel testing should be obtained at baseline and at periodic intervals (eg, 3, 6, and 12 months) to determine response and adverse events while on resmetirom therapy.”
> “In persons whose treatment candidacy was determined by liver stiffness measurements (VCTE or MRE), a repeat measurement at 12 months of therapy is recommended to assess for treatment response.”
> “Among persons with evidence of worsening liver disease at 12 months of treatment, discontinuation of resmetirom should be considered.”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

<a id="topic-2.2.2.4-6"></a>

###### Response and futility assessment for semaglutide at 72 weeks (AASLD November 2025 update)

> “Based on a collective assessment of available data, a reduction from baseline to 72 weeks of VCTE LSM ≥30%, MRE LSM ≥20%, ALT ≥17 U/L or ≥20%, likely reflects a beneficial response. Response below these thresholds but without evidence of worsening or progression to cirrhosis requires individual patient evaluation (Figure 2).”
> “In the absence of data, we recommend consideration of previously recommended criteria,”

Source: [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated)

<a id="topic-2.2.2.4-7"></a>

###### Treatment response definition at 1 year (updated global consensus 2026)

> “The panel endorsed a sequential risk-stratification strategy beginning with Fibrosis-4 Index (FIB-4) as the first-line assessment, followed by vibration-controlled transient elastography or Enhanced Liver Fibrosis (ELF) testing for secondary stratification.”
> “Treatment response at 1 year was defined as a ≥30% reduction in liver stiffness or a ≥0.5-point reduction in ELF.”

Source: [Younossi et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/41950980/)

<a id="topic-2.2.2.4-8"></a>

###### Pharmacist-led prescription pathway for resmetirom in a US health system

> “Our health system allocated a senior and experienced PharmD pharmacist (Phoebe Shackelford) to champion the resmetirom prescription pathway.”
> “Our prescription pathway effectively dispensed resmetirom to nearly all patients who were prescribed resmetirom.”
> “One in 6 patients discontinued resmetirom, primarily due to side effects. This high discontinuation rate may be mitigated by modifying our follow-up from”

Source: [Ravela et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11970881/)

<a id="topic-2.2.2.4-9"></a>

###### Utilization management: national formulary prior authorization criteria for resmetirom and semaglutide in MASH

> “Approve for 1 year if the patient meets ONE of the following (A or B):”
> “Liver biopsy performed within the 3 years preceding treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet [documentation required]; OR”
> “Vibration-controlled transient elastography (VCTE) performed within the 6 months preceding treatment with Rezdiffra, Wegovy injection, Wegovy HD injection, or Wegovy tablet [documentation required]; OR”
> “Patient has completed ≥ 1 year of therapy with Rezdiffra AND according to the prescriber, the patient has not had worsening of fibrosis or MASH/NASH; AND”

Source: [Cigna Rezdiffra prior authorization policy (2026)](https://a.static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_852_coveragepositioncriteria_hepatology_rezdiffra_pa.pdf)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Summary

In the NATIVE trial at week 24, in the full analysis population with missing data handled by multiple imputation, a decrease of at least 2 points in the SAF-A score without worsening of fibrosis (the primary end point) occurred in 55% of participants receiving lanifibranor 1200 mg (significant) and 48% receiving 800 mg (not significant), compared with 33% receiving placebo; resolution of NASH without worsening of fibrosis occurred in 49%, 39%, and 22%. The company topline release reported the primary end point in the ITT population as 49% (1200 mg, P=0.004), 41% (800 mg, P=0.061), and 27% (placebo). The trial publication states that fibrosis is the primary predictor of complications and death in NASH and that regression of fibrosis is associated with decreased risk of liver-related events.

Evidence linking fibrosis stage to outcomes comes from pooled cohort studies and models. Across cohort studies of biopsy-proven NAFLD, stage 3 to 4 fibrosis carried higher all-cause (HR 3.32) and liver-related mortality (HR 10.40) than stage 0 to 2. The estimated time to progress by one stage was 13.3 years from F2 and 22.2 years from F3, and the time to regress by one stage was 12.5 years from F3 and 20.4 years from F2. A US model estimated that a hypothetical therapy halting fibrosis progression in MASLD would reduce cases of decompensated cirrhosis by 11-39%, hepatocellular carcinoma by 10-34%, and liver-related deaths by 8-31%. The AASLD resmetirom update states that stabilization of fibrosis may portend important long-term benefits. The EASL guideline states that agents receiving accelerated approval for MASH must demonstrate beneficial effects on clinical outcomes (mortality, decompensation, liver transplantation, and hepatocellular carcinoma).

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205); [Inventiva NATIVE topline results release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATIVE-top-line-results-EN-15062020.pdf); [Ng et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10792524/); [Le et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9898457/); [Wallace et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39832655/); [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated); [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.7-2"></a>

###### NATIVE: histologic response at week 24, full analysis population with multiple imputation

> “In the full analysis population in which missing data were handled with multiple imputation, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis (the primary end point) was significantly higher among those who received the 1200-mg dose (55%), but not among those who received the 800-mg dose (48%), of lanifibranor than among those who received placebo (33%)”
> “Resolution of NASH without worsening of fibrosis at week 24 from baseline was observed in 49% of patients who received the 1200-mg dose of lanifibranor, in 39% of patients who received the 800-mg dose, and in 22% of patients who received placebo”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-2.2.2.7-3"></a>

###### Fibrosis regression as a predictor of reduced liver-related events (NATIVE discussion)

> “Fibrosis is the primary predictor of medical complications and death in patients with NASH”
> “Regression of fibrosis in NASH is associated with decreased risk of liver-related events”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-2.2.2.7-4"></a>

###### Mortality by fibrosis stage in biopsy-proven NAFLD (meta-analysis of 14 studies)

> “Compared with stage 0 fibrosis, all-cause mortality increased with fibrosis stage: stage 2; HR, 1.46 (95% confidence interval [CI], 1.08–1.98), stage 3; HR, 1.96 (95% CI, 1.41–2.72), and stage 4; HR, 3.66 (95% CI, 2.65–5.05). Risk for liver-related mortality increased exponentially as fibrosis stage increased: stage 2; HR, 4.07 (95% CI, 1.44–11.5), stage 3; HR, 7.59 (95% CI, 2.80–20.5), and stage 4; HR, 15.1 (95% CI, 5.27–43.4).”
> “Stage 3 to 4 fibrosis had a higher all-cause (HR, 3.32) and liver-related mortality (HR, 10.40) compared with stage 0 to 2 fibrosis”

Source: [Ng et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10792524/)

<a id="topic-2.2.2.7-5"></a>

###### Untreated progression and regression times per fibrosis stage (meta-analysis of 54 studies)

> “Time to progress by 1 fibrosis stage was 9.9, 10.3, 13.3 and 22.2 years for F0, F1, F2, and F3, respectively. Time to regress by 1 stage was 21.3, 12.5, 20.4, and 40.0 years for F4, F3, F2, and F1, respectively.”

Source: [Le et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9898457/)

<a id="topic-2.2.2.7-6"></a>

###### Modeled US outcomes of a therapy that halts fibrosis progression in MASLD with moderate-to-advanced fibrosis

> “The scenarios in which a hypothetical therapy halts fibrosis progression resulted in reductions in cases of decompensated cirrhosis (11-39%), hepatocellular carcinoma (10-34%), and liver-related deaths (8-31%), a 9-31% reduction in cumulative DALYs, and $40.5 to $99.1B incremental healthcare costs averted.”
> “Increasing diagnosis and treatment for the MASLD population with moderate-to-advanced fibrosis will prevent advanced liver disease and death and will result in reducing the associated direct healthcare costs.”

Source: [Wallace et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39832655/)

<a id="topic-2.2.2.7-7"></a>

###### Fibrosis stabilization as a treatment goal (AASLD October 2024 update)

> “An important consideration is that stabilization of fibrosis may portend important long-term benefits; for persons with advanced fibrosis, apparent lack of fibrosis improvement should not mandate discontinuation of resmetirom therapy.”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

<a id="topic-2.2.2.7-8"></a>

###### Clinical outcomes not yet demonstrated for therapies approved on histologic endpoints (EASL-EASD-EASO)

> “All pharmacological agents receiving accelerated approval for the treatment of MASH must demonstrate beneficial effects on clinical outcomes (i.e. mortality, decompensation, liver transplantation, HCC) in the extended period of phase III clinical trials and real-world studies.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
